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³7KH EUHDWK RI ZLQG WKDW PRYHG WKHP ZDV VWLOO FKLOO\
on this day in May; the flowers gently resisted, curling 
up with a kind of trembling grace and turning their 
pale stamens towards the ground. The sun shone 
through them, revealing a pattern of interlacing, 
delicate blue veins, visible through the opaque petals; 
this added something alive to the flower's fragility, to 
it¶s ethereal quality, something almost human, in the 
way that human can mean frailty and endurance both 
at the same time. The wind could ruffle these 
ravishing creations but it couldn't destroy them, or 
even crush them; they swayed there, dreamily; they 
seemed ready to fall but held fast to their slim strong 
branches-´ 
 
 
Irène Némirovsky 
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Abstract 
Mucosal delivery of biotherapeutics as a non-invasive means of delivery could 
potentially be enhanced using nanoscale therapeutic carriers. However, nanoparticles 
do not readily cross the mucosal barriers, with the epithelium severely restricting their 
translocation into the systemic circulation. Translocation of nanocarriers across the 
mucosae may be improved by employing ligands capable of exploiting receptor-
mediated cell uptake processes.  
 
This work explores the potential of vitamin B12 transport pathway for mucosal delivery 
of B12-decorated model nanoparticles and investigates the cell trafficking pathways 
involved in these processes. Cyanocobalamin (vitamin B12) was chemically modified to 
produce the Į-Ȧ-aminohexylcarbamate B12 derivative ± as a suitable bioconjugate ± 
which was then conjugated to fluorescent, carboxy-functional nanoparticles (<200 
nm). These systems were applied to intestinal Caco-2 monolayers, expressing the 
relevant proteins involved in B12 trafficking and endocytic processes.  
 
Vitamin B12-conjugated nanoparticles demonstrated notably increased cell uptake and 
transport capacities in Caco-2 monolayers, compared to their unconjugated 
counterparts. Importantly, the cell uptake of B12-conjugated nanoparticles occurred via 
a pathway that was different to that used by both soluble B12 and unmodified 
nanoparticles. B12-conjugated nanoparticles circumnavigated the lysosomal 
compartment and were transported by a route perturbed by caveolae-specific 
inhibitors, unlike the clathrin-mediated trafficking of soluble vitamin B12. These 
previously unreported observations are important and have potential implications in 
the field of bioconjugate and nanocarrier-mediated drug delivery. 
 
Epithelial cell uptake and transport of B12-conjugated nanoparticles was also 
investigated in airway-derived Calu-3 cells, shown to express the B12-intrinsic factor 
receptor, cubilin. B12-nanoparticles showed markedly larger cell uptake and transport 
capacities in Calu-3 layers, with B12-conjugation dramatically influencing the 
VI 
 
intracellular trafficking of the particles in a similar way to Caco-2 cells. The B12 
endocytotic machinery therefore shows potential for delivery of nanocarrier-associated 
therapeutics across the airways. 
 
Present work also aimed to establish methods for the production of stable nano-sized 
protein crystals displaying a slow drug release profile, based on evidence that protein 
therapeutics which are formulated in this manner, offer beneficial drug-delivery 
properties and can be targeted using biological ligands. Nano- and micron-sized 
insulin crystals were prepared by an adaptation of the batch crystallisation approach. 
The crystals were stabilised using a chemical crosslinker, namely ȕ-
[Tris(hydroxymethyl) phosphino] propionic acid (THPP). The resulting insulin crystals 
were generally stable in the absence of crystalisation buffer, displayed a slow-release 
profile, with the released insulin retaining its biological activity. This study therefore 
shows that formulating protein bioactives in this form is possible and may provide a 
promising strategy to develop biotherapeutics with improved drug delivery properties.  
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Chapter 1: Delivery of protein therapeutics across 
mucosal surfaces 
1.1 The rationale behind mucosal protein delivery 
There is an increasing demand for non-invasive methods for the delivery of protein 
pharmaceuticals, which has emanated from the overwhelming growth of 
biotechnology. In 2009, over 12 billion U.S dollars were invested in 
biologics/biotechnology research and development (R&D), representing a 26% share 
in the total R&D expenditure [1]. Furthermore, a recent report by the Pharmaceutical 
Research and Manufacturers of America (PhRMA) states that  in 2011 there were 901 
biologicals in development, targeting more than 100 diseases [2]. A significant 
proportion of these are therapeutics based on different proteins, with monoclonal 
antibodies becoming increasingly popular (Figure 1.1). 
 
 
Figure 1.1 1XPEHU RI µELRORJLFV¶ LQ Gevelopment (by product category) 2011. Adapted 
from a report by PhRMA [1]. 
Despite considerable interest in protein and peptide therapies (and biologicals in 
general) the development of non-invasive delivery systems for this drug category 
remains a huge challenge. This challenge is due to the physicochemical properties of 
this class of therapeutics, including large molecular size, susceptibility to enzymatic 
degradation, short plasma half-life, immunogenicity, and the tendency to undergo 
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aggregation, adsorption and denaturation [3-5]. Oral administration of drugs in general 
is desirable due to the obvious advantage of patient acceptability. However, there are 
several physiological barriers that limit the oral bioavailability of protein and peptide 
drugs, such as the pH across the GI tract (pH 1~8), digestive enzymes, intestinal flora, 
and the epithelial barrier. Consequently, the bioavailability of most peptides and 
proteins following oral administration is less than 1% [6].  
 
The choice of drug delivery system undoubtedly requires an in-depth understanding of 
the physicochemical characteristics, the pharmacology and the intended clinical 
application of any chosen therapeutic. In view of the aforementioned problems, protein 
drugs are predominantly administered parenterally. However, disadvantages 
associated with the parenteral route, include patient discomfort (a barrier influencing 
patient compliance), high cost and the requirement for administration by a healthcare 
professional. This necessitates research into alternative ways of administering this 
class of therapeutics. From the drug delivery perspective, the ideal goal is to develop 
a preferentially oral delivery system for biological therapeutics that would achieve 
therapeutically relevant systemic bioavailability, with controlled release being an 
added advantage for a prolonged therapeutic effect. Many biologicals are very potent 
e.g. growth factors such as fibroblast growth factor [7], vascular endothelial growth 
factor [8] and bone morphogenic proteins [9]. Localised delivery may also be 
necessary in these cases since high systemic levels of these factors are required to 
achieve the local effect in the target tissues and this often leads to systemic toxicity.  
 
Research into identification of non-invasive administration routes is intensifying. 
Although major breakthroughs in the form of popular products on the market are still 
not apparent, some commercial progress has been made in the past several years. 
Examples of non-parenteral delivery technologies, their associated companies and 
therapeutic proteins/peptides under development are listed in Table 1.1.  
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Delivery 
Pathway Buccal Nasal Pulmonary Oral 
Technologies 
(associated 
companies) 
5DSLGPLVW
(Generex) 
 
CPE-215® (CPEX 
Pharmaceuticals) 
Thiomers 
(ThioMatrix) 
Promaxx (Baxter 
Healthcare 
Corporation) 
 
Eligen® (Emisphere) 
6SKHURPHUVDQG
3,16SKHULFV 
 
Thiomers 
(ThioMatrix) 
Intravail® (Aegis 
Therapeutics) 
 
Technosphere® 
(MannKind 
Corporation) 
 
/30'25
Biopharma) 
 
MicroDose 
Electronic dry 
powder inhaler 
(MicroDose 
Therapeutx) 
 
Polymer/Bioadhesive 
platform (CoreMed, 
Inc.) 
Polymer/Bioadhesive 
platform (CoreMed, 
Inc) 
Therapeutic 
proteins 
in research 
(associated 
companies) 
 
Insulin (CPEX 
Pharmaceutics, 
Inc.) 
 
 
Insulin, GLP-1 
(MannKind 
Corporation) 
Insulin (Oramed) 
 
Insulin, Glucagon-
like-peptide-1 
(GLP-1) (MDRNA) 
 
Salmon calcitonin, 
heparin, GLP-1, 
Insulin, (Emisphere) 
 
Insulin, PTH, and 
desmopressin 
(Unigene) 
 
Salmon calcitonin 
(Unigene/Tarsa 
therapeutics) 
 
Cyclosporin (APT 
Pharmaceuticals, 
Inc) 
GLP-1 (Amylin) 
Insulin (Diabetology, 
Ltd.) 
 
Nodlin, Nodexen 
(NOD 
Pharmaceuticals, 
Inc.) 
Marketed 
products 
(therapeutic 
protein, 
associated 
companies) 
Oral-lyn 
(India) 
(Generax) 
Miacalcin 
(calcitonin, 
Novartis) 
None known 
Minirin (Ferring) 
 
Leuprolide (DOR 
Biopharma) 
 
Nocutil (Gebro 
Pharma) 
Minirin 
(desmopressin, 
Ferring) 
 
Suprecur (Sanofi-
Aventis) 
 
Fortical® 
(Unigene) 
 
Table 1.1. Delivery technologies and marketed/researched therapeutic proteins. Table 
sourced and modified from [10, 11] (Colour-coding denotes preclinical, phase I, phase II, 
phase III, and discontinued). 
Some of the potential benefits offered by the mucosal route for drug delivery include 
high surface area for absorption (e.g. intestinal and pulmonary routes), rapid 
absorption (nasal, pulmonary, sublingual, vaginal routes) and avoidance of first pass 
(hepatic) metabolism. However, as will be discussed in the later sections of this 
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chapter, mucosal administration presents unique challenges for the delivery of µIUDJLOH¶
macromolecules such as protein therapeutics.  
1.2  Possible routes for mucosal protein delivery 
1.2.1 Oral Route 
For biological drugs to be absorbed through the gastrointestinal (GI) tract, they must 
be protected from proteolytic enzymes and traverse the epithelial barrier, passing into 
the bloodstream. In addition, the high acidity in the gastrointestinal environment 
causes protein denaturation prior to absorption [12, 13]. The severity of the biological 
barriers of the GI tract to macromolecular drug absorption is highlighted by an in vivo 
study on the oral absorption of native insulin in a murine model, which revealed 
bioavailabilities of less than 1% [14]. This low level of bioavailability means that 
development of unassisted oral delivery formulations is not economically viable with 
the current knowledge and technology, especially when considering the considerably 
higher cost of raw material associated with biologics compared to small chemical 
entities. 
 
Considering the physiological barriers to oral absorption of biologics in general, even if 
the therapeutic has sufficient stability and resilience to enzymatic degradation to 
survive transit through the stomach and into the intestines, it is then faced with a 
number of further barriers (Figure 1.2). The drug must first dissolve in the contents of 
the intestinal lumen (if it is not already in solution), before passing through a mucus 
layer, protecting the surface of the epithelial cells. The epithelial cell layer represents 
the next barrier stage. The therapeutic must cross the epithelial cells on its way to the 
capillaries. The lipid-based plasma membrane of epithelial cells makes penetration of 
hydrophilic macromolecules (e.g. protein therapeutics) into the circulation by 
partitioning and diffusion almost impossible. The epithelial cell barrier is particularly 
effective in limiting the absorption of proteins due its appearance as an almost 
continuous sheet, owing to the close intercellular distance of adjacent epithelial cells 
due to epithelial tight junctions (TJs). The small pore diameter of the TJs restricts the 
intercellular passage of molecules larger than 1000 Da [15, 16].  
Chapter 1: Delivery of protein therapeutics across mucosal surfaces 
5 
 
 
Figure 1.2. Drug absorption barriers in the intestine. Adapted from [17]. 
A few protein drug candidates intended for oral administration are showing promise in 
the development pipeline. For example, Glucagon-like peptide-1 (GLP-1, a gut 
hormone that stimulates insulin secretion for treatment of diabetes), is currently 
undergoing phase I clinical trials. &DSVXOLQ oral anti-diabetic (OAD) - an insulin 
product (by Diabetology) for treatment of type 2 diabetes mellitus is currently in phase 
II.  It incorporates absorption enhancers and exhibits a reported bioequivalence of 6-
10% relative to injected insulin [18]. 
1.2.2 Pulmonary route 
From a physiological perspective, the respiratory system can be categorised 
according to the conducting regions, consisting of the air-transmitting passages of the 
nose, nasopharynx, larynx, trachea, bronchi and bronchioles [19], and respiratory 
regions (where gaseous exchange occurs) comprising of alveolar ducts and saccules. 
The anatomical structure of the conducting airways subtly changes with the restriction 
in diameter of the respiratory tubes [20], with the pseudostratified, columnar and 
ciliated epithelium with goblet cells and submucosal glands transitioning into a 
flattened squamous organisation devoid of goblet cells or glands. These structural 
airway features are presented schematically in Figure 1.3.  
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Figure 1.3. Subdivisions and Structure of Intrapulmonary Airways. Taken from [21]. 
The large surface area of the lung (approximately 140 m2) for drug absorption [22] 
makes pulmonary delivery an attractive non-invasive option. Furthermore, first-pass 
metabolism is bypassed with this route and enzymatic activity has been reported as 
negligible [12]. The epithelial cells of the alveoli are very thin, hence the barrier to 
systemic drug absorption is potentially low. It is therefore unsurprising that pulmonary 
drug delivery is an exciting and emerging field for new pharmaceutical agents, with 
recent data estimating that the global pulmonary drug delivery technologies market 
may reach US$37.7 billion by 2015 [23].  
Aerosol-based formulations offer a number of advantages, including more rapid 
absorption into the systemic circulation (this may be especially important for drugs 
where fast onset of action is critical), higher bioavailability than with other non-invasive 
modes of administration [24], minimal systemic side effects and preferred alternatives 
to injections. In light of these benefits, the pharmaceutical industry is investing major 
resources in aerosol drug delivery and biotechnology, including research in particle 
engineering, dispersion technology, dry powder formulations and drug delivery device 
design [25]. The commercial interest in developing inhaled insulin formulations 
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remains ever popular despite the withdrawal of Exubera® (inhaled insulin product, 
marketed by Pfizer) in 2007. This is exemplified by the efforts of Mannkind to develop 
their ultra rapid-acting inhaled insulin therapy (Afrezza), which is in late stage 
clinical trial. Despite its advantages, drug delivery via the pulmonary route is 
influenced by factors such as lung disease, smoking and exercise [22], and this should 
be taken into account when offering treatment via this route to the patient. 
1.2.3  Other mucosal routes for systemic delivery of protein therapeutics 
The nasal route offers another attractive option for non-invasive protein delivery. The 
nasal mucosa is equipped with a robust epithelial cell layer and sub-epithelial 
vascularisation [12]. As per pulmonary delivery, nasal delivery avoids first pass 
metabolism [26] and experiences lower enzymatic activity in comparison to that found 
in the GI tract and liver [27] and importantly, provides ease of self-administration. 
There are however several limitations, including the rapid mucociliary clearance of 
foreign particulates (which might be problematic for protein delivery [28]), the 
sensitivity of the nasal cavity to changes in pH and the presence of nasal secretions 
[29]. Finally, the low molecular weight cut-off for the nasal route (approximately 1000 
Da), similar to other mucosal surfaces, necessitates the use of permeation enhancers 
which may trigger irritation to the nasal mucosa and permit access for pathogens and 
other harmful substances [27].  
The buccal administration route can also be exploited due to a good surface area for 
absorption and the highly vascularised supporting tissue. Despite avoidance of first 
pass metabolism by the liver, the presence of saliva acts as an additional barrier to 
drug transport, through its physiological role in the defence against foreign agents 
[30].  
Less common routes for transmucosal protein delivery are via the rectal [31], vaginal 
[32] and ocular [33] mucosal surfaces. Rectal delivery enables direct protein 
absorption by the lymphatic system, thereby circumventing the problems of liver 
degradation [22]. The disadvantages associated with this approach include longer 
transit/dissolution times in the colon milieu, bacterial activity and interference from 
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faecal matter [5]. Low and variable extents of absorption associated with the ocular 
and vaginal routes, even in the presence of absorption enhancers, and localised 
adverse reactions mean that both these routes show little promise for protein delivery 
[12, 22]. Low bioavailabilities prevail with the former route as a consequence of local 
irritation to the eye and subsequent tear production [34].  
1.3 The epithelial cell barrier: challenge at mucosal surfaces 
1.3.1  Pathways for macromolecular transport 
Small, amphipathic molecules readily internalise and exit from epithelial cells without a 
specific transport system by having the ability to partition in and out of lipid bilayer 
membranes (apical and basolateral) (Figure 1.4A). The transport of smaller hydrophilic 
macromolecules is limited largely to the paracellular route (i.e. between adjacent cells; 
Figure 1.4B). Larger macromolecules and nano-sized particles may be transported 
across the cells via transcytosis, through a series of tightly regulated vesicular 
structures involving highly complex signalling pathways, which control and restrict their 
passage into and out of the circulation (Figure 1.4C) [35, 36].  
 
Figure 1.4. Possible pathways for translocation of molecules and nanoparticles across 
the mucosal surfaces.  
A) Trancellular route, applicable to small, lipophilic molecules, B) Paracellular (between cells) route, relevant 
to relatively small, hydrophilic macromolecules, and C) Transcytosis (which may be receptor mediated), 
through which large macromolecules and nanoparticles can potentially traverse the mucosal surfaces. 
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1.3.2  Physiological barriers to mucosal absorption 
Effective systemic delivery of protein therapeutics following mucosal administration 
faces a number of physiological barriers. These barriers are represented 
schematically in Figure 1.5. In addition to the epithelial cell layer barrier, drug 
absorption is also affected by mucus [37] and the mucociliary clearance mechanism. 
For example, mucociliary clearance alone is capable of clearing 50% of an 
administered nasal spray dose from the ciliated respiratory mucosa in less than 20 
minutes [38].  
 
 
 
Figure 1.5. Physiological barriers to mucosal drug absorption. 
In mucosal surfaces such as nasal bronchial and intestinal, epithelial cells are interconnected by tight 
junctions. Cells are covered by a thick mucus layer, which is normally secreted by goblet cells (not shown). 
Cilia beat in a synchronised fashion, resulting in unidirectional movement of mucus (represented by the grey 
arrow). This mucociliary clearance mechanism clears the mucus-trapped material (which may include 
administered drugs) from the mucosal surfaces in the nose and lung and acts as a lubricant in the 
gastrointestinal tract. 
 
Proteolytic enzyme action may limit the availability of peptide and protein therapeutics 
in their active form at the mucosal surface [39]. However, the physicochemical 
properties of plasma membranes of epithelial cells and the close proximity of adjacent 
cells, which is enabled by the existence of epithelial TJs, present the most severe 
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barriers to macromolecular drug absorption. These barriers are discussed in detail 
below.  
1.3.3  Intercellular tight junctions 
The intercellular TJs surround the intestinal epithelial cells in a belt-like manner at the 
apical cellular borders. They form a paracellular seal between the lateral membranes 
of adjacent epithelial cells and act as both a VWUXFWXUDO³EDUULHU´and a strict regulator of 
the paracellular movement of water, ions, neutral molecules and inflammatory cells 
[40-42]. The TJs also limit the diffusion of proteins and lipids between the apical and 
basolateral domains of the plasma membrane [43] and recruit cytoskeletal and 
signalling molecules involved in cell polarity, growth, differentiation and apoptosis [44].  
 
On ultrathin section electron micrographs, TJs are viewed as a series of fusion points 
between the outer leaflets of the membrane of adjacent cells [45]. Freeze-fracture 
replica electron micrographs depict the TJs as a continuous anastomotic network of 
filaments on the protoplasmic face of the plasma membrane, with complementary 
grooves on the exoplasmic face [45]. These lateral contacts, define the extent of 
paracellular permeability [46, 47], which in turn is directly proportional to the number 
and density of tight junctional strands. Furthermore, it appears that the degree of 
permeability is related to the physiological role of the underlying tissue, with intestinal 
epithelial cells displaying higher permeability compared with airway epithelial cells and 
cells derived from the gall bladder [48, 49].  
 
The TJs themselves are comprised of various cortical and integral proteins. Of the 
former, at least 16 different molecules have been discovered [45]. While some of 
these proteins serve as scaffolds linking the integral proteins of the TJ to the actin 
cytoskeleton, others serve as cross linkers of transmembrane junctional proteins. 
Many proteins also play key roles in vesicular trafficking through their association to 
kinases and Ras. At the TJ, three integral proteins are found: occludin, claudins and 
JAM (junction adhesion molecule), as well as cytoplasmic plaque proteins, including 
zonula occludens-1/2/3, cingulin and 7H6 [45]. Both the occludins and the claudins 
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consist of four transmembrane regions and two extracellular domains and interact with 
complementary molecules on adjacent cells leading to the creation of critical adhesion 
points [50]. These proteins comprise the backbone of the TJ strands. On the other 
hand, cytoplasmic plaque proteins are thought to link claudin and occludin to the actin 
cytoskeleton through PDZ (acronym for post synaptic density protein (PSD95), 
Drosophila disc large tumor suppressor (Dlg1), and zonula occludens-1 protein (ZO-
1)) domains. They cross-link the transmembrane junction proteins and play an 
important role in cell signalling and vesicular trafficking [44]. JAM is a glycosylated 43 
kDa protein with three distinct domains: an extracellular region of 215 amino acids that 
contains two variable type Ig domains, a single transmembrane domain, and a short 
intracellular tail (45 aa) that displays a classical type II PDZ binding motif [51].  
 
From the drug delivery perspective, TJs present a significant barrier towards mucosal 
delivery of biomolecular therapeutics such as proteins. This is expected in view of the 
fact that the dimensions of the paracellular space lie between ~20-50 Å and therefore 
larger solutes with a molecular radius within this range and greater are restricted to 
alternative routes of transmucosal transport (i.e. are inevitably excluded from the 
paracellular route) [52, 53].  
 
1.3.4  Gastrointestinal barriers 
The GI tract provides a variety of physiological and morphological barriers against 
protein or peptide delivery, including:  (i) proteolytic enzymes in the gut lumen (e.g. 
pepsin, trypsin, chymotrypsin), (ii) proteolytic enzymes at the brush border membrane 
(endopeptidases), (iii) the mucus layer, (iv) the bacterial gut flora and (v) the epithelial 
cell lining itself. The histological architecture of the gut mucosa is therefore designed 
specifically to selectively prevent the uptake of particulate matter from the 
environment.  
 
Mucus-covered enterocytes represent the largest population of cells in the mucosa of 
the small intestine (ca. 90%) [54]. They are arranged as a single cell monolayer at the 
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GI surface and serve to control the absorption of nutrients, electrolytes and fluids and 
function as barrier to the environment. Immunological surveillance occurring at the 
surface of the GI tract [55], presents a further barrier to the delivery of 
biomacromolecules.  
 
Highly specialised enterocytes situated in the intestinal tissue, the membranous 
microfold (M) cells, gather antigens and macromolecules from the GI surface. 
Morphologically, crypt-derived M cells [56] differ from absorptive enterocytes by 
possessing immature microvillus and glycocalyx structures, apical microfolds, 
increased intracellular vacuolisation and absence of mucus. Absorptive enterocytes 
and M cells constitute the follicle associated epithelia (FAE) RIWKH3H\HU¶VSDWFK. The 
FAE collectively shuttles colloidal (particulate) antigens, small bacteria and viruses via 
a transcytotic mechanism to lymphoid micro-compartments, which are in close 
proximity to their casing epithelia [55]. The PH\HU¶VSDWFKHV themselves are described 
as oval aggregates (assembled from solitary lymphoid nodules) situated in the 
antimesometrial gut wall (ileum) [57]. From a drug delivery perspective, the 
physiological role RI WKH 3H\HU¶V SDWFKHV (including the transport mechanism) is 
thought to be important for the delivery of nano-sized colloidal carriers. 
 
In the 1960s and 1970s, extensive research was conducted to decipher the nature of 
the enzymatic barrier in the intestines [58-61], with research initially focusing on its 
role in nutrient absorption. The hydrolysis of peptides and proteins occurs at different 
sites; either luminally, at the brush border, or intracellularly. Protein digestion is 
initiated in the gastric juice by a family of aspartic proteinases, commonly known as 
pepsins, which are most active at pH 2-3, but become inactive at a pH of above 5. The 
mixture of peptides resulting from the partial digestion of proteins in the stomach by 
pepsins will then be acted upon by pancreatic proteases upon reaching the duodenum 
and beyond. SXFK SURWHDVHV LQFOXGH WU\SVLQ Į-chymotrypsin, elastase, and 
carboxypeptidase A. These proteases act in concert to cleave the majority of the 
internal peptide linkages and have an optimum pH of about 8.  
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1.3.5  The mucus barrier 
The presence of mucus lining the mucosal surfaces is crucial for protection from 
invasion by foreign agents such as bacteria, viruses, allergens and irritants. Mucus 
also displays lubricating properties, important in assisting in daily functions such as 
eye movement and the passage of food through the digestive tract [11]. The mucus 
gel is largely composed of linear, glycosylated mucin fibres entwined in a dense 
network [62, 63], enabling particle entrapment and further hindrance of movement 
through the dense gel layer [64, 65]. The rate of diffusion through the mucus layer is 
thought to be affected by the relative size of the permeant, the effective mesh size of 
the mucus gel and interactions between the permeant and the components of mucus 
[66].  
 
Contrary to the initial belief that the mucus barrier prevents mucosal uptake of large 
molecules primarily by hindering their diffusion, it is now known that most proteins, 
including large antibodies diffuse relatively easily through mucus [67]. This is thought 
to be because the mesh size (approxLPDWHO\ȝP of mucin fibres within mucus  is 
much larger than most proteins, as demonstrated by an interesting study conducted 
by Saltzman and co-workers [68]. However, there is a body of evidence to suggest 
that human mucus largely prevents the movement of nanoparticles [69-71], which is 
an important consideration when designing a carrier-based therapeutic formulation for 
mucosal delivery.  
 
Various attempts have been made to enhance nanoparticle transport across the 
mucus layer ± a popular approach being attachment of polyethylene glycol (PEG) to 
the nanoparticle surface [69, 72]. In a study by Wang et al. [72], an alteration of the 
surface charge of negatively charged polystyrene particles (220 nm diameter) towards 
a more neutral charge, as a consequence of modification by short-chain length PEG, 
resulted in enhanced diffusion across cervicovaginal mucus. Furthermore, a reduction 
of PEG coating density on the surface of particles decreased the rate of particle 
transport, leading the authors to conclude that particle transport through mucus could 
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potentially be improved by the presence of a net neutral surface (to avoid binding to 
mucus) and a small radius to present entanglement with the mucin network. In a 
separate study reporting diffusion in cervical mucus, Cu et al. [73] examined the effect 
of immobilisation of different molecular weight PEG (2, 5 and 10 kDa) onto the surface 
of poly(lactic-coglycolic) acid (PLGA) nanoparticles (170 nm diameter).  Surface 
modification with PEG enhanced the diffusion of particles (by 3- to 10-fold compared 
to unmodified particles), with the extent of increase in diffusion being dependent on 
the molecular weight of PEG and the coating density. A study by Lai et al. [69] also 
demonstrated that relatively large (500 nm and 200 nm) PEGylated nanoparticles can 
rapidly penetrate human mucus, with an effective diffusion coefficient only 4- and 6-
fold lower than that for the same particles in water. Comparatively, the diffusion 
coefficient of uncoated particles of equivalent size was 2,400- to 40,000-fold lower in 
mucus than in water.  
 
1.4  Enhancing mucosal protein delivery: commonly 
investigated strategies 
Various approaches have been explored with the view to improve mucosal absorption 
and the subsequent bioavailability of protein therapeutics (Figure 1.6). These include 
the use of delivery systems that prolong the duration of drug contact with the mucosal 
surface (mucoadhesive polymers) [74, 75] (Figure 1.6A), chemical agents that 
increase membrane fluidity and/or disrupt cell membranes (e.g. surfactants) [76-78] 
(Figure 1.6B) and compounds that promote a transient opening of the epithelial TJs 
[79, 80] (Figure 1.6C). Receptor-mediated transcytotic pathways (Figure 1.6D) have 
also been exploited for the mucosal delivery of protein therapeutics (reviewed in 
section 1.4.3). Furthermore, chemicals that reduce mucus viscosity (mucolytics) [81-
84], those that improve the stability of the administered protein drug, e.g. proteolytic 
enzyme inhibitors [85, 86], and agents which trigger dissociation of protein aggregates 
(e.g. cyclodextrins) [87] have also been investigated. 
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Figure 1.6. Visited strategies for improved mucosal absorption of protein therapeutics.  
A) Mucoadhesive polymers prolonging the residence t ime of the complexed protein drug 
at the mucosal surface, B) Surface-act ive permeabil i ty enhancers compromising cel l  
membrane integri ty,  whereby otherwise membrane -impermeable protein drug crosses the 
epithel ial barrier,  C) TJ opening where the paracel lular space is increased, improving the 
paracel lular access of protein molecules, and D) Exploit ing epithel ial t ranscytot ic 
mechanisms by conjugating the drug (or a drug carrier nanopart iculate system) to a 
l igand (not shown) that is transported transepithel ial ly v ia thisroute.  
 
1.4.1 Surfactants and tight junction modulating absorption enhancers  
A range of ionic and non-ionic surfactants have been explored for their potential as 
mucosal absorption enhancers [88-90]. However, many investigations have revealed 
that the use of surfactants as permeability enhancers is associated with cell toxicity, 
frequently observed in the form of cell membrane damage, altered cell morphology 
[88, 91, 92] and mucociliary arrest [93], which fundamentally flaws their application.  
 
The biodegradable, biocompatible,  compound chitosan (deacetylated form of chitin) is 
by far the most extensively studied polymeric absorption enhancer [94, 95]. Chitsosan 
has been approved for use in wound dressings and for dietary applications the USA 
by the FDA and by comparable institutions in several other countries. Its capacity to 
enhance macromolecule absorption across the mucosae has been demonstrated in 
numerous studies, both in vitro [80, 96] and in vivo [97-99]. Chitosan displays mildly 
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basic properties and requires acidic conditions to transform it into the positively 
charged, water-soluble form. Therefore, at neutral or physiological pH most chitosan 
molecules will lose their charge and precipitate from solution [100], which is a problem 
from the drug delivery perspective. To overcome this problem, chitosan derivatives 
such as N-trimethyl chitosan chloride (TMC) and PEGylated chitosan have been 
synthesised in an attempt to improve its solubility at neutral pH. Both these derivatives 
demonstrate absorption enhancing properties: in an aqueous solution, in the 1.5±2.5% 
concentration range, TMC was found to markedly increase the permeability of peptide 
drugs (buserelin and porcine insulin) across Caco-2 monolayers at pH 7.4 [96]. 
Although PEGylation notably improves the aqueous solubility of chitosan at neutral 
pH, this derivative still required mildly acidic conditions for a permeability promoting 
effect [79]. 
 
Different compounds with an ability to bind calcium so to reduce its extracellular 
levels, have been investigated for their potential to enhance the mucosal absorption of 
macromolecules via the paracellular route. This is due to early studies showing that 
depletion of extracellular calcium induces opening of the epithelial TJs [48, 101], 
thereby increasing paracellular permeability [48, 102-105]. Despite these studies, the 
conditions under which calcium reduction sufficiently modulates the epithelial barrier to 
result in meaningful improvements in mucosal drug absorption are unclear. In this 
respect, recent work from our group by Vllasaliu et al. [106] revealed that apical 
calcium removal produces only a modest effect on the tight junctions, whilst 
basolateral calcium exhaustion leads to a notably larger effect on the epithelial barrier. 
This is important from the drug delivery perspective as removal of calcium on the 
basal (as opposed to the luminal) side of the epithelium is probably unrealistic, hence 
rendering this approach inefficient for enhancing mucosal delivery of macromolecules.    
 
Some of the more recent studies have employed relatively novel experimental 
approaches, such as RNA interference, to identify and exploit TJ targets for 
paracellular drug delivery. For example, Dutzar et al. [107] evaluated the effects of 
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siRNA knockdown of different TJ proteins (different claudins, JAM-1 and occludin) in 
assays establishing the effect on the epithelial barrier. The work reported that 
knockdown of claudin 4 inhibited TJ formation and produced a significant decrease in 
transepithelial electrical resistance (TEER) and an increase in FD4 permeability. 
Combination knockdowns between claudin 4 and occludin or JAM-1 were found to 
produce synergistic effects.  
 
1.4.2 Bioadhesive polymers 
The use of bioadhesive polymers as a means of delivering therapeutic agents to the 
gastrointestinal tract has attracted considerable attention in recent decades [108, 109]. 
Bioadhesive oral drug delivery systems are based on the concept that an interaction 
will occur between the mucus and the bioadhesive material (usually polymer) included 
in the drug formulation. This strategy offers advantages such as site specific drug 
delivery and prolonged residence time at the mucosal surface for improved absorption 
and bioavailability [110, 111]. With such systems, an improvement in oral 
bioavailability is often noticed as a direct consequence of more opportunity for the 
therapeutic to interact closely with the absorption site [112, 113]. The ability to retain 
an oral delivery system at the target location over a prolonged duration also potentially 
enables treatment of local conditions and may permit sustained systemic absorption 
[114, 115]. Despite extensive research on bioadhesive polymer systems, the 
phenomenon of bioadhesion is not yet entirely understood [116]. The term 
bioadhesion is defined as adhesion to a biological surface (i.e. mucus, mucosal 
surface or cell membranes). The scenario in which the polymeric system interacts with 
the mucus coating only is referred to as mucoadhesion [117].  
The complex interactions between bioadhesive polymers and mucus are governed 
largely by the intrinsic properties of the concerned polymer and the surrounding 
physiological environment [118]. Physiologically, the gastrointestinal mucosa is 
composed of high  MW glycoproteins underlying a continuous adherent blanket of 
mucin [119]. The consistency of the mucin gel is affected by the glycoprotein 
concentration. The mucin glycoproteins are rich with fucose and sialic acid groups at 
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their terminal ends housing a net negative charge in the acidic environment. The 
thickness of the mucin layer raQJHVEHWZHHQDQGȝPLQWKHVWRPDFKWR±150 
ȝPLQWKHFRORQThe variation in thickness is attributed to the steady state equilibrium 
between the mucus secretions and its erosion via mechanical and enzymatic 
degradation.  
The vast majority of bioadhesive drug delivery systems are based on hydrophilic 
hydrogel polymers and are designed primarily for buccal or sublingual applications 
[120]. The use of these hydrophilic polymers for GIT delivery would result in untimely 
hydration upon contact with the stomach contents, before developing interactions with 
the mucosal surface. A bioadhesive system for gastric delivery requires a rapid 
interaction with the mucosal surface, which must be sufficiently strong to resist the 
propulsion forces of the stomach wall. The system must remain effective irrespective 
of continuous production of mucus by the gastric mucosa to replenish the mucus that 
is lost through peristaltic contractions, as well as dilution of the stomach contents. 
Hydrophilic bioadhesive polymers often lose adhesiveness upon hydration, therefore, 
in order to prolong the adhesion, controlled hydration and/or formation of a firm gel 
network are desirable attributes [121]. The environmental pH is another important 
factor influencing the success of a bioadhesive system, as shown by recent studies 
indicating that the bioadhesiveness of polymers with ionisable groups, such as 
polyacrylic acid, is affected by surrounding pH [122]. As with the other classes of 
absorption enhancers, bioadhesive polymers/systems must be biocompatible and not 
trigger local tissue irritation or long-term toxicity. Other desirable characteristics of a 
bioadhesive dosage form include high drug loading and complete drug release.  
1.4.3  Encapsulation systems  
Minimisation of drug degradation and loss, prevention of harmful side-effects of the 
therapeutic, optimal drug bioavailability and site specific absorption are important 
requirements for some therapeutics. These attributes can potentially be achieved by 
encapsulating the therapeutic ZLWKLQµFDUULHUV¶. Various such carrier systems are under 
development, ranging from nano- and micro-particles made of insoluble or 
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biodegradable natural and synthetic polymers, to liposomes and micelles. These 
carriers can be tailored to suit the therapeutic need or route of administration. 
Researchers have endeavoured to produce (singularly or in combination) bio-
degradable, stimuli-reactive (e.g. pH- or temperature-sensitive) and target responsive 
systems, which anchor the drug-loaded system to the site of interest. These targeted 
systems can be further classified into passive and active targeting strategies. The 
former is best exemplified in the case of the preferential accumulation of 
chemotherapeutic agents in solid tumors as a result of the enhanced vascular 
permeability of tumor tissues compared with healthy tissue [123]. Active targeting 
involves the surface functionalisation of drug encapulated systems with ligands that 
are selectively recognised by receptors on the surface of the cells of interest. Since 
ligand±receptor interactions can be highly selective, this could allow a more precise 
targeting of the site of interest.  
Colloidal drug encapsulation systems such as micelles, vesicle and liquid crystal 
dispersions, as well as nanoparticle dispersions consisting of small particles of 10±400 
nm in diameter, have attracted considerable attention in recent years. In the late 
1960s, micelles became popular as drug carriers owing to their easily controllable 
properties and good pharmacological characteristics [124, 125]. Micelles formed from 
hydrated amphiphiles consist of an inner core of assembled hydrophobic segments 
capable of solubilising lipophilic substances and an outer hydrophilic corona serving 
as a stabilising interface between the hydrophobic core and the external aqueous 
environment [126]. Depending on the delivery purpose, one can select the size, 
charge, and surface properties of these carriers simply via the addition of new 
ingredients to the mixture of amphiphilic substances before micelle preparation and/or 
by variation of the preparation method [127]. Micelles as drug carriers potentially offer 
many advantages. Drug bioavailability is potentially enhanced by the ability of micelles 
to physically entrap the sparingly soluble pharmaceutical and delivering it to the 
desired site of action at concentrations that can exceed its intrinsic water solubility. 
Furthermore, the drug is potentially protected as its contact with inactivating species, 
such as enzymes present in biological fluids, is minimised [128-130]. By far, the most 
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important feature of micellar delivery systems distinguishing them from other 
particulate drug carriers, is their small size (~10 to 30 nm) and the narrow size 
distribution [131].  
Liposome carriers, which are capable of entrapping lipid-soluble drugs in the lipid 
bilayer and water-soluble drugs in the aqueous core [132], are another popular drug 
encapsulating strategy. Routine preparations are carried out under relatively mild 
conditions, thereby minimising drug denaturation during encapsulation. However, a 
significant disadvantage arises from their susceptibility to degradation by intestinal 
phospholipases and sensitivity to intestinal detergents (e.g. bile salts).  Consequently, 
this degradation will trigger the premature release of the liposome-entrapped drug in 
the GI fluid [133, 134]. Other colloidal formulations, including emulsions and 
microemulsions, are effective in the oral administration of drugs with inadequate 
solubility in biological fluids [135, 136]. Microemulsions (oil/water) are bicontinuous 
systems composed of a continuous water phase containing nanometer-sized oil 
droplets, separated by a surfactant/co-surfactant-rich interfacial region [127]. 
Compared to emulsions, these offer several additional advantages, such as ease of 
preparation and good thermodynamic stability [136]. However, administration of 
microemulsions has triggered unwanted effects in vivo, especially formulations based 
on castor oil, wherein renal dysfunction, hypertension, and hepatotoxicity have been 
reported [127, 137]. 
More recently, nanoparticle-based encapsulation systems ranging in size from ~15 to 
150 nm [138, 139] such as nanospheres [54] and nanocapsules [140, 141], hydrogels 
[4, 142, 143] and drug-coated silica particles have become popular. In terms of 
polymers investigated in nanocarrier formulations for oral drug delivery, there is a 
broad range of materials used for this application, including poly(alkylcyanoacrylates) 
[141] and terpolymers of methyl methacrylate, 2-hydroxyethylmethacrylate, and n-
butylacrylate [144]. The reader is referred to additional references for a more 
comprehensive review of these systems [145-149].  
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1.4.4  Ligand-receptor mediated drug delivery 
Biological processes of receptor-mediated cellular uptake and transport have become 
attractive in the field of drug/gene delivery in the past several years. These processes 
can potentially be exploited for designing site-specific delivery systems. Ligand-
mediated active targeting has emerged as a novel paradigm in targeting either 
vascular compartment (first-order), cellular (second-order), or intracellular (third-order) 
levels [150]. Some of the drug carrier systems described above can potentially be 
used as cargo units for the site-specific presentation and delivery of various bioactives 
using biorelevant ligands, including antibodies, polypeptides, oligosaccharides 
(carbohydrates), viral proteins, fusogenic residues, and molecules of endogenous 
origin. Of particular relevance in this thesis, is the use of ligand-functionalised 
nanoparticulate systems (as carriers of therapeutics) for transmucosal delivery of 
biotherapeutics. The biological transport systems targeted by these appropriately 
formulated drug delivery systems are diverse and include carbohydrate (lectin) 
receptors, Fc receptors, complement receptors, interleukin receptors, lipoprotein 
receptors, transferrin receptors, scavenger receptors, receptors/epitopes expressed 
on tumor cells, and cell adhesion receptors.  
1.5 Crossing the epithelium via the transcytotic route: cellular 
uptake and trafficking of protein therapeutics 
1.5.1  Endocytosis in epithelial cells 
Mucosal drug absorption via the transcellular route is wholly dependent on 
overcoming the plasma membrane barrier at the epithelial cell surface. Generally 
speaking, clathrin- or caveolin-mediated endocytosis, macropinocytosis and 
phagocytosis are all extensively described endocytic mechanisms which play an 
important role in the uptake of macromolecules [151]. Moreover, alternative, clathrin- 
and caveolin-independent pathways have also been implicated in the cellular uptake 
of material [152]. A schematic representation of these endocytic pathways is 
presented in Figure 1.7. From a systemic mucosal drug delivery perspective, the 
therapeutic must be both effectively internalised via epithelial cells and sufficiently 
transported and released at the basolateral side.  
Chapter 1: Delivery of protein therapeutics across mucosal surfaces 
22 
 
 
 
Figure 1.7. A schematic representation of cell endocytosis pathways.  
Large particles can internalise via phagocytosis, whereas fluid uptake occurs by macropinocytosis (A). 
Phagocytosis and Macropinocytosis events often result in the formation of larger vesicles.Cargoes can also 
be endocytosed by mechanisms which are independent (B, F) of the coat protein clathrin (C) and the fission 
GTPase, dynamin (D, E). Most internalised cargoes are delivered to the early endosome through vesicular 
(clathrin- or caveolin-coated vesicles) intermediates derived from the plasma membrane. Some pathways 
may first traffic to intermediate compartments, such as the caveosome before reaching the early endosome. 
Adapted from [153]. 
1.5.1.1  Clathrin-mediated endocytosis 
Clathrin-mediated endocytosis, which is responsible for the internalisation of nutrients, 
pathogens, antigens, growth factors and receptors, is the most extensively 
characterised mechanism for the entry of molecules into cells. Detailed progression of 
the entire process has been explicitly detailed in a number of reviews [154, 155]. In 
short, integral membrane proteins (e.g. activated receptors) bind to cytosolic adaptors, 
which then form links to the clathrin lattice. Accessory proteins, such as the GTPase 
dynamin, play a crucial role in the process of endocytosis, e.g. through initiating 
clathrin polymerisation or inducing membrane curvature. Furthermore, both adaptors 
and accessory proteins have the capacity to bind PtdIns(4,5)P2, a phospholipid 
concentrated at sites of clathrin-mediated endocytosis [156-159]. Important roles for 
actin have also been demonstrated in the process of clathrin-mediated endocytosis 
[160]. Lastly, the nascent coated vesicle is severed from the plasma membrane 
through a fission reaction thought to be mediated by dynamin [161]. 
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1.5.1.2  Clathrin-independent endocytosis 
Clathrin-independent endocytosis can be further sub-divided into dynamin-dependent 
and dynamin-independent processes [152]. Of the former, caveolae-mediated 
endocytosis is perhaps the most extensively characterised. Caveolae are inverted 
omega-shaped invaginations with a maximal diameter of 50-100 nm, connected to the 
plasma membrane or plasmalemma by a neck-like structure, which provides spatial 
continuity with the extracellular environment [162]. The principal component, which is 
also a crucial functional element, is a protein called caveolin [163]. Cholesterol is 
another essential component of caveolae and is required to maintain structural 
integrity; caveolae disappear in cells that are depleted of cholesterol [164]. 
Functioning as both intracellular and transcellular transport systems, caveolae appear 
to deliver their cargo either to endosomes or across the cell to opposite cell membrane 
surface [165]. This transcytosis process is thought to occur by one of two mechanisms 
- either caveolae could either pinch off from the plasma membrane, travel across the 
cell and fuse with the opposite surface, or, they may transiently fuse with each other 
producing channels through which material passes [35]. In contrast to the classical 
clathrin-dependent pathway, there is evidence that caveolar internalisation avoids 
lysosomes and hence the degradation of engulfed material [166]. The ability to 
distinguish the caveolae-mediated pathway from both clathrin-mediated and 
pinocytosis routes using cholesterol depleting agents such as filipin, nystatin, or 
methyl-cyclodextrin gives researches an important tool to characterise biological 
mechanisms of cell internalisation and transport (discussed in more detail in Chapter 5 
of this thesis).  
1.5.2  Cellular uptake and transport of cargo across epithelial cells 
Poor absorption of macromolecular drugs across the mucosal surfaces in part result 
from the low rate of endocytotic activity occurring at the apical plasma membrane of 
epithelial cells, which can be further attributed to the important physiological role of the 
epithelium, which selectively filters and discriminates foreign substances in order to 
protect cells and organs from the external milieu [167]. This is best exemplified in 
Chapter 1: Delivery of protein therapeutics across mucosal surfaces 
24 
 
polarised cells where a higher rate of endocytosis operates at the basolateral plasma 
membrane (several-fold higher) than at the apical plasma membrane [168, 169].   
 
However, polarised epithelial cells demonstrate some capacity to internalise 
macromolecules from both apical and basolateral plasma membrane domains [170]. 
Researchers commonly employ Madin-Darby Canine Kidney (MDCK) cells to study 
membrane trafficking in polarised epithelial cells [171], where endocytosis has been 
found to occur by both clathrin-dependent and clathrin-independent mechanisms 
[172]. Following cellular internalisation (from both apical and basolateral membranes), 
fluid-phase markers (cargo) have been shown to enter distinct populations of apical 
early endosomes and basolateral early endosomes [173, 174]. The fate of this 
material is entirely dependent on the cell sorting machinery, with a proportion of 
apically internalised fluid thought to either recycle or transcytose, and the remainder 
delivered to a shared population of late endosomes and lysosomes [170]. This 
becomes an important focus in later sections of this thesis.  
1.5.2.1  IgG/FcRn pathway 
Immunoglobulin G (IgG) is actively transferred from mother to offspring, conferring 
short-term passive immunity [175, 176]. In addition, IgG has been shown to traverse a 
number of mucosal surfaces in man ± a process that is important in immune 
surveillance and host defense at mucosal surfaces [177]. IgG is transported by the 
neonatal Fc receptor (FcRn) [178, 179], which undergoes transcytosis in both apical-
to-basolateral and basolateral-to-apical directions [180]. Briefly, IgG either binds to 
FcRn at the apical surface of the cells or is internalised by fluid phase endocytosis, 
encountering FcRn in the apical early endosome. Thereafter, IgG/FcRn is either 
delivered to the apical recycling endosomes or to the common recycling endosomes. 
Within the recycling endosomes, IgG/FcRn is sorted into coated vesicles that could 
serve as exocytic carriers to the basolateral cell surface [180].  
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The IgG/FcRn transport pathway could potentially be exploited for mucosal delivery of 
biotherapeutics (for a systemic effect) as this system is functional in several organs 
and tissues, including the lung [181] and intestine [182]. The expression of the FcRn 
receptor in the lung presumably results from the differentiation of mesenchymal stem 
cells (common progenitors) in early development. Previous studies investigating 
pulmonary absorption of therapeutic proteins (erythropoietin and follicle-stimulating 
hormone) through the FcRn pathway in non-human primates showed promising 
results [183, 184]. Furthermore, Bitonti et al. [185] demonstrated a dose-dependent 
absorption of protein therapeutics following pulmonary administration in healthy male 
volunteers. A recent publication from our group by Vllasaliu et al. [186] evaluated the 
IgG/FcRn pathway for mucosal delivery of nanoparticles as therapeutic carriers across 
airway Calu-3 cells, documenting a potential for Fc-PRGLILHGQDQRSDUWLFOHVWRµVKXWWOH¶
a model therapeutic antibody fragment across the airway mucosa.  
1.5.2.2  Folate-mediated pathway 
Folic acid is a vitamin necessary for one-carbon transfer reactions in several metabolic 
pathways. Because folic acid is essential for the biosynthesis of nucleotide bases, the 
vitamin is consumed in vast quantities by proliferating cells [187]. Normal cells 
transport physiological folates across the plasma membrane using either the reduced 
folate carrier or the glycosylphosphatidylinisotol (GPI)-anchored folate receptor (FR). 
The former is found in the majority of cells and constitutes the primary pathway 
responsible for the physiological uptake of folates. The latter is primarily found on 
polarised epithelial cells and activated macrophages [188, 189] and preferentially 
binds and internalises oxidised folates via receptor-mediated endocytosis [190]. FR is 
over-expressed in cancer cells, making it an obvious target for ligand- and antibody-
directed cancer therapeutics [191]. FR is capable of transporting both folic acid and a 
variety of different folate-linked cargos (i.e. imaging agents, proteins, liposomes, 
chemotherapeutics, nanoparticles, etc.) [192]. Following FR binding at the cell surface, 
folate conjugates are internalised via receptor-mediated endocytosis [193-195].  
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Receptor-mediated uptake of folate-drug conjugates proceeds through a series of 
stages, commencing with conjugate binding to cell surface FR and ending with the 
release of a portion of the therapeutic entity into the cytoplasm. Following membrane 
invagination and internalisation to form an endocytic vesicle, acidification of the 
endosomal compartment to pH 5 results in release of some (but not all) folate 
conjugates from their receptor [196, 197]. Subsequent trafficking of the acidic 
endosome to a recycling intracellular region then allows separation of membrane-
bound FR from released conjugates/free drug [192]. Released folate conjugates are 
thought to be able to circumnavigate the endosome via an unknown mechanism, 
resulting in drug deposition in the cytoplasm. In contrast, membrane-bound-FRs 
largely recycle back to the cell surface, allowing for delivery of additional folate-linked 
drugs into the cell. Moreover, it has been observed that relatively few folate 
conjugates enter lysosomes for destruction [198], which has important implications for  
delivery of sensitive drugs.  
 
There have been conflicting reports on the mechanism of endocytosis and subsequent 
trafficking of GPI-anchored FR [199, 200], with early studies disputing internalisation 
via the clathrin-mediated pathway [201] and postulating that the receptor is organised 
into submicron domains at the cell surface. These studies also claimed that the GPI-
anchor was responsible for mediating receptor clustering in association with caveolae 
[199]. Further investigations revealed that the multimerisation of the GPI-anchored FR 
does not occur in caveolae but instead remains diffuse across the cytoplasm pending 
folate binding [200]. Later studies indicated that the GPI-anchor organises the FRs 
LQWR ³OLSLG-UDIWV´ RU UHFHSWRU-rich complexes at the plasma membrane. These 
submicron domains (<70 nm in diameter) were found devoid of caveolae but rich in 
sphingolipid and cholesterol [202, 203]. 
 
In terms of exploiting folate mediated pathway for mucosal delivery, a recent study by 
Moradi et al. [204] investigated the internalisation of folate decorated nanoparticles in 
airway Calu-3 cells. More specifically, the study determined the effects of surface 
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folate-ligand distribution pattern (ligand clustering and density) on the extent of 
internalisation. The model particulate system consisted of polystyrene nanoparticles, 
surface-decorated via the adsorption of ovalbumin with conjugated folate ligand. The 
authors demonstrated that increasing overall ligand density on the nanoparticle 
surface resulted in increased nanoparticle internalisation, up to a saturation point. 
Surface ligand density was also shown to affect the cellular uptake pathway, with a 
switch from predominantly clathrin to predominantly caveolae-mediated route as the 
ligand density was increased. The study also inferred that surface clustering of the 
folate ligand enhanced cellular internalisation of nanoparticles, relative to its dispersed 
surface distribution.  
1.5.2.3  Vitamin B12-mediated pathway 
Like folate, the consumption of vitamin B12 (B12; cobalamin) is vital for the survival of all 
living cells and although bacteria naturally produce vitamin B12, all other species must 
acquire it through their diet [205]. The cobalamin family comprises molecules with a 
central cobalt atom, surrounded by a tetrapyrrole ring similar to chlorophyll or 
porphyrin. The core of vitamin B12 is often referred to as a corrinoid or corrin ring [206]. 
The cobalt atom is DGGLWLRQDOO\DWWDFKHG WRDQXFOHRWLGH¶-di-methylbenzimidazole 
ribonucleotide) and another group, which dictates its nomenclature (Figure 1.8). 
Attachment of cyanide as a sixth ligand produces cyanocobalamin (vitamin B12). An 
attached hydroxyl group yields hydroxycobalamin (vitamin B12a), which is also the 
dietary form. There are two predominantly active forms of B12: methylocobalamin and 
adenosylcobalamin, which adopt essential roles in intracellular metabolism. 
Methionine synthase uses methylcobalamin to produce the amino acid methionine 
from homocysteine, and methylmalonyl-CoA mutase uses adenosylcobalamin as a 
cofactor to produce succinyl CoA, which is important in the tricarboxylic acid (TCA) 
cycle [207]. Mammals have evolved a complex uptake pathway for B12 involving a 
series of transport proteins [207-209]. In this thesis, the uptake pathway is covered in 
considerable depth. However, the distinct roles of the transport proteins are discussed 
only superficially. Amongst the cobalamin binding proteins, transcobalamin II (TCII) 
and intrinsic factor (IF) are probably the most physiologically important [206]. The 
Chapter 1: Delivery of protein therapeutics across mucosal surfaces 
28 
 
reader is referred to recent reviews by Banerjee et al. [207] and Randaccio et al. [210] 
for a more in depth discussion of these transport proteins.  
 
Figure 1.8. Chemical structure of vitamin B12. Taken from [211].  
Cyanocobalamin is moderately soluble in water at room temperature (12 g/L) and also 
in lower alcohols and phenol. It is, however, insoluble in acetone, ether and 
chloroform. B12 is neutral in water and is stable within the pH range of 4-7. The 
molecular weight of B12 is 1355.4 g/mol and its empirical formula reads 
C63H88N14O14PCo [212]. Several functional groups are readily available for 
modification on B12. Of importance, however, only a few modification sites maintain 
the recognition needed to utilise the biological B12 uptake pathway for oral delivery 
[205] (See Chapter 4 for further details).  
 
The absorption of B12 in humans is complex (Figure 1.9) [213, 214]. Upon ingestion, 
B12 is initially released from the food by the action of peptic enzymes and the acidic 
environment of the GI system [215]. This is then followed by binding to and transport 
by two glycoproteins, haptocorrin (HC; also sometimes referred to as cobalophilin, R 
binder and transcobalamin I) and IF [208]. HC is the first protein to bind to B12, in the 
saliva and gastric secretions, and has a high affinity for B12 under acidic conditions 
(pH < 3) thus protecting B12 from acid hydrolysis. The HC:B12 complex travels from the 
stomach to the duodenum, where the higher pH decreases the affinity of HC for B12 
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[216]. Following its release from HC (which is subsequently enzymatically digested), 
B12 binds to IF ± a 43.4 kDa glycosylated protein secreted from the pancreas and 
gastric mucosa [208]. IF facilitates transport across the intestinal enterocyte, which 
occurs by receptor-mediated endocytosis, via the apically located IF-B12 receptor, 
cubilin [217]. Cubilin works synergistically with amnionless, an anchoring protein to 
transport B12 [215]. Cathepsin L degrades IF within the lysosomes of the enterocytes 
[218]. A  fraction of vitamin B12 will inevitably pass into the circulation by passively 
diffusing through the ileum [219]. 2-4 hrs following ingestion, B12 transcytoses across 
the enterocytes, appearing in the blood plasma bound to transcobalamin II (TCII). 
Holo-TCII is internalised by the TCII-receptor (TCII-R) situated on the basolateral side 
of metabolically active cells [220]. Another receptor, megalin can reabsorb holo-TCII 
from primary urine. Thus, TCII-R and megalin receptors act in concert to ensure 
widespread delivery and maximal use of B12 in the body. 
 
The exploitation of B12 cell transport route for drug delivery purposes undoubtedly 
requires knowledge of the binding between B12 and its various transport proteins and 
the resulting receptor recognition, cell uptake and trafficking of B12 bioconjugated 
pharmaceuticals. These phenomena have implications for formulation design and drug 
delivery. The potential of the vitamin B12 pathway for mucosal delivery of nanoparticles 
as potential carriers of biotherapeutics is central to this thesis and will be explored in 
Chapters 4-7.  
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Figure 1.9. Cellular uptake of B12 from dietary sources.  
The uptake capacity of B12 is ~2.5 µg per day for an adult human [221]. HC: Haptocorrin; IF: Intrinsic factor; 
Am: Amnionless; Cb: Cubilin receptor; Mg: Megalin; TCII: Transcobalamin II; TCII-R: Transcobalamin II 
receptor. Adapted from [205].  
 
1.5.3  Exploiting transcytotic systems for mucosal delivery: general 
considerations 
Although efforts have been made to identify cargo, uncover numerous cellular 
pathways and delineate the possible mechanisms involved, many issues remain 
unaddressed in attempts to successfully exploit the self-functioning cell machinery for 
therapeutic delivery. Firstly, the choice of the in vitro model(s) to study transcytosis is 
of paramount significance. The use of in vitro cell models to investigate transcytosis 
has many advantages over in vivo systems. Animal variability is eliminated, as is the 
perplexing issue of cargo being either modified or engulfed by cell types other than the 
one under study. Furthermore, in vitro systems can be manipulated in ways not 
possible in vivo, enabling one to measure the effects of different variables (e.g., 
temperatures, pharmacological agents, etc.) with greater accuracy and precision and 
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to uncover the molecular mechanisms of transcytosis. These advantages however, 
are compensated by the loss of in vivo context (e.g. the role of the extracellular matrix 
and the influence of other cell types). In view of this, one should employ a degree of 
caution when extrapolating in vitro results to the in vivo situation and when comparing 
results obtained from the two systems. To this end, researchers should also be wary 
of findings obtained from cancerous cell lines, which is especially relevant in the case 
of transcytotic systems, whereby over-expression of receptors and other transporters 
may give the misguided impression of high levels of transcytotic activity and hence 
drug delivery, when in reality this activity may be of a therapeutically limited capacity. 
Another important consideration is the functioning of the biological process of 
transcytosis in health and disease. Evidence of dysfunctional transcytosis in some 
disease states has recently emerged, with recent studies implicating abnormal 
enterocyte transcytosis in the early etio-SDWKRJHQHVLVRI&URKQ¶VGLVHDVH[222].  
Currently, drug delivery via the biological cell uptake/transport is restricted by an 
overall lack of understanding in the complex cell sorting processes involved at the 
molecular level. Our understanding of how the cell is effectively able to discriminate 
between cargo destined for transcytosis versus degradation in the lysosomes remains 
poor. In peripheral endothelial cells, apparently separate entry points dictate different 
fates; internalisation via coated pits sends cargo to the endocytic pathway, whereas 
caveolae-mediated internalisation will ensure a transcytotic fate [35]. In epithelial cells, 
the transcytotic pathway is a recognised branch of the endocytic pathway, but the 
destination and the point at which the transcytotic cargo is sorted away from the 
remainder of the internalised material remains a mystery. And although in some cases 
signals have been identified in distinct regions of molecules, governing their sub-
cellular fate, the precise means of recognition is not fully understood. In enterocytes, 
megalin recycles to the plasma membrane from endosomes after internalisation and 
dissociation from its transcytotic cargo. But by contrast, in the thyroid, the same 
membrane receptor escorts thyroglobulin across the cell [35]. Whilst researchers have 
been able to pinpoint alternative navigation routes for megalin which appear to be cell 
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or tissue dependent, the crucial signals which drive it along these different itineraries 
remain unidentified.  
 
Another unsolved mystery is how the cell discriminates cargo for transcytosis and 
cargo intended for its own use. Transcytosis is not the only pathway that molecules 
take to a specific plasma membrane domain and the mechanisms which regulate 
vesicular transport are highly complex. Knowledge of the binding between a ligand 
and its various carrier proteins and receptors is essential if the system is to be 
successfully exploited in drug delivery.  
 
1.5.4  Nanoparticle-mediated delivery of protein therapeutics 
The pharmacokinetics and biodistribution of drugs can be tailored to the therapeutic 
need through the selection of an appropriate drug delivery system [223]. Maintaining 
constant localised drug delivery to a target site exerts a greater therapeutic effect with 
potentially lower systemic drug levels than alternative dosing methods. Therapeutic 
molecules, including proteins, can be encapsulated inside carrier systems composed 
of materials such as polymers and lipids. As discussed in the earlier sections of this 
chapter, this encapsulation may protect the therapeutic and provide controlled drug 
release.  
 
The following attributes are desirable for nanoparticles used for drug delivery: a 
particle core, a biocompatible protective layer, and a linker molecular layer for 
bioactivity [224]. The linker layer comprises reactive groups at both ends, permitting 
attachment of the linker to the core and to the bioactive molecules. Conjugation of 
functional groups can enhance biocompatibility, increase circulation times, and ensue 
selective targeting of nanoparticles. Hydrophilic polymers, such as PEG, are often 
coated onto the surface of nanoparticles to minimise their uptake by the 
reticuloendothelial system (RES) and thus increase the circulation time of 
administrated nanoparticle-linked drugs. This is important as nano-scale drug carriers 
administrated systemically have been shown to be taken up primarily by the RES 
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through the phagocytotic pathway [225, 226]. Liposomes coated with PEG display 
longer circulation times after intravenous administration in mice [227]. 
 
For nanoparticle-mediated drug delivery, size ranges of 10 to 200 nm are typically 
employed. The small size allows nanoparticles to penetrate tissues, especially tumors 
with a high level of specificity [228], improving the targeted delivery of drug. Table 1.2 
broadly summarises the types of nanoparticles developed so far for enhancing drug 
delivery.  
Particle Class Materials Size Toxicity Application 
liposomes lipid mixtures 30-200 nm low drug/gene delivery 
dendrimers branched polymers 5-50 nm depends on cell type drug/gene delivery 
polymer carriers 
polylactic acid, 
polysaccharides, 
poly(cyano)acrylates, 
poly(lactide-co-
glycolide) 
50-2000 nm low drug/gene delivery 
magnetic 
nanoparticles Iron oxide 100-200 nm low 
diagnosis/drug 
delivery 
gold 
nanoparticles 
chlorauric acid, 
sodium citrate 30 nm - 1.6 µm low drug delivery 
 
Table 1.2. Applications of nanoparticles in Drug/gene delivery [224]. 
From a pharmaceutical perspective, polymeric nanoparticles are of great interest 
owing to their potential resilience in the GI tract and the protection provided for 
encapsulated drugs. By incorporating various polymeric materials within or on the 
nanoparticle surface, the physicochemical properties (e.g. hydrophobicity and surface 
charge) can be modulated to improve behavioural characteristics in the physiological 
environment. The targeting of nanoparticles, bioadhesive properties and cellular 
uptake can be greatly enhanced and the drug release properties tailored to suit the 
therapeutic need [229]. In modifying the surface of the nanoparticle by adsorption or 
chemical grafting with molecules such as PEG, poloxamers and bioactive components 
(e.g. lectins and invasins), they are further protected from the harsh gastrointestinal 
environment and this further helps to enhance their transmucosal transport [230-232].  
 
In terms of the types of materials employed to formulate nano-scale therapeutic 
carriers, biodegradable and biocompatible PLGA is perhaps the most widely used 
material for synthesising nanoparticles for sustainable drug release [233-236]. PLGA 
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is non-toxic and displays a good sustained release profile (through diffusion and by 
the degradation of the nanoparticles) [237, 238]. PLGA undergoes hydrolysis following 
administration, forming biocompatible and metabolisable moieties such as lactic acid 
and glycolic acid, which are later removed from the body by the citric acid cycle [239]. 
These nanoparticles are generally made by emulsion solvent evaporation or by 
solvent displacement techniques [240].  
 
The surface properties of nanoparticles have important implications for their in vivo 
fate, including nanoparticle-cell interaction, in addition to drug release properties [241]. 
In view of this, alteration of the surface properties of nanoparticles becomes critical to 
targeted drug delivery [242], with surface conjugation or coating of ligands that 
specifically bind to target cells or tissues, being a common approach. The choice of 
such ligands depends on the desired application of the delivery system, with 
antibodies [243], folate [244, 245] and peptides [246] commonly explored for targeted 
drug delivery in cancer therapy.  
 
Considering the use of nano-carriers for systemic drug delivery following oral 
administration, considerable efforts have been made to improve nanoparticle 
formulation and uptake through the intestinal mucosa. However, some important 
questions remain: is it possible for nanoparticles to reach the systemic circulation in 
sufficient number to induce the desired pharmacological response? The majority of 
studies conducted for drug delivery research purposes, generate assumptions from 
data based on in vitro cell transport studies or from animal models: can we afford to 
ascertain nanoparticle behaviours and drug release properties from these and 
extrapolate this to valid predictions in man? With focus on nanoparticle transport 
across the gut mucosa, researchers must first of all appreciate that two types of 
intestinal cells are concerned with the uptake and transport of particulate matter: the 
enterocytes and the M cells. Despite comprising the majority of cells in the 
gastrointestinal tract, the enterocytes possess a low endocytic activity. It is generally 
agreed that particles are mostly transcytosed in the FAE [247-249] and because M 
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cells are capable of transporting a wide range of materials, it seems logical to expand 
on efforts to exploit these cells in drug delivery.  
 
Particle transport by M cells is predominantly transcellular and energy-requiring [250]. 
Following their uptake by M cells, nanoparticles below 1 µm are delivered to the basal 
side [251], while particles larger than 5 PEHFRPHWUDSSHGLQ3H\HU¶VSDWFKHV [252]. 
Particles below 1 µm and more desirably below 200 nm are likely to be optimal for M 
cell uptake [247, 253]. Of further interest is the relationship between nanoparticle 
surface charge and its subsequent interaction with M cells. Of note, Jung et al. [254] 
report that absorption through M cells is optimised with the use of hydrophobic, 
negatively charged nanoparticles.  
 
The chemical stability of nanoparticles is essential for biodegradability and subsequent 
release of the encapsulated drug [255]. Undoubtedly, colloidal stability is also 
important as a number of biological processes are affected by nanoparticle size. In 
this regard, PEG coated nanoparticles offer greater colloidal stability, together with 
diminished immunogenicity, resulting from reduced adsorption of plasma proteins onto 
the polymer surface [256, 257]. Whilst researchers have speculated over which 
polymer(s) would be most efficient for nanoparticle oral delivery, there is a problematic 
lack of comparative studies. However, it is generally agreed that the smaller the size, 
the better the uptake regarding both enterocytes and M cells.  
1.5.5  Lectin-mediated transcellular protein delivery 
Lectins are proteins or glycoproteins of plant, bacterial or vertebrate origin that 
specifically recognise and bind to polysaccharide or glycoconjugate moieties [258]. In 
particular, plant lectins (e.g. tomato lectin [259]) are a popular choice for oral drug 
delivery because of their non-toxic properties, tendency to bind to sugar moieties of 
glycocalyx expressed on the intestinal epithelial cells and their intrinsic resistance to 
digestion in the gastrointestinal tract [258]. A study carried out by Russell-Jones et al. 
[260] explored the effect of particle size, lectin ligand density and inhibitors on the 
uptake of lectin-coated nanoparticles by epithelial cells for oral drug delivery 
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applications. The degree of uptake was most influenced by the density of lectin on the 
particle, which when increased from 2 times to 8 times, resulted in a linear increase in 
the uptake of material. In another study [261], tomato lectin-conjugated nanoparticles 
were found to efficiently penetrate the mucus gel and were transported across 
epithelial cells. However, a severe limitation of tomato lectin arises from its apparent 
cross-reactivity with N-acetylglucosamine in the mucus layer, resulting in a reduced 
amount of tomato lectin conjugates available for epithelial cell surface binding [262].   
 
1.6. Protein crystals for the delivery of biopharmaceuticals 
The concept for drug crystal formulations has been around for decades, especially in 
the case of small therapeutic molecules. The main advantages of crystal preparations 
include better handling, stability, and varied dissolution characteristics, which allow 
better control over bioavailability [263]. Moreover, the possibility of chemical 
degradation is extensively minimised in crystalline versus amorphous or soluble forms. 
However, rapid advances made in the development of crystal formulations for small 
molecular therapeutics are not yet been matched by those of protein crystals. It is, 
nevertheless, envisaged that at least some of desirable traits observed for small 
molecule therapeutic crystals, could one day be mirrored for some protein 
formulations, including protection of the integrity and biological/biochemical function of 
the therapeutic agent, sustained release, improved bioavailability and abolishment of 
repetitive dosing regimens [263].  
1.6.1  An Introduction to crystallisation 
Protein crystals are solids comprised of an ordered packing of molecular units into 
defined lattice space groups and are formed from the same processes as small 
molecule crystals [263]. In crystalline form, proteins adopt a more energetically 
favourable state (3-6 kcal greater than in solution) [264]. The dimensions of protein 
crystals are usually smaller than non-biologic crystals and thus, are restricted to a 
µWHUPLQDO¶ VL]H [265]. The intrinsic stability of protein crystals is governed by 
hydrophobic interactions, H-bonds and salt bridges between or within proteins. Fewer 
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and weaker intermolecular interactions undoubtedly means that they are more fragile 
than non-biologic crystals [265]. Water (solvent) molecules reside within the protein 
crystal structure, as well as loosely associated in channels within the crystal lattice 
around the protein molecules. This moisture is thought to be important for maintaining 
the hydrated configuration of proteins [263, 266].  
 
Generally, theories based on the nucleation dynamics and crystal growth kinetics of 
small molecule crystals can be applied to macromolecular crystals [267, 268]. In this 
regard, the processes of crystal nucleation and growth depend on both the solubility 
and the supersaturation of the protein in its environment. Initiation of crystal formation 
is thus dependent on both the supersaturated chemical potential of the molecule and 
its chemical potential in the saturated solution [263]. Thus, to grow a crystal from 
solution, the solute molecules must be brought into a thermodynamically unstable 
state. Figure 1.10 shows a phase diagram used in crystallisation literature. The 
parameter represented on the x-axis can be temperature, pH or another variable 
which influences the solubility of the protein. In the under-saturated region, crystals 
will not form or grow. Above the saturation limit, the solution is supersaturated. 
Supersaturation is further divided into the higher labile region, which promotes 
spontaneous nucleation and the lower metastable region, which is closer to the 
saturation limit and therefore growth of existing nuclei may occur, whereas nucleation 
is impossible (but these conditions will permit crystal growth). When a solution is 
supersaturated, the thermodynamics of the system drive the exclusion of solute 
molecules from the solution, resulting in the net accumulation of the solid state. The 
control of this process leads to formation of crystals from the solute. It must be noted 
that the nucleation of protein crystals generally requires a high degree of super 
saturation (2-10 times that of saturation) [269]. Indeed, too high saturation is likely to 
cause random precipitation. 
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Figure 1. 10. Solubility phase diagram used for the crystallisation of proteins, shown here 
as a function of precipitant concentration. Adapted from [263]. 
1.6.2  Protein crystallisation techniques 
Small scale protein crystal production methods include slow vapour diffusion of the 
solvent over a miniature reservoir (hanging and sitting drop method), direct mixing of 
protein solution with a strong precipitant (batch method) and dialysis of the protein-
electrolyte solution [270]. Supersaturation of the system can also be achieved by 
changing the temperature of the solution [271, 272]. Despite the necessity for 
supersaturated conditions for protein crystal growth, growing conditions must be 
carefully monitored to prevent rampant growth and resultant defects in the crystals. 
Metastable supersaturated conditions are often employed with the view to avoid this 
unwanted outcome. In this process, crystal seeds are used as nuclei, which then 
promote further growth. Homogeneous methods employ crystal seeds of the same 
protein (usually spontaneous nucleation in a bulk fluid) and heterogeneous techniques 
whereby seeds of a different nature are used (typically crystals of another protein 
bearing structural similarities to the one being grown).  
In practice, a well studied example in the field of protein crystal drug delivery is insulin. 
Amorphous insulin formulations are by and large fast acting, but insulin crystals can 
be formulated and fine-tuned to display slow and medium release properties. Slow-
acting insulin formulations are usually crystallised with Zn2+ [273]. Variations in the 
experimental conditions (i.e. amount of co-precipitated zinc, temperature, pH, and 
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addition of protamine) have led to many formulations of varying action profiles [273]. 
Importantly, bovine and porcine insulin formulations have been shown to display 
different action properties, compared to human insulin [274]. In vivo, the crystalline 
forms of insulin have proved efficient in allowing prolonged therapeutic action following 
delivery. However, in vitro, crystalline suspensions of insulin were found to be only two 
times more stable than amorphous insulin (small therapeutic molecules typically 
achieve an order of magnitude higher stability) [275]. 
1.6.3  Drug Nanocrystals as therapeutic agents 
Drug delivery systems based on crystallisation approaches are becoming increasingly 
popular. In one such example, Pechenov et al. [276], developed and characterised 
injectable controlled release systems comprising D-amylase crystals. Their findings 
indicated that protein crystals could be incorporated into in situ formable gels with 
changes in crystal morphology allowing modulation of the protein release profiles. In 
another such study by Kraft and co-workers [277], the authors evaluated 
nanobudesonide (nanocrystal budesonide) for nebulisation in patients with steroid-
responsive pulmonary disease. The crystals (75-300 nm size range) were found to 
possess more favourable release properties than the traditionally prepared 
formulations (Pulmicort Respules). Ostrander et al. [278] compared the effectiveness 
of DFRQFHQWUDWHG1DQR&U\VWDOFROORLGDOGLVSHUVLRQRIEHFORPHWKDVRQHGLSURSLRQDWH 
(mean particle size of 164 nm) with commercialised Vanceril and demonstrated a 
greater potential for drug delivery to the conductive airways of the lung in both quantity 
as well as percent of emitted dose. Moschwitzer et al. [279] developed hydrocortisone 
acetate nanocrystals using a high pressure homogenisation technique. Evaluation of 
crystal size by Photon Correlation Spectroscopy (PCS) revealed an average size of 
716 nm ± 64 nm and in vitro dissolution tests showed improved drug release for 
pellets containing the drug nanocrystals. Govardhan et al. [280], produced 
nanocrystals of human growth hormone coated with a monomolecular layer of 
positively charged poly(arginine), which the authors claimed produced a highly 
efficient means of extending the half-life of therapeutic proteins. 
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Crystal formation has also proved a successful method for the delivery of vaccines. 
The progress towards subunit vaccines has been limited by their poor immunogenicity 
and limited stability. To enhance the immune response, subunit vaccines require 
improved adjuvants and delivery vehicles [281]. A crystalline vaccine formulation of 
human serum albumin showed a 10-fold increase in antibody titer for highly cross-
linked crystals and a 30-fold increase for lightly-cross-linked crystals [281]. In another 
study by Murdan et al. [282], diphtheria toxoid was crystallised to form protein-coated 
micro-crystals to improve the thermal stability of the vaccine. The diphtheria toxoid 
was crystallised in the presence of L-glutamine and produced crystals in the region of 
10 µm. The crystalline formulation produced was shown not to result in any change in 
antibody response to the toxoid.  
Promising crystal drug candidates are those that have sufficient physical robustness 
outside of their crystallisation buffer. Alas, this is seldom the case, with fragile protein 
FU\VWDOVµPHOWLQJ¶RUGLVVROYLQJZKHQUHPRYHGIURPWKHLUVXSHUVDWXUDWHGFU\VWDOOLVDWLRQ
medium. Furthermore, crystals often lose their stability through mechanical processing 
e.g. by stirring, shaking or pipetting. To an extent, this can be remedied either by 
cross-linking fragile forms of protein crystals with reversible cross-linking agents [283, 
284] or by co-precipitation of the protein with biocompatible multivalent ions like Zn2+ 
[273]. The former strategy becomes a subject of investigation in the final chapter of 
this thesis.  
1.7 Conclusion 
Research into non-invasive protein delivery has continued to evolve over the past 
decade, although extensive research and development is still needed to produce 
strategies which are feasible for commercialisation. The universal aim of mucosal 
delivery strategies involves the design of formulations (likely to be based on multi-
component systems) that exhibit no toxicity upon repeated administration, preserve 
the biological function of the therapeutic molecule, achieving adequate bioavailability, 
with acceptable production costs and can be tailored to a range of protein drugs. 
Commonly visited strategies so far have included the use of absorption enhancers, 
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mucoadhesive excipients and attempts to exploit epithelial transcytotic mechanisms, 
with or without the use of drug delivery systems based on nanoparticulate carriers. 
Novel approaches in tackling the mucosal barrier for drug delivery purposes continue 
to provide hope that in the not too distant future, non-invasive administration of protein 
drugs will be an option for the patient.  
1.8 Project Preview 
This chapter has reviewed the current situation in the field of non-invasive delivery of 
protein therapeutics, discussing some of the challenges and pitfalls faced by 
researchers. The work presented in this thesis is predominantly based on investigating 
the potential of the vitamin B12 biological transport pathway for the mucosal delivery of 
nanoparticles as biotherapeutic carriers. Work initially focuses on assessing the 
suitability of Caco-2 cells, as a commonly used model of the intestinal mucosa, as a 
system to study the vitamin B12 transport pathway. The synthesis and characterisation 
of the Į-Ȧ-aminohexylcarbamate derivative of B12, together with its attachment to 
carboxy functionalised synthetic polymer nanoparticles (50-200 nm scale) will be 
described. This is followed by investigation of the intracellular trafficking and transport 
behaviour of these nanoparticles in Caco-2 (as well as airway Calu-3 cells), which is 
the central aim of the thesis. The final chapter describes the design and 
FKDUDFWHULVDWLRQRI µVWDELOLVHG¶PLFUR- and nano- crystals, which show promise for the 
development of a suitable oral delivery platform for protein bioactives.  
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Chapter 2: Materials and general methods 
2.1 Materials 
2.1.1  Cells, culture media, media components and cell solutions  
 
Caco-2 and NIH 3T3 cells were obtained from the European Collection of Cell 
Cultures (ECACC) and used at passages 45-60 and 35-50, respectively. Calu-3 were 
obtained from the American Type Culture Collection (ATCC) and used between 
passages 20- (VVHQWLDO 0LQLPXP (DJOH¶V 0HGLXP (0(0 PHGLXP, DulbecFR¶V
Modified Eagles Medium (DMEM), Hanks Balanced Salt Solution (HBSS) with sodium 
bicarbonate and without phenol red, 2.5% Trypsin/EDTA solution, 
Antibiotic/Antimycotic solution (containing penicillin, streptomycin and amphotericin), 
L-glutamine, sodium pyruvate and Foetal Bovine Serum (FBS, non-USA origin) were 
all obtained from Sigma-Aldrich (UK). Phosphate buffered saline (PBS) tablets were 
purchased from Oxoid (UK). Cell media (EMEM and DMEM) were supplemented with 
penicillin, streptomycin and amphotericin at final concentrations of 100 units/ml, 0.1 
PJPODQGȝJPOUHVSHFWLYHO\DQG)%6DWa final concentration of 10% v/v. For 
Caco-2 and NIH 3T3 cell culture, both EMEM and DMEM were further supplemented 
with L-glutamine and non-essential amino acids (NEAA, Fisher Scientific, UK). For 
Calu-3 culture, EMEM was also supplemented with sodium pyruvate (1mM) and L-
glutamine. Hereafter, supplemented media are referred to as cell media, DMEM, or 
EMEM. Dimethylsulphoxide (DMSO, used as cryopreservant), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), Hoechst 33342, 1,4-
diazabicyclo[2.2.2]octane (DABCO) and 2 (NMorpholino)ethanesulfonic acid (MES) 
were all obtained from Sigma-Aldrich (UK). 
 
2.1.2  Plasticware and glassware 
Polystyrene transwell® permeable supports, referred to in this thesis as 'filters' or 
µWUDQVZHOOV¶, of 12 mm GLDPHWHU  ȝP SRUH VL]H ZLWK D VXUIDFH DUHD RI 1.1 cm2) 
were obtained from Corning Life Sciences (Holland). Cell culture flasks (75 cm2, 
Chapter 2: Materials and general methods 
56 
 
canted neck with vented caps), 96-well polystyrene microplates (black or clear, non-
cell culture treated) and sterile pipettes, used routinely for the maintenance of cells, 
were also purchased from Corning Life Sciences (Holland). Clear, tissue culture 
treated 96-well plates, black 96-well microplates (used for fluorescence measurement) 
and sterile cryovials (1 ml capacity) were supplied by Nunc. Sterile centrifuge tubes (of 
15 ml and 50 ml volume capacity) were purchased from Greiner (USA) and sterile 
universals (5 ml and 30 ml volume capacity) were obtained from Sterilin (UK). 
Freezing container ('Mr Frosty'), providing a controlled cooling rate of 1°C per minute, 
was purchased from Nalgene® Labware (USA). Haemocytometer (Improved 
Neubauer, to British Standard 748) was purchased from Scientific Laboratory Supplies 
(SLS, UK). 
 
2.1.3  Cell toxicity assay reagents 
3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethonyphenol)-2-(4-sulfophenyl)-2H-
tetrazolium-(MTS) reagent (commercially known as 'CellTiter 96 AQueous One 
Solution Cell Proliferation Assay') was purchased from Promega (UK). Lactate 
Dehydrogenase (LDH) assay kit (known commercially as 'In Vitro Toxicology Assay 
Kit, TOX7') was purchased from Sigma-Aldrich (UK). The BCA protein assay kit was 
obtained from Novagen® (UK). 
 
2.1.4  Antibodies 
Mouse, anti-human Zonula Occludens-1 (ZO-1, TJ protein) was purchased from 
Zymed (part of Invitrogen, USA). Rabbit, anti-human lysosomal associated membrane 
protein 1 (LAMP1); goat, anti-mouse FITC-IgG and goat, anti-rabbit FITC-IgG were 
purchased from Sigma-Aldrich (UK). Rabbit, anti-human cubilin antibody (polyclonal 
IgG); rabbit, anti-human caveolin-1 (polyclonal IgG); rabbit, anti-human 
transcobalamin II (TCII); goat, anti-rabbit FITC-IgG and goat anti-rabbit rhodamine-IgG 
were purchased from Santa Cruz (USA). Alexa-fluor® 594 labelled goat anti-mouse 
antibody was purchased from Invitrogen. 
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2.1.5  Chemicals 
FITC-labelled dextrans ('FDs') of approximate average MW of 4 kDa (µFD4¶), 10 kDa 
(µFD10¶), 20 kDa (µFD20¶), 40 kDa (µFD40¶), 70 kDa (µFD70¶) and 150 kDa (µFD150¶), 
FITC-labelled insulin (FITC-insulin), ethylene diamine tetraacetic acid (EDTA), 
paraformaldehyde, osmium tetroxide, Triton X-100, Bovine Serum Albumin (BSA), 
glutaraldehyde and 1,4-Diazabicyclo-octane (DABCO, UV mountant) were all obtained 
from Sigma-Aldrich (UK). DAPI (4',6-diamidino-2-phenylindole) with antifade mounting 
media (commercially known as Slowfade-Gold®) anG /\VRWUDFNHU *UHHQ ZHUH
obtained from Invitrogen. Fluorescent polystyrene carboxy-modified nanoparticles 
(YO, Fluoresbrite®) of 50, 100 and 200 nm nominal diameter were supplied by 
Polysciences Europe GmbH (Germany). 6ROLG ¶-carbonyldiimidazole (CDI), 
anhydrous dimethyl sulfoxide, cyanocobalamin and N-hydroxy-succinimide (NHS) 
were purchased from Acros® (Belgium). 1,6-hexanediamine, ethyl acetate and 
acetone were obtained from Fisher Scientific (UK). 1-ethyl-3-[3-
Dimethylaminopropyl]carbodiimide (EDAC) was purchased from Calbiochem (UK). 
Insulin from bovine pancreas was purchased from Sigma-Aldrich (UK). THPP (ß-
[Tris(hydroxymethyl) phosphino] propionic acid (betaine) (THPP) was obtained from 
Fisher Scientific. All water was obtained from an ELGA purification system (resistivity 
15 MV cm-3, Maxima USF ELGA, UK). All other chemicals and materials unless 
otherwise stated, were purchased from Sigma-Aldrich (UK) or Fisher Scientific.  
 
2.2 Methods 
2.2.1  Maintenance of cells 
2.2.1.1  Maintenance of cells in culture flasks 
All cell lines were routinely cultured in 75 cm2 flasks at 5% CO2, 95% relative humidity 
and 37°C until confluence (in this work confluence was considered as approximately 
75-95% coverage of the flask surface by cells). Cell culture medium was replaced 
every other day by aspirating the old culture media from the flasks, followed by the 
addition of 12-14 ml of fresh media, pre-warmed to 37°C. Cell growth was monitored 
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regularly by viewing the cells under an optical microscope. Once confluent, cells were 
passaged using the following procedure: culture medium was removed (aspirated) 
from the flask and cells washed with PBS (6 ml, pre-warmed to 37°C), which was 
added to the flask and the flask gently swirled. Fresh PBS was used to remove any 
dead cells remaining in the flask and traces of media; it was important to perform this 
step prior to the addition of trypsin/EDTA solution to cells since FBS present in the cell 
culture media inhibits the action of trypsin. PBS was then aspirated and replaced with 
2.5-3 ml of pre-warmed (37°C) 2.5% trypsin/EDTA solution. The flask was gently 
swirled to ensure that trypsin/EDTA solution covered the cells and then transferred to 
the incubator at 37°C. The flask was observed at regular intervals for cell detachment 
from the tissue culture flask plastic. The period of incubation with trypsin/EDTA 
solution was dependent on the cell line and the extent of confluence. Generally, for 
NIH 3T3 and Caco-2 cells an incubation period of approximately 15 min was sufficient 
for complete cell detachment from the flask plastic. On the other hand, Calu-3 cells 
required no less than 20 min incubation with trypsin/EDTA for complete detachment. 
Following cell detachment, approximately 9 ml of pre-warmed (37°C) culture medium 
was added to the flasks in order to dilute the cell suspension and deactivate trypsin 
(different media were used for each cell line, as will be described later). The resulting 
cell suspension was transferred to a sterile centrifuge tube and the cells centrifuged 
(pelleted) at 13,000 rpm for 5 min. Trypsin-containing supernatant was aspirated and 
pre-warmed culture medium (37°C, 5-10 ml) added to the cell pellet to create a cell 
suspension. A proportion of the resulting cell suspension was transferred to a new 
flask (containing pre-warmed culture medium appropriate for the cell line) for further 
culturing. Split ratios between 1:3 and 1:5 were normally used for Calu-3 cells, while 
higher ratios between 1:6 and 1:10 were typically used for both NIH 3T3 and Caco-2 
cells. Although both Caco-2 and Calu-3 cells were cultured in EMEM, media 
components were varied in order to achieve optimal cell growth in each respective cell 
line. Mouse NIH 3T3 fibroblasts were cultured in DMEM. Culture media were 
supplemented with various components as described above (section 2.1.1). 
Chapter 2: Materials and general methods 
59 
 
2.2.1.2  Frozen storage of cells 
Cells were cultured to confluence and then detached from the flask as described 
previously (section 2.2.1.1). Following centrifugation of the cell suspension, the 
supernatant was aspirated, and the cell pellet re-suspended in 1 ml of complete 
culture medium containing sterile DMSO. The concentration of DMSO used was 5% 
v/v for Calu-3 and Caco-2 cells and 7.5% v/v for NIH 3T3 cells. The cell suspension 
was added to a sterile cryovial (clearly labelled with the cell type, passage number, 
user name and date), which was placed into a freezing container ('Mr Frosty') in a -
80°C freezer for a gradual, controlled temperature decrease. Cells were stored at ±
80°C for up to 4 weeks. Thereafter, cells were transferred into a liquid nitrogen cell 
storage tank. Note that cells from a single confluent monolayer in one 75 cm2 tissue 
culture flask were transferred and stored frozen in a single cryovial; multiple flasks of 
cells were routinely detached and transferred into the equivalent number or sterile 
cryovials for frozen storage. 
 
2.2.1.3  Cell revival 
Cryovials containing frozen cells were removed from the liquid nitrogen-containing 
storage tank and thawed by placing the cryovial in the incubator at 37°C for 
approximately 5 min. DMSO-containing medium was removed by transferring the cell 
suspension into a centrifuge tube containing approximately 8 ml of warm (37°C) 
culture medium, centrifuging the resulting suspension at 13,000 rpm for 5 min and 
aspirating the supernatant. The cell pellet was thereafter suspended in approximately 
5 ml of culture medium and transferred into a 75 cm2 flask containing approximately 
10 ml of fresh, warmed (37°C) culture medium. Note that cells from one cryovial were 
revived and transferred into one tissue culture flask. 
 
2.2.1.4  Culture of cells on transwells 
2.2.1.4.1 Calu-3 cells 
Calu-3 cells were cultured to confluence in 75 cm2 flasks at 5% CO2 and 37°C. Cells 
were then detached from the flasks using the method described above (2.2.1.1). 
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Transwell® ILOWHUV ZHUH LQFXEDWHG ZLWK (0(0  ȝO DQG  PO RQ WKH DSLFDO DQG 
basolateral chambers, respectively) at 37°C for approximately 15 min prior to the 
addition of cells. This was performed in order to coat the surface of the filter plastic 
with proteins present in the culture medium (serum), to encourage cell attachment to 
plastic. It should be noted that polystyrene transwell® filters were used for all 
experiments in this thesis, as opposed to polycarbonate filters due to better 
attachment by cells. Cells were counted using a haemocytometer and the volume of 
the cell suspension containing the required number of cells was calculated. These 
volumes were subsequently added to the donor compartments of the transwells. The 
number of cells added ('seeding density') was 105 per 1.1 cm2 of the Transwell® filter 
area. The apical chamber volume was made up to ȝOE\DGGLQJZDUPHG(0(0
After seeding on filters, cells were maintained at 5% CO2, 37°C with EMEM. Following 
initial seeding on filters, Calu-3 cells can be cultured in two different ways:, cells can 
either be continuously exposed to the culture medium on both apical and basolateral 
sides (0.5 ml and 1.5 ml, respectively), i.e. cells grown using liquid-covered culture 
(LCC); or cells can be cultured on transwells with medium (0.5 ml) present in the 
basolateral chamber only. The latter culture condition is known as air-interfaced 
culture (AIC). In this thesis, LCC conditions were employed for all experiments. Calu-3 
cells were typically cultured on filters for 21 days prior to their use in experiments as 
confluent and polarised cell layers. Hereafter WKH WHUP µSRODULVHG¶ LV XVHG WR GHILQH
fully differentiated, filter-cultured cell layers. 
 
2.2.1.4.2 Caco-2 cells 
Caco-2 cells were seeded on filters in a similar way to Calu-3 cells, except that a 
density of 2x105 cells/cm2 was used. Caco-2 cells were cultured using LCC conditions, 
with EMEM as the culture medium and were routinely grown on filters for 21-23 days 
(with culture medium replaced every other day) prior to their use in experiments as 
confluent, polarised cell monolayers. 
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2.2.2  Measurement of TEER 
Transepithelial electrical resistance (TEER) is a convenient, reliable and non-
destructive method to monitor the growth of epithelial tissue cultures in vitro, evaluate 
cell layer integrity and determine the presence and the tightness of the cellular tight 
junctions (TJs) [1]. Formally a measure of resistance to ion flux across an epithelial 
layer, it further enables the measurement of changes in paracellular ion flux linked to 
tight junctional disruption [2] and can also be employed as an indirect measure of cell 
toxicity [2, 3]. TEER can be conveniently measured using a portable ohmmeter 
(EVOM, World Precision Instruments) FRPSULVLQJD VHWRI ³FKRSVWLFN´HOHFWURGHVDV
illustrated in Figure 2.1. The chopstick electrodes were firstly pre-sterilised by 
immersing in absolute ethanol for approximately 30 min prior to their use. The 
electrodes were then washed with PBS and carefully placed in the culture medium 
bathing the cell layers; the shorter electrode was submerged in the medium present in 
the apical chamber, while the longer electrode was placed in the basal medium. The 
resulting readings were recorded and are expressed in this thesis as the mean of 5 
separate measurements (unless otherwise stated) ± standard deviation.  
 
Figure 2. 1. Schematic representation of TEER measurement using an epithelial volt 
ohmmeter. 
 
For simply monitoring cell growth, TEER was measured in the culture medium. TEER 
was measured following the incubation of cells with the culture medium on both sides 
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(apical and basolateral) after the cells were allowed to equilibrate for at least 30 min. 
Routinely, following TEER measurement, the culture medium was replaced to prevent 
any damage that may result from leakage of ions from the electrodes. 
 
During the initial culture of Caco-2 and Calu-3 cells on filters, TEER was measured 
every other day, starting from day 5 to 21 of culture. This routine was continued until 
the TEER development profile was found to be reproducible. In order to prevent 
unnecessary damage to the cell layers during the measurement process 
(predominantly from leakage of ions from the electrodes), TEER was subsequently 
only measured prior to the use of cell layers in experiments in order to verify cell layer 
intactness and TJ formation. TEER values reported in this thesis take into account the 
area of the cell layer (assumed to amount to the area of the transwell® filter) and are 
H[SUHVVHG DV ȍ.cm2. In addition, electrical resistance across the cell-free transwell® 
filters (background resistance) was also measured on every batch of transwell® filters 
used in the experiments. This value typically ranged between 100 and 115 ȍ.cm2 and 
was subtracted from the measured cell layer TEER in all experiments [4]. 
 
Only polarised cell layers H[KLELWLQJ7((5RIȍ.cm2 (for Calu-3) and 800 ȍ.cm2 
(for Caco-2) or above were included in the cell uptake and transport experiments 
detailed in this thesis.  
 
The experiments were conducted in HBSS in all cases, which was buffered at pH 6.0 
(with 10 mM MES) or pH 7.4 (using 25 mM HEPES), depending on the nature of the 
sample applied. Prior to the application of test samples to cells, the culture medium 
was removed, cells washed with PBS and HBSS (warmed to 37°C; pH 7.4) added to 
both sides of the cell layers. Cells were equilibrated in HBSS (i.e. incubated at 37°C, 
5% CO2) for approximately 45 min, following which initial TEER measurements were 
conducted. After the 3 hour transport period, the test sample was removed from the 
apical chamber and following a repeated wash step with PBS (3 times), the HBSS was 
replaced on both the apical and basolateral sides, after which a final TEER 
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measurement was made to verify that cell layer integrity was maintained throughout 
the course of the experiment. In the case of application of a test compound (i.e. for 
toxicity assessment), HBSS was then removed from the apical side of the cell layers 
and replaced with the test samples (previously warmed to 37°C). Unless otherwise 
stated, cells were incubated with the samples for 3 hours, with TEER measurements 
made every 30 min following sample application in the presence of the tested samples 
in HBSS. The samples were removed from the cells 3 hours post-application and cells 
washed with PBS (3 times). Culture medium (appropriate for the cell line, see section 
2.2.1.1) was then added to the cell layers and cells incubated with the culture medium 
overnight. In order to determine whether the effect of the tested samples on TEER 
was reversible, TEER was measured (in culture medium) 24 hours (the following day) 
after test sample application.  
 
2.2.3  FITC-dextran (FD) permeability measurements 
An alternative method to assess monolayer integrity is to study the transport of a 
hydrophilic marker molecule representative of a model drug that is passively 
transported through the cell layer, either transcellularly or paracellularly [4]. In these 
studies, fluorescein isothiocyanate (FITC)±labelled dextrans (FDs) of varying MWs 
were used as macromolecular markers, modelling hydrophilic, large MW protein 
drugs. The availability of FDs in different MWs and as fluorescently labelled (enabling 
a relatively simple quantification) makes these molecules highly appropriate for use in 
experiments investigating macromolecular permeability across epithelial cell layers. As 
detailed in the previous section, TEER measurements were conducted prior to the 
permeability experiments in order to ensure that the cell layers were confluent and 
intact. TEER was also assessed after the experiment to YHULI\ WKDW WKH FHOO µEDUULHU¶
was maintained throughout the course of the permeability studies. As previously 
discussed, only cell layers exhibiting T((5  ȍ.cm2 (Calu-3) and  800 ȍ.cm2 
(Caco-2) (i.e. 'confluent cell layers') were deemed suitable for FD permeability 
experiments. Unless otherwise indicated in subsequent chapters, permeability 
experiments were conducted as follows. Culture medium was removed from the cell 
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layers and cells washed with warm (37°C) PBS. Buffered HBSS (with 25mM HEPES, 
pH 7.4) was then added to the apical (0.5 ml) and basolateral (1.5 ml) chambers of the 
Transwell® system. Cells were incubated (at 37°C/5% CO2) with HBSS for 
approximately 45 min for the purpose of equilibration. TEER was then measured in 
order to confirm the 'confluence' and the intactness of the cell layers, following which 
HBSS was removed from the apical side. FDs were dissolved in HBSS (ȝJPO) 
and were then applied to the apical side of the cells (donor compartment of the 
transwells). FD permeability was determined by sampling (100 µl) the basolateral 
solution at regular time intervals (every 30 min over 3 hours). The sampled solutions 
were immediately replaced with an equivalent volume of the transport medium 
(HBSS). Between sampling times, cells were incubated at 37°C/5% CO2. Sampled 
solutions were transferred into a black 96-well plate, which was then covered with 
aluminium foil to protect from light. Sample solution fluorescence (485 nm excitation, 
535 nm emission) was then determined using an MFX microtiter plate fluorometer 
(Dynex Technologies, USA). Transported FD in the basolateral solutions was 
quantified by converting the fluorescence readings into FD concentrations and 
ultimately amounts, through construction of calibration curves. The fluorescence 
intensity of progressively diluted FD solutions of known FD concentrations was 
measured. At least three such calibration curves were established; the mean values 
were then calculated and used for FD quantification in each experiment. In this thesis, 
all FD permeability data is expressed as the apparent permeability coefficient (Papp), 
calculated using the following equation: 
  ? ? ? ?ൌ ൬ ? ? ? ?൰ ൈ ൬  ? ? ൈ  ? ?൰ 
 
Where: 
3app is the apparent permeability in cm s-1 
  ? ? ? ? LVWKHSHUPHDELOLW\UDWH>DPRXQW)'ȝJWUDYHUVLQJWKHFHOOOD\HUVRYHU time (s)]. 
This was determined by plotting the amount of transported solute over time and 
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calculating the gradient of the straight-line (i.e. steady state) portion (typically transport 
over time points 30 min ± 3 h) of the resulting curve (and conversion into seconds) 
$LVWKHGLIIXVLRQDUHDRIWKHOD\HUFP2), and 
&0 is the initial FD concentratioQȝJPO 
2.2.4  Cell toxicity studies 
2.2.4.1  Background information 
The MTS assay uses a colorimetric method to determine the number of viable cells in 
proliferation or cytotoxicity assays. This method can be used to replace the classic 3H-
thymidine incorporation assay. The one solution assay system contains a novel 
tetrazolium compound 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)- 2-(4-
sulfophenyl)-2Htetrazolium (inner salt), MTS, and an electron-coupling reagent, 
(phenazine ethosulfate, PES). PES combines with MTS and confers enhanced 
chemical stability and allows the formation of a stable solution. The principle of the 
assay is that the MTS tetrazolium compound is reduced in cells into a coloured 
formazan compound which is soluble in tissue culture media. This conversion occurs 
via the production of NADPH/NADH by dehydrogenase enzymes, present in 
metabolically active cells [5]. 
 
The Lactate dehydrogenase (LDH) assay (first described by Legrand et al. [1, 6]) is 
another cytotoxicity analysis that can be used alongside the MTS assay. Lactate 
dehydrogenase (LDH) is a soluble cytosolic enzyme that is released into the culture 
medium following loss of membrane integrity resulting from cell death. LDH activity, 
therefore, can be used as an indicator of cell membrane integrity and serves as a 
general means to assess both cell viability and cytotoxicity resulting from chemical 
compounds or environmental toxic factors [7]. The numerous commercially available 
kits measure LDH activity present in the culture medium using a coupled two-step 
reaction. In the first step, LDH catalyses the reduction of NAD+ to NADH and H+ by 
oxidation of lactate to pyruvate. In the second step of the reaction, diaphorase uses 
the newly-formed NADH and H+ to catalyze the reduction of a tetrazolium salt (INT) to 
highly-coloured formazan which absorbs strongly at 490-520 nm. The relative 
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cytotoxicity caused by the test agent can be standardised against a series of controls 
(as described in Chapter 8).  
2.2.4.2  MTS Cell metabolic activity assay 
The MTS assay was performed on Caco-2 cells unless otherwise stated. In all 
experiments, cells were seeded on 96-well plates (sterile, cell culture treated) at a 
density of 104 cells per well and incubated at 37°C/5%CO2 for 24 hours, unless 
otherwise stated. This seeding density was chosen (optimised), based on previous 
observations made within our group as it produced an absorbance value within the 
linear range of the assay, as recommended by the manufacturer. The culture medium 
was aspirated and replaced with test sample solutions (at different concentrations), 
dissolved in HBSS (at pH 7.4). Cells incubated with HBSS (at the same pH as the test 
samples) were used as the negative control, whereas cells incubated with Triton X-
100 (0.2% v/v in HBSS at pH identical to that of the test samples) were used as the 
positive control. Samples were previously warmed and applied to cells at 37°C. 
Following the application of the samples, cells were incubated at 37°C/5%CO2 for 2 
hours. Sample solutions were then DVSLUDWHG DQG FHOOV ZDVKHG ZLWK 3%6  ȝO RI
culture medium (at 37°C) was added RQWR HDFK ZHOO IROORZHG E\  ȝO RI WKH 076
reagent. Cells were incubated with the combined culture medium/MTS reagent for 2-3 
hours, following which absorbance (492 nm) was measured using a Dynex 
absorbance microplate reader (Dynex Technologies, USA). The relative cell metabolic 
activity (%) was calculated using the following equation: 
 ሺ ? ሻ ൌ  ሺ ?െ ? ?ሻሺ ? ? ? ?െ ? ?ሻ 
Where: 
Abss is the absorbance with the tested samples 
AbsTx is the absorbance with Triton X-100 
AbsHBSS is the absorbance with HBSS 
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2.2.4.3  LDH assay 
The LDH assay was performed to test the membrane toxicity of different compounds 
on Caco-2 cells. Cells were seeded on 96-well plates (sterile, cell culture treated) at 
104 cells per well and cultured for 24 hours (unless otherwise stated) before the assay. 
Culture medium was removed and cells washed with PBS. Test compounds of 
different concentrations dissolved in HBSS (pH 7.4, at 37°C) were then applied. Triton 
X-100 (0.2% v/v in HBSS) was used as the positive control (assuming it caused 
complete LDH release), whereas HBSS (pH 7.4) was used as the negative control. 
Cells werH LQFXEDWHGZLWKVDPSOHVDQGFRQWUROV IRUKRXUVDIWHUZKLFKȝORI WKH 
solutions were removed from each well and transferred to a new 96-ZHOOSODWHȝO 
of the LDH reagent was added to the samples and the plate was incubated at room 
temperature for 30 min. After this period, absorbance (490 nm) was measured using 
the Dynex absorbance microplate reader. LDH release was calculated as the 
percentage relative to the controls, using the following equation: 
 ሺ ? ሻ ൌ  ሺ ?െ ? ? ? ?ሻሺ ? ?െ ? ? ? ?ሻ 
 
Where: 
Abss is the absorbance obtained with the tested samples 
AbsHBSS is the absorbance with HBSS 
AbsTx is the absorbance with Triton X-100 
 
2.2.5  Cell imaging and labelling 
2.2.5.1  Scanning Electron Microscopy (SEM) 
Filter-cultured confluent Caco-2 and Calu-3 cell layers were fixed by replacing the 
culture medium with 1:1 mixture of culture medium and fixing solution, which 
comprised 2.5% v/v glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.2) on 
both apical and basolateral sides of the transwells. Following an incubation interval of 
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5 min, this solution was removed and replaced with 100% of the fixing solution on the 
apical side only and incubated for a further 30 min. The fixing solution was then 
removed and the cell samples washed three times with 0.1M phosphate/cacodylate 
buffer. The samples were then post-fixed and stained with 1% w/v osmium tetroxide in 
distilled water by incubation at room temperature for 60 min. Osmium tetroxide 
solution was then removed and samples dehydrated in a graded series of ethanol in 
water (5 x 1 min in distilled water; 2 x 5 min in 50% ethanol, 2 x 5 min in 70% ethanol, 
2 x 5 min in 90% ethanol, 3 x 10 min in 100% ethanol). Samples were dried using a 
critical point dryer (CPD). This technique has been shown to give rise to significantly 
fewer dehydration artifacts compared with other dehydration methods. Following the 
CPD process, the samples were removed and mounted on aluminium stubs with 
adhesive double-sided carbon tape. The samples were gold coated for 3 minutes 
under an argon atmosphere in a Blazers Union SCD030 sputter coater unit (Blazers 
Ltd, UK). The CPD, mounting and coating of the samples was carried out by the 
Advanced Microscopy unit (School of Biomedical Sciences) at the University of 
Nottingham. Coated samples were examined with a JEOL 6060LV (JEOL, Welwyn, 
UK) variable pressure scanning electron microscope operating at an accelerating 
voltage of 10 kV. Image analysis was carried out using the in-built SEM control user 
interface software (version 6.57) and digital imaging system.  
 
2.2.5.2  Transmission Electron Microscopy (TEM) 
Filter-cultured confluent Caco-2 and Calu-3 layers were fixed with 4% 
paraformaldehyde and then washed with 0.1 M phosphate/cacodylate buffer. Cells 
were post fixed with 1% aqueous osmium tetroxide for 30 mins, followed by extensive 
washing (5x1 min) with distilled water. Samples were then dehydrated in a graded 
ethanol series by washing the cells for 5 min (twice) with 50% ethanol, followed by 
70% ethanol, followed by 90% ethanol and then finally with 3x10 min washes with 
100% ethanol. Finally, two 5 min washes were performed with 100% dried acetone. 
Cell samples were then infiltrated with resin for a duration of 30 minutes in 1:3 
resin:acetone mix, 1 hour in 1:1 resin:acetone mix and 3x1 hour incubations in pure 
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resin. Samples were embedded in the resin and left in the embedding oven for 48 
hours at 60°C. Once the resin block polymerised, the substrate was removed from the 
cells by immersing the block in liquid nitrogen and snapping the substrate from the 
block. The block was then embedded in a microcentrifuge tube containing fresh resin 
and was polymerised as before, enclosing the cell layer in a resin block. The layer was 
cut out of the block by sawing either side of it to give a disc of resin with the layer 
running through the middle. The disc was cut in half to form 2 semi-circles, which were 
stuck onto the top of a blank resin block (using Araldite® epoxy resin). The Araldite® 
was left to set for 1 hour. Ultrathin sections were cut using a cryoultramicrotome (Leica 
EM, UC6/FC6, Milton Keynes, UK) and viewed by TEM (Jeol JEM 1010 Electron 
Microscope, Japan). Note that the late stages of sample preparation for TEM were 
performed by the Advanced Microscopy Unit group, School of Biomedical Sciences, 
University of Nottingham. 
2.2.5.3  /\VRWUDFNHUVWDLQLQJDQGLAMP1 immunostaining 
To enable the assessment of intracellular nanoparticle fate in filter-cultured cells, two 
complementary techniques were selHFWHG WKHXVHRI/\VRWUDFNHUSUREH WR LGHQWLI\
active lysosomal compartments [8], and immunostaining for lysosomal associated 
membrane protein (LAMP1) - a heavily glycosylated lysosomal membrane protein, 
thought to play an important role in protecting the lysosomal membrane from 
proteolytic enzymes within the lysosomes [9, 10]. Because the protein is ubiquitously 
expressed, its antibody was used in this case to identify localised or clustered regions, 
likely to be representative of lysosomal structures. Caco-2 and Calu-3 cell layers were 
FXOWXUHG LQ WKH PDQQHU GHVFULEHG LQ VHFWLRQ  /\VRWUDFNHU *UHHQ '1'-26 
,QYLWURJHQ ZDV GLOXWHG DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V LQVWUXFWLRQV LQ +%66 DQG
nanoparticles (unmodified and B12-conjugated) were suspended in this solution to 
achieve a final incubation concentration of 250 µg/ml. The IF-B12-nanoparticle 
complexes were prepared as described in Chapter 5. As detailed in section 2.2.2, 
TEER measurements were conducted prior to the nanoparticle trafficking experiments 
in order to ensure that the cells were confluent and the cell layer intact. As previously 
GLVFXVVHG RQO\ FHOO OD\HUV H[KLELWLQJ 7((5  ȍFP2 (Calu- DQG   ȍFP2 
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(Caco-2) (i.e. 'confluent cell layers') were deemed suitable for these studies. Culture 
medium was removed from the cell layers and cells washed with warm (37°C) PBS. 
Buffered HBSS (with 25 mM HEPES, pH 7.4) was then added to the apical (0.5 ml) 
and basolateral (1.5 ml) chambers of the transwell® system. Cells were incubated (at 
37°C/5% CO2) with HBSS for approximately 45 min for the purpose of equilibration. 
The lysotracker-containing nanoparticle suspensions (0.5 ml) were applied to the 
apical sidHRIWKHFHOOPRQROD\HUVDQGLQFXEDWHGDWÛ&IRU hrs. Following a series 
of wash steps with PBS and fixation with 4% paraformaldehyde (PFA), 300 µl of 
Hoechst dye solution (100 µg/ml) was added to the samples (for nuclei staining) and 
incubated at room temperature for 5 min. The Hoechst solution was then removed and 
the cells were washed 4 times with PBS. Transwell® filters (containing cells) were then 
excised and mounted (using DABCO mounting medium) on glass slides for confocal 
imaging. Cells were imaged using a Leica TCS SP2 system mounted on a Leica 
DMIRE2 inverted microscope. 
Although imaging was conducted using a sequential scanning mode where cross 
emission between different fluorophores is minimised, a control set of experiments 
were conducted to verify that the imaged pattern did not result from fluorophore cross 
HPLVVLRQ EHWZHHQ WKH /\VRWUDFNHUPDUNHU DQG IOXRUHVFHQW QDQRSDUWLFOHV ,Q WKHVH
H[SHULPHQWV FHOOV ZHUH WUHDWHG ZLWK HLWKHU WKH /\VRWUDFNHU SUREH RU WKH <2
nanoparticles (Table 2.1), followed by imaging using the optimised sequential scan 
VHWWLQJV &HOO VDPSOHV LQFXEDWHG ZLWK WKH /\VRWUDFNHU SUREH ZHUH LPDJHG XVLQJ
nanoparticle scan settings (529 nm/546 nm, ex/em) and cells treated with 
nanoparticles were visualisHGXVLQJ/\VRWUDFNHUVettings (504 nm/511 nm). 
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Cell treatment with 
 
/\VRWUDFNHU*UHHQ
DND-26 (Lysosomal 
marker) 
Unlabelled  (non-
fluorescent) 50 nm 
NPs 
YO 50 nm NPs 
Experiment 
   
A. Scanning for 
/\VRWUDFNHU  + + 
B. Scanning for 
YO 50 nm 
NPs 
+ + 
 
C. Scanning for 
/\VRWUDFNHU   + 
D. Scanning for 
YO 50 nm 
NPs 
+ 
  
E. Scanning for 
/\VRWUDFNHU + +  
 
Table 2. 1. Experimental set-XSIRUFRQWURO/\VRVRPDOVWXGLHVXVLQJ/\VRWUDFNHU*UHHQ
DND-26 (Exc. 504/ Em. 511 nm) with unmodified NPs (50 nm, Exc. 529/Em. 546 nm) in 
Caco-2 monolayers. 
ZKHUH µ¶ GHQRWHV µSUHVHQW¶ LQ HDFK VDPSOH )RU H[SHULPHQWs A-B, cells were incubated with either YO 
fluorescent NPs and unlabelled (non-fluorescent) particles or with WKH/\VRWUDFNHUSUREH and unlabelled 
NPs. For experiments C-E, cells were incubated only with YO fluorescent NPs/unlabelled NPs or the 
/\VRWUDFNHUSUREH 
For anti-LAMP 1 immunostaining studies, nanoparticles (unmodified and B12-
conjugated) were applied (in HEPES-buffered HBSS) to the apical side and the cells 
incubated at 37°C over 2 hrs. Following aspiration of the nanoparticle suspensions, 
the cells were fixed with 4% PFA. The cells were then permeabilised with 0.2% Triton 
X-100 over 10 min and after another wash step, incubated in PBS/1% BSA at 4°C for 
1 hr before the addition of anti-LAMP1 (lysosomal associated membrane protein-1) 
antibody (Sigma-Aldrich, UK), diluted 1:50 in PBS/1% BSA for 30 min. The cells were 
washed with PBS and incubated with the secondary antibody (goat, anti-rabbit IgG-
FITC, Sigma-Aldrich) diluted 1:100 (in 1% BSA/PBS) for another 30 min (whilst 
protecting from light). Staining for cell nuclei and confocal microscopy were conducted 
as described above.   
2.2.5.4  Zonula Occludens (ZO-1) TJ staining 
Confluent, filter-cultured cell layers (Caco-2 and Calu-3) were fixed in 
paraformaldehyde for approximately 10 min at room temperature. Cells were then 
washed with PBS and permeabilised by incubating with Triton X-100 (0.2% v/v in 
PBS) for approximately 10 min. Cells were then washed with PBS, followed by the 
application of 1% BSA/PBS for approximately 1 hour. Thereafter, BSA/PBS solution 
was aspirated and replaced with mouse, anti-human ZO-1 (primary) antibody, diluted 
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in 1% BSA/PBS to a final concentration of 10 ȝg/ml. The cell samples were incubated 
with the primary antibody for 45 min. The primary antibody solution was then removed 
and cells washed with PBS (5 times). Alexa fluor® 594-labelled goat, anti-mouse 
(secondary) DQWLERG\GLOXWHGDFFRUGLQJWRPDQXIDFWXUHU¶VLQVWUXFWLRQVLQ%6$3%6
was then applied to the cells for 30 min. The secondary antibody solution was then 
aspirated and cells washed with PBS extensively. 300 µl of Hoechst 33342 (100 
µg/ml) was added to the samples (for nuclei staining) and incubated at room 
temperature for 5 min. The Hoechst solution was then removed and the cells were 
washed 4 times with PBS. Transwell® filters (containing cells) were then excised and 
mounted using 1,4-diazabicyclo[2.2.2]octane (DABCO) (1% diluted in 9:1 
glycerol:PBS) on glass slides for confocal imaging, using the system described above. 
2.2.5.5  Clathrin and Caveolin-1 staining  
Filter-confluent Caco-2 and Calu-3 cells were fixed with 4% paraformaldehyde (PFA) 
(diluted in PBS) for 10 min at room temperature. The cells were permeabilised via the 
addition of 0.2% v/v Triton X-100 for 10 min. The cells were washed with PBS, before 
incubation with 1% BSA/PBS (for 1hr). The primary antibody rabbit, anti-human 
caveolin-1 (Santa Cruz Biotechnology, Inc.) was diluted 1:50 with 1% BSA/PBS and 
incubated with the cells for 30 min. For clathrin immunostaining, the primary antibody 
(rabbit, anti-clathrin (Abcam, UK)) was diluted 1:200 in 1% BSA/PBS. The cells were 
washed 3 times with PBS and incubated with the secondary antibody (goat, anti-rabbit 
IgG-rhodamine and goat, anti-rabbit IgG-FITC for caveolin-1 and clathrin, respectively) 
diluted 1:100 (in 1% BSA/PBS) for another 30 min. The control cell layers were 
incubated with the appropriate secondary antibody only. Following extensive washes 
with PBS, the cell nuclei were stained with Hoechst 33342 (100 µg/ml), the cells 
washed and the filter membrane excised from the insert. Cells were mounted on a 
slide using DABCO mounting medium and covered with a glass cover slip. Confocal 
imaging was carried out as detailed in sections above. 
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2.2.6  Molecular Biology techniques 
2.2.6.1  cDNA synthesis 
2.2.6.1.1 Isolation of mRNA from cells 
7KHFRPPHUFLDOO\DYDLODEOH0$&6NLW0LOWHQ\L%LRWHF8.ZDVXVHGWRH[WUDFWDQG
reverse transcribe mRNA from filter-cultured Caco-2 and Calu-3 cells on day 7 (Caco-
2 only), day 14 (Caco-2 only) and day 21 of Transwell® culture. This single-step 
method captures mRNA magnetically with oligo-dT magnetic beads. Before beginning, 
DOO VXUIDFHVZHUHFOHDQHGZLWK51DVH=$3VROXWLRQ7KHFHOOV were harvested and 
resuspended in 1 ml of lysis buffer (high salt buffer containing 1% SDS) per 107 cells. 
The cells were lysed completely by applying shear stress with vigorous vortexing for 3-
5 min. The resulting lysate was passed through a lysate column by centrifugation at 
14000 rpm in a desktop centrifuge for 3 min and mixed with oligo dT magnetic 
microbeads (50 µg/ml cell lysate), which bind to the mRNA. For mRNA isolation, the 
magnetically labelled mRNA contained in the lysate was applied to the MACSµ 
FROXPQ LQ WKH PDJQHWLF ILHOG RI WKH WKHUPR0$&6 VHSDUDWRU 7KH FROXPQ ZDV
prepared by rinsing with 100 µl of lysis/binding buffer and allowed to pass through. 
The column was rinsed twice with 200 µl lysis buffer and washed four times with 100 
µl low salt wash buffer containing NaCl, Tris-HCl and EDTA. The purpose of this step 
was to ensure complete removal of proteins and DNA from the lysate. The µMACS 
column was rinsed with lysis buffer before applying the lysate.  
2.2.6.1.2 cDNA synthesis 
Continuing from above (2.2.6.1.1), with mRNA remaining in the MACSµ column. 20 µl 
of the enzyme mix containing the reverse transcriptase and dNTPs was applied on the 
column matrix and incubated at 42°C for 1 hour. To prevent evaporation, sealing 
solution (1 µl) was applied at the top of the column matrix. The column was then 
rinsed twice with 100 µl of equilibration/wash buffer. 20 µl of cDNA release solution 
was then applied (for 10 min at 42°C). The newly synthesised cDNA was eluted with 
50 µl of cDNA elution buffer. Note, that 50 µl of sscDNA was collected per tube of 
which 20 µl was collected and pooled for primer optimisation.  
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2.2.6.2  Polymerase chain reaction (PCR) 
2.2.6.2.1 PCR Primer design 
Oligonucleotides for PCR amplification were designed using Primer-blast on the NCBI 
website. This program generates primer pair sequences based on a series of input 
criteria including intron exclusion and exon spanning regions, enabling differentiation 
between genomic DNA and complementary DNA (cDNA) of interest. Two different 
sets of PCR primers were used for human cubilin in Calu-3 and Caco-2 cells 
respectively. For Calu-3 work, HsCUBN_FOR and HsCUBN_REV primer pairs were 
employed (Table 2.2) and were designed from human cubilin sequence, National 
Center for Biotechnology Information (NCBI) Reference Sequence NM_001081.3. For 
caco-2 work, primer pairs HsCubilin_FOR and HsCubilin_REV were used (NCBI 
Reference Sequence NM_001081.3). PCR primers for human CD320; 
HsCD320_FOR and HsCD320_REV were designed from human CD320 sequence, 
NCBI Reference Sequence NM_016579.3. Finally, PCR primers for human caveolin-1: 
HsCAV1_FOR and HsCAV2_REV, with NCBI Reference Sequences: 
NM_001172897.1 NM_001172896.1, NM_001172895.1, NM_001753.4 were 
designed and synthesised by Sigma-Aldrich.  For verification of specificity (i.e. primers 
specific within the human genome) and assessment of amplification of known splice 
variants, all primers were blasted against the human genomic and reference mRNA 
sequences.  
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Primer 
 
¶- ¶VHTXHQFH 
 
Expected size 
(bp) 
 
HsCD320_FOR 
HsCD320_REV 
 
CACCCACCAAGTTCCAGTGCCG 
GTTCCACAGCCGAGCTCGTCG 
 
cDNA 
343/gDNA 
1,285 
 
 
HsCAV-1_FOR 
HsCAV-1_REV 
 
GAGCGAGAAGCAAGTGTACGA 
ACAGACGGTGTTGGACGTAGAT 
 
cDNA 
362/gDNA * 
 
HsCubilin_FOR 
HsCubilin_REV 
 
ACTCTTACCTGCCAACCAACCTGGGAGG 
AGCAGACCCCGTAAGAAACACCAA 
 
cDNA 
201/gDNA 594 
 
HsCUBN_FOR 
HsCUBN_REV 
 
TCCGGCAGACATTGGGGCCT 
TCCGTGACCCTGCGGTGAGT 
cDNA 
602/gDNA 292-
4170 
 
Table 2.2.  Oligonucleotide primer sequences for TCIIR, Caveolin-1 and cubilin 
expression analysis.  
PCR primers designed for human TCIIR (CD320), human Caveolin-1 (CAV-1), and human cubilin 
(Cubilin/CUBN) shown with respective cDNA and genomic DNA sizes. The resulting amplified PCR product 
was the size of the cDNA.* denotes primers are specific for cDNA amplification (no target on genomic DNA).  
 
2.2.6.2.2 Sample preparation  
Standard 2x PCR ready-to-XVH 0DVWHU 0L[ 5HGG\0L[ $%JHQH®), containing the 
following components: 1.25 units Thermoprime plus DNA polymerase, 75 mM Tris-HCl 
(pH 8.8 at 25°C), 20 mM Ammonium sulphate, 1.5 mM MgCl2, 0.01% (w/v) Tween 20, 
0.2 mM (each of) dATP, dCTP, dGTP and dTTP, was used in PCR experiments. The 
5HGG\0L[ 3&50DVWHU 0L[ LV IRUPXODWHG ZLWK D UHGG\HDQG SUHFLSLWDQW IRU GLUHFW
loading of PCR products onto agarose gels for electrophoresis. The final PCR reaction 
mixture consisted of 10 µl PCR Master-Mix, 1 µl each of forward and reverse primers 
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for the gene of interest (5 µM each final concentration), 1 µl DNA template (extracted 
cDNA of filter-cultured Caco-2 and Calu-3 cells) and 7 µl nuclease free water (Roche, 
UK), making a final volume of 20 µl per micro tube. The master mix prepared for 
CD320 samples comprised a hot start enzyme. The final reaction mixture (per tube) 
here consisted of 7.5 µl of GoTaq® Hot Start Green Master Mix, 2x (Promega), 5.25 µl 
nuclease free water, 1.5 µl each of CD320 forward and reverse primers (5 µM final 
concentration) and 0.75 µl DNA template. GoTaq® Hot Start Polymerase is supplied 
LQ;*UHHQ*R7DT5HDFWLRQ%XIIHU S+ȝ0G$73ȝ0G*73ȝ0
G&73ȝ0G773DQGP00J&O2. Green GoTaq® Reaction Buffer is a proprietary 
buffer containing a compound that increases sample density, and yellow and blue 
dyes, which function as loading dyes when reaction products are analysed by agarose 
gel electrophoresis. 
2.2.6.2.3 PCR cycles 
PCR amplification of calu-3 cDNA for human cubilin was performed using the following 
sequential cycles: initial heating at 94°C for 5 min, 94 for 30 sec, annealing at 60°C for 
45 sec, extension at 72°C for 90 sec, and this cycling repeated 34 times, followed by a 
final extension at 72°C for 5 min to ensure completion of all strands. A similar PCR 
programme was followed for human CD320, human cubilin (for Caco-2 cDNA only) 
and human caveolin-1 with both Caco-2 and Calu-3 cDNA templates, but with 
annealing steps at 58°C. Reactions were carried out in a PTC-200 Peltier Thermal 
Cycler (MJ Research, UK). The reaction mixes were incubated at 4°C prior to DNA 
agarose gel electrophoresis. 
2.2.6.2.4 DNA Agarose Gel electrophoresis 
Agarose gels were prepared using a well-established protocol, developed by the 
group and adapted from Sambrook et al. [12]. Briefly, 1% (w/v) agarose gels were 
prepared using analytical grade agarose (Promega, UK) in 0.5X TBE buffer (1 M Tris-
HCl; 1 M Boric Acid; 0.05 M EDTA; pH 8.0) with the addition of ethidium bromide (10 
JPOȝOȝJRI7UL'\HES'1$/DGder (New England Biolabs) was loaded 
per gel lane (2 lanes per gel on either side of DNA samples). The DNA samples were 
loaded (15-20 µl per gel lane) and the gels were run in 0.5X TBE buffer and 
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electrophoresis was performed using a horizontal gel apparatus (Fisher Scientific, UK) 
at 100-110 V. DNA fragments were visualised on a UV transilluminator with Gene 
Genius Bio imaging software (UVP, USA).  
2.2.7  Statistical Analysis  
Statistical comparisons (for a maximum of two data sets in any given comparison) 
were performed by Student's t-test generated using Microsoft Excel (2007). Values of 
p<0.05 were considered statistically significant. One way analysis of variance 
(ANOVA) followed by Bonferroni post-hoc test was applied for comparison of group 
means of three or more groups. P values of < 0.05 were considered statistically 
significant. *, **, *** and **** indicate p<0.05, p<0.01, p<0.001 and p<0.0001, 
respectively.  
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Chapter 3: Characterisation of the Caco-2 intestinal 
model 
3.1 Introduction 
Mucosal drug absorption has been extensively investigated in vitro with the aim of 
understanding, and potentially predicting, drug absorption and bioavailability in vivo. 
This requires the use of mucosal tissue models, either based on excised mucosal 
tissues, three dimensional models based on multiple cell types or epithelial cell layers 
of primary and cancerous cell lines (Figure 3.1). Each of these systems is associated 
with its advantages and disadvantages. For example, although the in vivo tissue 
characteristics are most closely represented by an excised tissue of interest (usually 
from animals with similar tissue characteristics to humans), this model undoubtedly 
requires animal sacrifice and suffers from limited viability of the tissue ex vivo.  
 
Models based on polarised epithelial cell monolayers are extensively used as suitable 
in vitro alternatives to animal work in the early phase drug development process. In 
this respect, the Caco-2 cell line is commonly used to produce such a monolayer 
model of the intestinal epithelium. Apart from offering reduced operational costs and 
potentially reducing animal usage [1], in vitro cell systems can be manipulated in ways 
that would be impossible in vivo, enabling studies on the effects of different variables 
(e.g. temperature and pharmacological agents), which is particularly useful for 
investigating the mechanisms of drug absorption. A significant amount of knowledge 
related to drug transport mechanisms has been obtained from studies in various 
epithelial cell cultures and these models are routinely used as a screening tool in the 
pharmaceutical industry for the prediction of intestinal drug absorption [2]. This is due 
to a reasonably acceptable correlation between passive drug transport through the 
epithelial cell monolayers and that observed across the human intestine in vivo [3-5]. 
The importance and credibility of the data obtained from drug transport experiments 
on epithelial cell monolayers is reflected in the fact that both the FDA and the 
European Medicines Agency [6] recommend the use of monolayers of suitable 
epithelial cells for classifying the permeability of drug compounds and for monitoring 
Chapter 3: Characterisation of the Caco-2 intestinal model 
80 
 
drug-drug interactions. From the pharmaceutical industry perspective, in vitro 
monolayer systems are useful in early phases of drug development and are central to 
the process of the Biopharmaceutics Classification System (BCS), serving to identify 
promising drug candidates, which are then subject to more rigorous (qualitative) in 
vivo investigations. However, homogenous epithelial cell cultures lack the structural 
complexity and variability found in vivo and for this reason it is important to be 
cautious when extrapolating in vitro cell model results to the in vivo situation and to 
compare results obtained from the two systems.  
 
Figure 3.1. Schematic representation of the Transwell® system: cells cultured on 
permeable supports. 
 
Reproducing the features of the mucosal tissue in vivo is an obvious consideration for 
the establishment of a successful epithelial cell layer model. In this respect, selecting 
the appropriate cell line expressing relevant morphological features, transporters and 
enzymes which reflect the tissue of interest is of paramount importance. Once an 
adequate cell line is chosen, culture conditions may require optimisation. This includes 
parameters such as seeding density (on permeable supports), time to differentiation, 
and growth medium. In the process of culturing epithelial cells as mucosal tissue 
models (as polarised monolayers on permeable supports), measurement of 
transepithelial electrical resistance (TEER) is routinely employed as an indication of 
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cell confluence, tight junction formation and cell layer integrity [7] and is also used as 
an indirect measure of cell toxicity [8, 9]. 
Colorectal carcinoma-derived Caco-2 cells, when differentiated, resemble enterocytes 
lining the small intestine [10, 11]. These cells express tight junctions, microvilli, a great 
number of relevant enzymes and transporters and evidence from extensive research 
with this cell line has generally demonstrated a good correlation between the in vitro 
permeability and the in vivo drug absorption [3].  
The work detailed in this chapter assessed the suitability of Caco-2 cell monolayers as 
a model for the vitamin B12 transport system, laying the foundations for subsequent 
work (Chapters 4-7) investigating the use of the vitamin B12 transport pathway for the 
transmucosal delivery of nanoparticulate carriers. Additionally, the Caco-2 cell line 
used in this work was also validated as an epithelial barrier that is suitable to study 
macromolecular absorption (by determining cell morphology and testing the 
permeability of model macromolecules). This was considered important as, although 
this cell line has been thoroughly characterised as an intestinal model [12-15], Caco-2 
cells are a diverse line consisting of subpopulations that may vary in terms of the 
extent of differentiation, which are further influenced by culture conditions, time in 
culture, and batch to batch differences [16-18]. Consequently, large inter-laboratory 
differences in characteristics exist and therefore it is crucial that the specific batch of 
cells is independently assessed. With respect to establishing the appropriateness of 
the Caco-2 model to study the vitamin B12 transport system, work was conducted to 
determine gene expression and immunohistochemical analyses for the key proteins 
involved in the internalisation and transport of vitamin B12 in vivo, including the B12-IF 
receptor, cubilin; the secondary receptor, transcobalamin II receptor (TCIIR), and the 
TCII carrier protein.  
3.2 Methods 
3.2.1  TEER profile  
Caco-2 cells were cultured on flasks until confluence. Cells were detached from the 
flasks, seeded on Transwell® permeable supports, following the methods detailed 
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previously (section 2.2.1). TEER measurements were conducted (in the manner 
described in section 2.2.2) every 2 or 3 days, starting from day 2 to day 30 of culture.  
3.2.2  Morphological characterisation  
Caco-2 cells were cultured on permeable supports to form polarised monolayers, as 
detailed in section 2.2.1. Cells were imaged on day 21 of culture as confluent and 
polarised monolayers (as judged by TEER measurements). SEM, TEM, and Zonula 
Occludens-1 (ZO-1) staining were performed according to methods described in 
section 2.2.5. 
3.2.3  Barrier property of Caco-2 monolayers  
3.2.3.1  Permeability of varying molecular weight FITC-labelled dextrans 
FITC-dextrans (FD) of varying molar mass were used as model macromolecules. The 
permeability experiments were conducted at 37 °C or 4 °C. Culture medium was 
initially replaced with warmed (37 °C) HBSS (transport medium). Cell monolayers  
were allowed to equilibrate in HBSS for approximately 15 min prior to TEER 
measurements, which were conducted in order to confirm cell layer intactness and 
selection of those with appropriate values (sections 2.2.2 and 2.2.3). Prior to 
application of FDs, cells were equilibrated in HBSS (pre-warmed to 37 °C or cooled to 
4 °C) for approximately 45 min. HBSS was then removed from the apical side and 
replaced with FD solutions, comprising of FD4, FD10, FD20, FD40, FD70 or FD150 
GLVVROYHG LQ +%66  Û& RU  & DW  JPO &HOOV ZHUH HLWKHU placed in the 
LQFXEDWRU DW  Û& RU LQ WKH IULGJH DW  Û& LQ EHWZHHQ VDPSOLQJ LQWHUYDOV )'
permeability was determined as detailed in section 2.2.3.  
3.2.3.2  Dynamic light scattering characterisation of FITC-labelled dextrans 
The mean hydrodynamic diameter of FDs was determined by Dynamic Light 
Scattering (DLS) using a Viskotec 802 system. FD4, FD10, FD20, FD40, FD70 and 
FD150 were dissolved in HBSS at 1 mg/ml (at pH 7.4) to replicate the conditions in 
which the FDs were applied to cells and were analysed using the default programme 
setting, wherein the optimal intensity count was 300 k counts and the temperature was 
25 °C. An average of 10 readings per sample were taken. Omnisize software was 
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used to calculate the size data.  The experimental values obtained were plotted 
against the nominal diameters provided the FD's supplier, Sigma-Aldrich. 
3.2.3.3  Insulin translocation across Caco-2 monolayers 
Caco-2 cells were cultured on filters as before and used as polarised monolayers. 
Permeability experiments commenced after replacement of the culture medium with 
HBSS and equilibration in HBSS (for approximately 30 min). Stock solutions of FITC-
insulin dissolved in HBSS DWS+DWDFRQFHQWUDWLRQRIȝJPOZHUHSUHSDUHG
on the day of the permeability experiment. FITC-insulin solution was applied to the 
DSLFDOVLGHRIWKHFHOOVDWDILQDOFRQFHQWUDWLRQRIȝJPOLQ+%66S+DQGLWV
transport across the cell layers was determined by sampling the basolateral solution 
ȝODWUHJXODUWLPHLQWHUYDOV7KHVDPSOHGYROXPHVIURPWKHEDVRODWHUDOFKDPEHU
were replaced with fresh HBSS. FITC-Insulin transport was quantified by fluorescence 
measurements (485 nm excitation, 535 nm emission), with reference to a pre-
constructed calibration curve of fluorescence intensity against concentration. The 
known concentration was converted into the amount and data is expressed as 
apparent permeability coefficient (Papp), as well as in micrograms (µg) transported over 
time.   
3.2.3.4  Nanoparticle (NP) transport across Caco-2 monolayers 
Caco-2 cells were cultured on filters in the manner described previously (section 
2.2.1). Cell monolayers were equilibrated in HBSS for approximately 45 min. TEER 
was measured just before the addition of nanoparticles; Caco-2 monolayers with a 
7((5 800 ȍFP2 were included in the experiment. Carboxy-modified, fluorescent 
(yellow-orange) polystyrene nanoparticles (Fluoresbrite®) of 50 nm, 100 and 200  nm 
nominal diameter, were diluted in HBSS (to a final concentration of 400 µg/ml) and 
applied to the apical side of the cell layers. Apical-to-basolateral translocation was 
PHDVXUHGE\VDPSOLQJWKHEDVRODWHUDOVROXWLRQȝODWPLQLQWHUYDOVIRUhours, 
with an initial sampling point after 15 min. The extent of NP translocation across the 
cell layers was determined by measuring the fluorescence (529 nm excitation, 546 nm 
emission) of the basolateral solutions and converting the values obtained into 
concentrations and through pre-constructed calibration curves (based on the same 
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principle as for FITC-Insulin quantitation). NP transport across the cell layers is 
expressed as amount in micrograms over time.  
 
3.2.5  Validation of Caco-2 monolayers as a model for vitamin B12 transport 
3.2.5.1  Immunohistochemical analysis of cubilin and TCII 
Filter-cultured Caco-2 cells were selected for immunostaining experiments on day 21 
of culture. The culture medium was removed and cells incubated with HBSS for 45 
min, followed by measurement of TEER. The cell monolayers were then fixed with 4% 
paraformaldehyde (diluted in PBS) for 10 min at room temperature. For TCII samples, 
an additional permeabilisation step was conducted via the addition of 0.2% (v/v) Triton 
X-100 for 10 min. Cells were washed with PBS, before incubation with 1% BSA/PBS 
(for 1hr). The primary antibodies for cubilin and TCII (cubilin H-300; Transcobalamin II 
H-260; both rabbit, anti-human; Santa Cruz Biotechnology, Inc.) were diluted 1:50 with 
1% BSA/PBS and incubated with the cells for 30 min. The cells were washed 3 times 
with PBS and incubated with the secondary antibody (goat, anti-rabbit IgG-rhodamine) 
diluted 1:100 (in 1% BSA/PBS) for another 30 min. The control cell layers were 
incubated with the secondary antibody only. Following a final wash step, the cell nuclei 
were stained with Hoechst 33342 (0.1mg/ml), cells washed and the filter membrane 
excised from the insert. Cells were mounted on a slide using 1,4-
diazabicyclo[2.2.2]octane (DABCO) (1%, diluted in 9:1 glycerol:PBS) and covered with 
a glass cover slip. Confocal imaging was carried out using a Leica SP2 CLSM 
confocal microscope. 
 
3.2.5.2  mRNA expression of cubilin and Transcobalamin II receptor  
mRNA was isolated from filter-cultured Caco-2 on day 7, day 14 and day 21 of culture 
on Transwell® inserts, using the method described in section 2.2.6.1.1. cDNA was 
synthesised using the protocol described in section 2.2.6.1.2. A conventional PCR 
was performed on the PTC-200 Thermal Cycler to amplify the cDNA, which was then 
visualised using gel electrophoresis (section 2.2.6.2). The expected size of the 
amplified cDNA fragments was 201 bp for cubilin and 343bp for CD320 (encoding 
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Transcobalamin II receptor). The reader is referred to section 2.2.6.2.1 for primer 
details.  
3.3 Results and discussion 
3.3.1  TEER profile  
TEER is a convenient, reliable and non-destructive method to monitor the growth of 
epithelial tissue cultures in vitro, evaluate cell layer integrity and indicate the presence 
of the cellular tight junctions (TJs) [7] (Chapter 2, section 2.2.2 contains further 
details). Figure 3.2 shows the TEER profile over time in culture for Caco-2 cells grown 
on permeable supports. Cells exhibited a continuous and steady increase in TEER, 
which reached up to 2250 ȍFP2 (on day 21 of culture). TEER values then 
progressively decreased from day 21 to day 30 of culture (cells displayed lower values 
of ~1430 ȍFP2 at the terminal measurement point), presumably as a result of altered 
cell morphology, changes in TJ distribution and loss of single cell layer organisation. 
Reported TEER values in the literature for Caco-2 monolayers vary considerably from 
150-400 ȍFP2 [19], up to >2000ȍFP2 [20, 21], and this variability is thought to arise 
from differences in the culture conditions employed (e.g. culture medium or permeable 
supports used), passage number and also owing to the fact that different 
subpopulations of Caco-2 cell cultures exist, which may vary in terms of degree of 
differentiation [16].  
 
 
Figure 3. 2. TEER profile of Caco-2 cells cultured on permeable inserts.  
TEER is expressed as the measured resistance per area (cm2) of the cell layer. Background TEER due to 
the filter was subtracted from the reported TEER values. Data presented as the mean ± SD (n=5). 
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3.3.2  Morphological characterisation of Caco-2 cells 
3.3.2.1  Electron microscopy 
SEM micrographs (Figure 3.3a) reveal that Caco-2 cells cultured on permeable 
supports form a closely packed layer of cells, with distinct, heavily folded cell-cell 
boundaries (indicated within white boxes). Furthermore, structures likely representing 
microvilli on the cell surface are clearly apparent. TEM micrographs (Figure 3.3b) 
depict two adjacent Caco-2 cells inter-connected by a TJ (Tj). The intercellular TJs 
provide a structural barrier against paracellular permeation [22, 23], thus maintaining 
the restrictive barrier of the mucosae. As is shown in the figure, TJs typically encircle 
the epithelial cells in a belt-like manner at the apical cellular borders [24]. Other 
cellular structures, including the cell nuclei (Nu), mitochondria (Mc) and microvilli (Mv) 
are also clearly apparent, consistent with reports from other groups [25, 26]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. 3. Morphological characterisation of the Caco-2 monolayer model.  
a) SEM micrographs, with the expanded region of Caco -2 monolayer; ( i) showing cel l -cel l  
boundaries and magnif ied image (i i ) depict ing convolut ed cel l -cel l  boundaries (white 
boxes) and microvi l l i .  The observed cracks are  bel ieved to be art i facts result ing from 
sample processing for imaging. b) TEM micrographs of f i l ter cultured Caco -2 cel ls 
depict ing adjacent Caco-2 cel ls interconnected by a t igh t junct ion (Tj) ( i) and a magnif ied 
region of two cel ls ( i i ) depict ing a t ight junct ional boundary (Tj) and other cel lular 
structures including cel l  nuc leus (Nu), mitochondria (Mc) and microvi l l i  (Mv). Scale bars  
representing 2 µm (bi) and 1 µm (bi i).  
b) i ii 
a) i  ii 
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3.3.2.2  Zonula-Occludens-1 (ZO-1) staining 
Immunofluorescence staining of polarised Caco-2 cells with an antibody to ZO-1 
protein, a structural and functional component of TJs, revealed the distribution of this 
protein as continuous circumcellular 'rings' at cell-cell contacts (Figure 3.4). The 
images clearly highlight a relatively convoluted organisation of the cell-cell boundaries. 
This observation (which was reproducible) is important, as the obvious consequence 
of tight junction organisation in this manner is a large surface area of the paracellular 
space. Interestingly, similar ZO-1 organisation in Caco-2 cells was also observed by 
Man et al. [27], Lindmark et al. [28] and Dickman et al. [29], though the authors of 
these studies did not discuss the importance of this observation. 
  
 
 
 
 
 
 
Figure 3. 4. Staining of polarised Caco-2 cells for Zonula Occludens-1 (ZO-1) TJ protein.  
a) Overlay image of Caco-2 monolayer showing DAPI -label led cel l  nuclei  and ZO-1 
distribut ion (Alexa f luor®594-label led, ant i -mouse IgG, and mouse, ant i -human ZO-1), b) 
Red channel showing ZO-1 distribut ion (Alexa f luor ®594-label led goat,  ant i -mouse IgG, 
and mouse, ant i -human ZO-1).  
 
  
a) b) 
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3.3.3  Barrier properties of Caco-2 cell layers 
3.3.3.1  Permeability of varying Mw FITC-dextrans 
As detailed in Chapter 2 (section 2.2.3), epithelial monolayer integrity is often 
assessed by measuring the transport of a hydrophilic marker molecule (frequently 
used a macromolecular drug models) that is passively transported through the cell 
layer, paracellularly [30]. In these studies, fluorescein isothiocyanate (FITC)±labelled 
dextrans (FDs) of varying molecular weights (MWs) were used as macromolecular 
markers, modelling hydrophilic, large MW protein drugs. Figure 3.5 shows the 
permeability, expressed as the apparent permeability coefficient (Papp) (Section 2.2.3), 
of FITC-dextran of varying molecular mass across polarised Caco-2 monolayers. The 
permeability was tested under normal cell culture conditions (37 ºC) and at 4 ºC 
(where energy requiring transcellular transport processes are inhibited and passive 
transport through the paracellular route is not significantly affected). Up to a certain 
molecular mass, macromolecules preferentially traverse the epithelium via the 
paracellular route (the macromolecule is accommodated by the paracellular corridor), 
with active transport processes (such as pinocytosis) likely to be involved to a lesser 
extent. 
 
The data in Figure 3.5 shows a pattern of decreased transepithelial permeability with 
increasing solute molecular mass from 4 kDa (FD4) to 150 kDa (FD150). In this 
respect, Papp decreased from 227x10-9 to 14.1x10-9 cm/s across the range of FDs 
tested. The trend of reduced solute permeability with increasing molecular mass 
indicates that the Caco-2 cell monolayer model used in this work forms a functional 
epithelial barrier capable of discriminating between hydrophilic compounds depending 
on their size. This property is typical for polarised epithelial cells that are used as 
mucosal tissue models [14, 20, 31, 32]. Indeed, the pattern of reduced absorption 
(indicating decreasing permeability) with an increase in molecular mass of the 
permeant is observed in vivo, which is reflected by a decreased absorption as the 
molecular weight of the permeant (or therapeutic) increases. For example, Miyamoto 
et al. [33] reported an exponential decrease in the bioavailability of FDs with 
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increasing MW  from 4.3 to 167 kDa following nasal administration in rats, even when 
co-administered with a TJ-opening absorption enhancer, poly-L-arginine.  
 
It is interesting to note that at 37 ºC the difference in permeability between FD4 
(227x10-9 cm/s) and FD10 (222x10-9 cm/s) was not statistically significant, despite the 
considerable difference in molecular mass (4 kDa versus 10 kDa). The permeability of 
FD20 was approximately 2-fold lower than that of FD10 (101x10-9 cm/s versus 
222x10-9) and an increase in molar mass from 40 kDa to 70 kDa induced a 5-fold 
reduction in FD permeability (from 89.7x10-9 to 16.7x10-9 cm/s for FD40 and FD70, 
respectively). Further work assessing FD permeability at 4 °C (whereby any observed 
permeability predominantly occurs passively) was conducted to determine the 
contribution of the paracellular route to the overall transport. FD permeability was 
significantly reduced at 4 °C, as compared to that at 37 °C, a finding that is in 
agreement with a previously-reported study [34]. Comparing FD4 permeability at both 
temperatures, the data reveals a reduction in permeability at 4 °C that amounted to 
2.5-fold. For FDs in the middle of the tested molecular weight range, the extent of the 
suppression of permeability was higher and amounted to 4.3-, 6-, and 7.2-fold for 
FD10, FD20 and FD40, respectively. These results hence indicate that the 
contribution of the paracellular route towards the overall permeability across Caco-2 
monolayers is the largest for FD4 and then decreases as the molecular weight of the 
solute increases (from FD10 to FD40). The pattern of change in FD permeability with 
molecular weight hence indicates that there is a shift from approximately equal 
transcellular and paracellular contribution to overall transport with FD4 to 
predominantly transcellular route with larger dextrans such as FD20 and FD40. Note 
that although the difference in permeability between 37 °C and 4 °C for larger 
dextrans (FD70 and FD150) was not statistically significant, this is thought to result 
from the very low level of permeability at both temperatures. 
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Figure 3. 5. Permeability of model permeants, FITC-dextrans of varying molecular 
weights) across Caco-2 monolayers. 
FITC-dextrans of molecular weight:  4 kDa (FD4),  10 kDa (FD10), 20 kDa (FD20),  40kDa 
(FD40), 70 kDa (FD70) and 150 kDa (FD150) Permeabil i ty exper iment was conducted at  
37 ºC and at 4 ºC.  Permeabil i ty was expressed as apparent permeabil i ty coeff ic ient (P app)  
and data presented as the mean ± SD (n=4). Stat ist ical comparisons at 37°C (black) 
shown for FD10 vs. FD4, FD20 vs. FD10, FD40 vs. FD20, FD70 vs. FD40, FD150 vs. 
FD70. Stat ist ical comparisons at 37°C vs. 4°C (shown in blue) for each molecular weight  
FD. 
 
3.3.3.2 Dynamic light scattering study on different Mw dextrans: relating 
diameter with routes of transport 
Figure 3.6a shows DLS data for a series of FITC-dextrans used in the permeability 
study above. For the purpose of comparison, nominal radii information provided by the 
supplier (Sigma Aldrich) has been included. The results reveal a directly proportional 
relationship between the dynamic radii of the dextran and its molecular weight (plotted 
as a logarithmic scale), with the exception of FD150 (150kDa) where measurements 
show a larger standard deviation, possibly due to aggregation in solution. Obtaining 
data on the hydrodynamic radius of each dextran enables further interpretation of the 
permeability data. Plotting the Papp values against the molecular weight of FDs (data 
from figure 3.5) again highlights the extent to which permeability depends on the 
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molecular weight of the permeant (Figure 3.6b). Considering the molecular size 
(hydrodynamic radii determined by DLS), the overall contribution of the paracellular 
route is the largest with the smallest dextran of 3.6 nm (hydrodynamic radius: 1.8 nm), 
FD4, as suggested by the low reduction in permeability at 4 °C. The involvement of 
the paracellular pathway gradually decreases as solute molecular size (hydrodynamic 
radius) increases to 11.2 nm (FD40). The data hence indicates that the tight junctions 
of polarised Caco-2 monolayer model used in this work display some restriction in 
permeability of solutes of around 3.6 nm in diameter, though this barrier in 
permeability is notably higher for solutes larger than 5.4 nm (FD10-FD40). Again, 
FD70 and FD150 do not follow these trends, presumably due to the sensitivity of 
fluorescence quantitation at very low concentration levels (low permeability). 
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Figure 3. 6. Relationship between FDs molecular weight and particle size with 
permeability in Caco-2 monolayers.  
a) DLS measurements of FD4, 10, 20, 40, 70 and 150 (KDa), b) P ap p  data for FD4, 10, 20, 
40, 70 and 150(KDa) at 37°C and 4°C, plotted against a logarithmic scale of the 
molecular weight of each FD. Data expressed as mean ± SD (n=4).  
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3.3.3.3  Insulin translocation across Caco-2 monolayers 
In an attempt to confirm that the Caco-2 monolayers used in this study also exhibit a 
barrier to the permeability of a therapeutic peptide, the permeability of FITC-insulin 
across the polarised cells was investigated as a 'model' protein used in this field. The 
data in Figure 3.7 shows a linear transport profile of FITC-insulin over time, with a 
steady increase from 0.4-5.9 µg in the basal chamber after 3 hrs (calculated Papp value 
amounted to 1.34x10-6 cm/s), which is similar to the value reported by Sadeghi et al. 
[35], where cumulative insulin transport was reported to be reach around 7.5 µg over 4 
hrs in Caco-2 monolayers.  
 
 
 
  
 
 
 
 
 
 
 
Figure 3. 7. Translocation of FITC-insulin across Caco-2 monolayers over 3 hours. Data 
presented as the mean ± SD (n=4).  
 
Due to the similarity in molecular weight, it is tempting to compare the permeability of 
FITC-insulin with FD4. This would highlight a higher permeability of FITC-insulin 
relative to FD4 (Papp 1.34x10-6 cm/s versus 2.27x10-7). However, it must be noted that 
this comparison in permeability between insulin and FD4 may not be wholly 
appropriate considering the difference in molecular structure of the two compounds. In 
this respect, insulin is a globular molecule existing in aqueous environment as a 
mixture of dimers, tetramers, and hexamers in equilibrium [36], with the hexameric 
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conformation having a hydrodynamic radius of 2.8 nm [37]. On the other hand, FD4 
has a linear geometry with a hydrodynamic radius of 1.8 nm. 
3.3.3.4  Nanoparticle transport across Caco-2 monolayers 
In addition to testing the permeability of hydrophilic macromolecules and a model 
therapeutic protein, the movement of nanoparticles across Caco-2 monolayers was 
also assessed. This work was conducted to provide an initial indication of the extent of 
the barrier presented by Caco-2 monolayers to nanoparticle translocation since 
nanoparticle-mediated drug delivery is central to this thesis (as will be shown in 
subsequent chapters). Transmucosal transport of nano-scale materials is potentially 
beneficial to the field of drug delivery [38-43] due to their potential to act as therapeutic 
carriers and their ability to enhance drug delivery by providing protection of the 
therapeutic, controlled release, and/or altering drug clearance. Apical-to-basolateral 
movement of negatively charged polystyrene nanoparticles (nominal diameters of 
50,100 and 200 nm) across Caco-2 cells is depicted in Figure 3.8. Nanoparticle 
transport across the cell monolayers amounted to <1% of the applied amount over 3 
hours, highlighting the efficiency of the epithelial barrier towards the movement of 
nanoparticulates. The cumulative amount of nanoparticles traversing the cell 
monolayers reached between 1.2-2.2 µg (depending on nanoparticle size), which is 
similar to an earlier observation reported by Vllasaliu et al. [44] in bronchial Calu-3 
cells, where 1.25 µg of negatively charged polystyrene nanoparticles traversed the cell 
layers. Rates of transport are somewhat similar for all nanoparticle sizes, though there 
are small differences in the transported amount at the terminal time point, where the 
amount of transported 100 nm particles reached the highest value of 2.2 µg, 
compared to 50 nm and 200 nm particles (1.2 µg and 1.5 µg, respectively). Note that 
the uptake and translocation of nanoparticles across Caco-2 monolayers (together 
with the associated biological mechanisms involved in these processes) is studied in 
detail in the later sections of this thesis.  
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Figure 3. 8. Translocation of nanoparticles of 50 and 100 nm NPs across Caco-2 cell 
monolayers.  
Nanoparticles (fluorescently-labelled, carboxy-modified polystyrene of 50 nm, 100nm and 200 nm nominal 
diameter) were applied at 400 ȝJPO Nanoparticle translocation expressed as amount of nanoparticles 
transported to the basolateral chamber. Data presented as the mean ± SD (n=3).  
 
3.3.4  Validation of Caco-2 monolayers as a model for B12 transport 
3.3.4.1  Staining for cubilin and TC II 
Following appropriate morphological and barrier characterisation of Caco-2 (intestinal) 
model used in this thesis, subsequent work was conducted to confirm its suitability as 
a model to study the vitamin B12 uptake/transport pathway. Initial work determined 
whether the Caco-2 cultures expressed the appropriate structural components 
involved in vitamin B12 uptake and transport. In this respect, the expression of the 
vitamin B12 cell surface receptor, cubilin [45-47], was tested. Confocal micrographs of 
polarised Caco-2 monolayers, immunostained on day 21 of culture, indicate 
expression of the cubilin receptor (Figure 3.9a i), as suggested by the presence of red 
fluorescence signal (associated with the secondary antibody directed to primary, anti-
cubilin antibody) at the periphery of adjacent cells. By contrast, in the control sample 
(Figure 3.9a ii) where the treatment with the primary, anti-cubilin antibody was omitted, 
secondary antibody-associated fluorescence was not observed, almost eliminating the 
possibility of an experimental artefact (false fluorescence signal) resulting from non-
specific antibody binding.  
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Cubilin is just one component of the cell machinery responsible for trafficking of 
vitamin B12. Therefore, in addition to confirming cubilin expression, further work was 
conducted to determine whether polarised and differentiated Caco-2 cells express 
another relevant component of the transport pathway. Immunostaining for TCII, a key 
protein involved in the binding and transport of vitamin B12 out of the enterocytes in 
vivo [1], indicated its presence in Caco-2 cells (Figure 3.9b i). Furthermore, its 
distribution was not confined to single regions of the cell but was found throughout the 
entire cytoplasm, consistent with its function of binding to vitamin B12 upon exit from 
the lysosomes for transport out of the cell. In the control sample treated only with the 
secondary antibody fluorescence was not observed (Figure 3.9b ii), hence minimising 
the possibility of non-specific secondary antibody binding. It should be noted that 
immunostaining of the TCII receptor, which permits the active internalisation of vitamin 
B12 in the absence of intrinsic factor in vivo, was not carried out due to the lack of 
commercially-available primary antibodies at the time of study.  
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Figure 3. 9. Expression of cubilin (vitamin B12-IF receptor) and transcobalamin II (TCII) by 
immunohistochemistry in polarised Caco-2 monolayers on day 21 of culture.  
a) Expression of cubilin receptor by treatment of cells with anti-human cubilin H-300 followed by goat, anti-
rabbit IgG-Rhodamine (i) and control where cells were treated only with the secondary, goat, anti-rabbit IgG-
Rhodamine (ii). b) Expression of TCII, shown by treating cells with anti-human TCII H-260, followed by goat, 
anti-rabbit IgG-Rhodamine (i), and control monolayer, incubated with goat, anti-rabbit IgG-Rhodamine only 
(ii). Scale bar sizes represent 20, 50, 10 and 48 µm for ai, aii, bi and bii, respectively. 
3.3.4.2  mRNA expression of cubilin and Transcobalamin II receptor in Caco-2 
monolayers 
Caco-2 cells monolayers were analysed using RT-PCR and gel electrophoresis to 
determine mRNA expression of cubilin and CD320 (transcobalamin II receptor). 
mRNA expression analysis was conducted following culture of Caco-2 cells on 
permeable supports for 7, 14 and 21 days. This was done with the view of establishing 
whether the expression of these components at the mRNA level in Caco-2 cells 
occurs at earlier time points (day 7 and 14) than the usually used culture period for cell 
a) i ii 
i ii b) 
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differentiation (21 days, routinely used in this work). Figure 3.10 reveals expression of 
both cubilin (A) and CD320 (B) in Caco-2 cells on day 7, 14 and 21 (cDNA 
amplification products of 201 and 343 bp, respectively). Other non-specific bands 
were detected (day 7 and 14 for cubilin), depicting smaller fragments which may result 
from primer-cross reactivity, as a consequence of lower levels of cDNA template 
present in these samples, or primer adducts (e.g. primer dimers). Analysis of CD320 
mRNA reveals a secondary fragment (~260bp) in addition to the band detected at 343 
bp (Figure 3.10B) possibly resulting from an alternatively spliced transcript variant 
encoding a different isoform.  
 
Figure 3. 10. Expression of cubilin (A) and CD320 (B) mRNA in Caco-2 cell monolayers 
analysed on day 7 (D7), day 14 (D14) and day 21 (D21) of culture (n=2).  
 
As cubilin, the TCII receptor and the TCII carrier proteins are vital facilitators for a 
functional vitamin B12 transport pathway. Therefore, the findings confirming the 
expression of these components at mRNA level (Figure 3.10) were essential for the 
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validation of the Caco-2 cell line for further work on the vitamin B12 pathway. The 
expression of cubilin in Caco-2 cells has previously been shown, prompting 
investigations assessing the possibility of exploiting the vitamin B12 transport pathway 
for drug delivery purposes in this cell line [48-52]. However, whilst some authors have 
speculated over the expression of TCII receptor on the apical surface of Caco-2 cells 
[53], this work sought to provide further evidence for expression as a rationale behind 
receptor-mediated vitamin B12 uptake and transport in the absence of IF. 
Aforementioned, owing to the unavailability of antibodies for the TCII receptor, 
immunohistochemical analyses could not be used to show expression at the protein 
level. Instead, gene expression by PCR was used to verify that mRNA transcripts for 
CD320 exist in Caco-2 cells. Although the expression of the TCII receptor at the 
mRNA level does not guarantee downstream protein expression, later sections of this 
thesis show transport of vitamin B12 in the absence of IF (Chapter 6) ± findings that 
indicate its presence in Caco-2 cells. Moreover, confirmation of expression of the TCII 
carrier protein, whose biological function is to transport vitamin B12 out of the 
basolateral membrane following its internalisation by the TCII receptor, also provides 
some indication that Caco-2 cells express the TCII receptor.  
 
The data therefore confirmed that, following an appropriate culture method, the Caco-
2 cells employed in this work have the ability to form polarised monolayers that 
present a molecular weight-dependent barrier to macromolecular permeability. 
Although this is a generally reported finding with Caco-2 cells, conducting this work 
was considered important due to inter-laboratory variabilities generally observed with 
the Caco-2 cell line. Furthermore, confirming the presence of cellular components 
involved in absorption and transport of vitamin B12 was necessary and an essential 
prerequisite for the validation of the Caco-2 cell line as an in vitro model for studying 
vitamin B12 mediated drug delivery.  
 
3.4 Conclusion 
The work detailed in this chapter characterises the Caco-2 cell monolayer model in 
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terms of its barrier integrity, morphology and determined the appropriateness of its use 
as a system to study nanoparticle delivery via the vitamin B12 pathway. Following 
appropriate culture (on permeable supports; for a defined time period) intestinal Caco-
2 cells were shown to form polarised monolayers, express tight junctions and present 
a barrier to the permeability of macromolecules, with the extent of this barrier dictated 
by the molecular weight of the macromolecular solute. Polarised Caco-2 cell 
monolayers were further shown to restrict apical-to-basolateral translocation of 
nanoparticles of 50, 100 and 200 nm in size. In establishing whether the Caco-2 
model used in this work constitutes a suitable system to investigate the vitamin B12 
pathway for drug delivery purposes, cells were tested for the expression of specific 
cell components involved in vitamin B12 absorption in enterocytes. In this respect, 
immunohistochemical and gene expression analyses revealed that Caco-2 cells 
express the essential constituents of the vitamin B12 trafficking pathway, including 
cubilin, TCII carrier protein and TCII receptor. This work therefore confirmed that the 
monolayer model based on Caco-2 cells provides an adequate system to study drug 
delivery strategies exploiting the vitamin B12 trafficking pathway, as is explored in 
subsequent chapters of this thesis. 
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Chapter 4: The synthesis, characterisation and drug 
delivery application of the Į-Ȧ-aminohexylcarbamate 
derivative of Vitamin B12 
4.1 Introduction 
The vitamin B12 (B12) uptake system offers potential for enhancing the uptake of orally 
administered proteins, peptides and immunogens [1]. The oral delivery of large 
biological macromolecules is often impeded by the epithelial cell barrier and in the 
case of protein biologics, by proteolysis within the gastrointestinal tract. Efforts to 
enhance oral delivery have focused on ligands conjugated to the pharmaceutically 
active component and capable of exploiting specific receptor-mediated endocytosis 
(RME) to provide absorption. Assumptions are made that a ligand of choice will not 
affect the therapeutic activity of the drug following conjugation and that this complex 
will be internalised by the cells by RME mechanisms and subsequently transported 
across. It is also assumedthat the conjugation does not jeopardise the ligand-receptor 
interaction. Taking all this into consideration, it may be feasible to exploit these 
endocytic pathways for the import and transport of protein therapeutics across 
epithelial cells. In addition, oral delivery systems should provide protection to the 
pharmaceutically active component, the task typically given to the carriers/vectors 
encapsulating the bioactives. The B12 RME mechanism is an extensively studied 
system for the oral delivery of peptides and proteins, with uptake of B12 reported at ~ 
1.4 µg per intestinal passage and multiple dosing achievable at 2-3 times per hour [2]. 
This chapter focuses on some of the details of  B12 chemistry in the development of 
B12-bioconjugates and nanocarriers and the importance for recognition of modified B12 
by transport proteins. These have implications for B12-conjugate uptake and transport 
across cells and utility in drug delivery.  
4.1.1  Bioactivities of B12 conjugates 
Early work employed B12 as a ligand (attachment via spacers to part of B12), to aid in 
the internalisation of protein macromolecules. Russell-Jones and co-workers have 
shown that this system is capable of transporting luteinising hormone releasing factor 
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(LHRH)-analogues [3], granulocyte colony stimulating factor (G-CSF), erythropoietin, 
Į-interferon [4, 5] and the LHRH antagonist Antide [2]. Reports claim that the e-
monoacid conjugates possess 10-fold higher affinity for intrinsic factor (IF) and for 
Transcobalamin II (TCII) than the alternative b- and d-monoacids [6, 7].  Table 4.1 lists 
the peptide/protein B12 conjugates which have been reported in the literature. More 
recent work in the field has focused on both in vitro and in vivo studies of intestinal 
uptake of B12-conjugated nanoparticles, with the aim of delivering much larger protein 
therapeutics such as insulin or G-CSF and to enhance the overall uptake capacity. If 
B12 is covalently coupled to a nanoparticle, which in turn entraps and protects a 
number of protein therapeutic molecules, this could permit effective delivery, via 
physiological B12 uptake and transport processes.  
  
&KDSWHU7KHV\QWKHVLVFKDUDFWHULVDWLRQDQGGUXJGHOLYHU\DSSOLFDWLRQRIWKHĮ-Ȧ-
aminohexylcarbamate derivative of Vitamin B12 
107 
 
 
Molecule 
(direct 
conjugation and 
encapsulate 
insulin delivery) 
Size 
(kDa) 
Conjugation  
site 
Linker (coupling 
agent)§ Use Year/Ref 
Direct Conjugation 
BS albumin 66.0 Phosphate Phosphate-amine (EDAC) NA 1971 [8] 
YG-globulin 150.0 Phosphate Phosphate-amine (EDAC) NA 1971 [8] 
HS albumin 66.0 e-acid GABA (EDAC) Antibody response 1979 [9] 
IFN-con 22.0 Ribose-¶-OH Glutaroyl (CDI) 24-28% activity* 1994 [10] 
G-CSF 19.6 e-acid 
Disulphide (SPDP) 
 
61-66% activityۆ 
 
1995 [5] Amide (EDAC) 
 
29-85% activityۆ 
 
Hydrazide (EDAC) ND-100% activity
ۆ 
 
EPO 34.0 e-acid 
Amide (EDAC) ND-34% activity
ۆ 
 1995 [5] 
hydrazide (EDAC) 17-22% activity
ۆ 
 
ANTIDE-1 1.6 e-acid 
EGS (EDAC) ND 
 
1995 [3] 
Amide (EDAC) 30% IF recognition 
 
Disulphide (SPDP) 65% IF recognition 
 
Hindered thiol 
(SMPT) 
54% IF recognition 
 
Thioester (NHS 
ester of iodoacetic 
acid) 
81% IF recognition 
 
 
Transglutamase 
cleavable 
tetrapeptide (EDAC) 
60% IF recognition 
 
ANTIDE-3 1.6 e-acid 
EGS (EDAC) ND 
 
1995 [3] 
Amide (EDAC) ND 
Disulphide (2-
iminothiolane) ND 
Hindered thiol 
(SMPT) 
37% IF recognition 
 
Thioester (NHS 
ester of iodoacetic 
acid) 
65% IF recognition 
Transglutamase 
cleavable 
tetrapeptide (EDAC) 
48% IF recognition 
LHRH 1.2 e-acid Amide (DCC/NHS) 45% absorbed 2000 [11] 
DP3 0.9 e-acid Amide (EDAC) 23% absorbed 2000 [11] hexyl (EDAC) 42% absorbed 
Insulin 5.7 Ribose-¶-OH Amide (CDI, CDT) 26% drop in glucose 2007 [12] 
Encapsulate insulin delivery 
B12-coated 
dextran nano-
particles 
5.7 Ribose-¶-OH Amide (CDI) 70-75% drop in plasma glucose 2007 [13] 
Table 4. 1. B12-protein/peptide bioconjugates (directly conjugated and encapsulate 
insulin delivery) reported in the literature.  
Modified from [14]. *compared with native IFN-FRQۆFRPSDUHGZLWKXQFRQMXJDWHG*-CSF and EPO; §linker 
chosen on basis of yield/activity; ND:not determined; BS, HS: Bovine and human serum; IFN-con: 
Consensus interferon; G-CSF: Granulocyte-colony stimulating factor; EPO: erythropoietin; ANTIDE: N-Ac-
D-Na(2)D, D-Phe (pCl), D-Pal(3)ser, Lys(Nic), D-Lys(Nic), Leu,Lys(IPr), Pro, D-Ala-NH2; LHRH: Lutenizing 
hormone-releasing hormone; DP3:Octapeptide (Glu-Ala-Ser-Ala-Ser-Tyr-Ser-Ala); GABA: y ami no butyric 
acid; EDAC: l-ethyl-3-(3-GLPHWK\ODPLQRSURS\OFDUERGLLPLGH &', ¶-carbonyldiimidazole; SPDP: N-
succinimidyl 3-(2-pyridyldithiio)-propionateJ; SMPT: 4-[(Succinimidyloxy)-carbonyl]-Į-(2-
pyridyldithio)toluene; NHS: N-K\GUR[\VXFFLQLPLGH'&&11¶-GLF\FORKH[\OFDUERGLLPLGH&'7¶-carbonyl-
di-(1,2,4-triazole)T; EGS: Ethylene glycol bis(succinimidylsuccinate).  
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In order to exploit the B12 transport pathway for drug delivery, it is essential to 
understand the specific intracellular events occurring within enterocytes following RME 
of IF-B12. However, the models describing the early phases of the B12 absorption 
pathway, including recognition by IF are incomplete  [11]. Early studies implied that, 
with the exception of substitutions at the Co-ȕ SRVLWLRQ F\DQLGH LQ QDWLYH %12), any 
other substitutions of the molecule jeopardise its recognition by IF [15, 16]. On the 
contrary, some groups report that IF binds more effectively to B12 conjugates [17]. In 
this regard, the solvent accessible surface of B12 is considered critical when designing 
B12-based bioconjugates [14]. The solvent accessibility of TCII to B12 is around 6.5% 
(~80 Å2). For IF, this exposure is even higher, at ~13% (~163 Å2), with haptocorrin 
(HC) least accessible at 3.2% (~40 Å2) [14, 18]. Undoubtedly, this exposure has 
significant implications when designing a B12-conjugate, affecting binding to the 
transport proteins. B12 and the therapeutic molecule of interest can either be coupled 
GLUHFWO\ WRJHWKHU FDQ EH KHOG DSDUW E\ µVSDFHU¶ Xnits, or B12 can be conjugated to 
carriers, effectively entrapping the drug. Sites available for modification on B12 include 
the peripheral amides, hydroxyl groups, the cobalt (III) ion and the phosphate moiety 
[14]. However, it is important to note that not all of these modifications will retain 
biological recognition by the B12 transport proteins, thus rendering them ineffective as 
methods of attachment. It has been shown that successful modifications with B12 can 
occur at four major sites (Figure 4.1): i) WKURXJK WKH ¶-hydroxy group of the ribose 
PRLHW\RIWKHĮ-tail [12]LLWKURXJKWKH¶-K\GUR[\JURXSRIWKHULERVHPRLHW\RIWKHĮ-
tail [19], iii) to the peripheral corrin ring e-propionamide [20], and iv) to the cobalt 
cation [21]. 
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Figure 4. 1. Structure of vitamin B12 and potential conjugation sites.  
The central cobalt  atom is six -coordinated, with equatorial posit ions occupied by nitrogen 
atoms of corrin macrocycle. Corrin ring incorporates seven amide side chains, three  
acetamides (a,c,g) and four propionamides (b,d,e,f).  Four pyrrole rings indicated by 
A,B,C, and D. Groups highl ighted in blue have been used for conjugates that maintain 
binding to HC, TCII and IF. The port ion highl ighted red, namely the b -propionamide, has 
been used on conversion to the carboxyl ic acid, for HC -specif ic target ing [14].   
Importantly, although much more information has been obtained in recent years on the 
nature of the binding between B12 and its transport proteins [22, 23], currently, very 
little is known about the effect of modifying B12 and its subsequent interaction with 
these proteins, on receptor binding. In 2010, a landmark paper by Anderson et al. [24], 
presented the structure of cubilin(5-8)-IF-B12. This report shed light on the (then) 
unknown interaction of the IF-B12 complex with cubilin (Figure 4.2), which provided 
new insights into the inevitable influence of B12-conjugation on receptor binding. In 
addition, the results pointed to sites for directed mutagenesis of IF, facilitating the use 
of IF as a delivery agent [14]. As apparent in Figure 4.2, IF±B12 binds with high affinity 
to a region encompassed by four (CUB5±8) of the 27 CUB domains in cubilin [25].  
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Figure 4. 2. Crystal structure of the Cubilin(5±8)-IF-B12 complex (PDB 
accession 3KQ4).  Cubilin(5±8) is coloured in blue, IF is in green. Calcium ions are shown as 
red spheres and glycosylations as grey sticks. B12 and the cobalt atom are coloured pink and 
blue, respectively [24]. 
 
4.1.2  Chemistries for bioconjugation 
0F(ZDQ¶VJURXS [26] activated the ribose-¶-hydroxyl group of vitamin B12 via 
¶-FDUERQ\OGLLPLGD]ROH &', ¶-carbonyldi(1,2,4-triazole) (CDT), or di(1-
benzotriazolyl) carbonate (DBTC), and then reacted nucleophiles (aminoalkanes, 
diaminoalkanes and alkane diacid dihydrides) to attach the desired spacer (Figure 
4.3). 
 
 
Figure 4. 3. Derivatisation of the ribose-¶-hydroxyl group of vitamin B12. 
7KHLUZRUNH[DPLQHGWKHELQGLQJDIILQLW\RIWKH¶FDUEDPDWHGHULYDWLYHVIRU+&ZKLFK
WKH DXWKRUV UHIHU WR DV µQRQ-,)¶ DQG ,) DQG DOVR WKH XSWDNH RI QDQRSDUWLFOHV
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conjugated to these derivatives by Caco-2 cells. The ribose-¶-carbamate derivatives 
were shown to possess similar binding affinity for IF as that of the e-monocarboxylic 
acid of B12. Interestingly, the affinity for HC was similar to cyanocobalamin or even 
higher for some of the smaller derivatives. The data revealed that model polystyrene 
QDQRSDUWLFOHV FDQ EH FRXSOHG WR WKH ULERVH ¶-carbamate adipic dihydrazide B12 
derivative and undergo higher levels of transport in Caco-2 cells compared to 
unmodified particles.  
 
Other chemistries investigated for B12 conjugation include treatment and pre-activation 
RIWKH¶-OH group on B12 to generate an electrophilic intermediate (1), which can be 
isolated prior to further modification by a variety of nucleophiles (Figure 4.4). Reaction 
with a glycine methyl ester followed by saponification yields a product with a 
carboxylic acid handle (2). Diamines such as 1,6 diaminohexane and 4,7,10-trioxa-
1,13-tridecanediamine will react with (1), under dilute conditions, to yield products (3-
5) with convenient terminal primary amine functionality.  
 
Figure 4. 4. A reaction scheme for deriving amino- and carboxyl- VB12 from 
cyanocobalamin-¶-OH modification [27]. 
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To extend the utility of vitamin B12 derivatisation, fluorescent probes have been added 
WRWKH¶2+-ribose of vitamin B12, as shown by Fedosov et al. [28] and in related work 
[29]. The declining application of radioactive 57Co-labelled B12 on the grounds of safety 
has prompted investigation into the use of alternative methods for tracing B12 and its 
conjugates. The fluorescent conjugate of vitamin B12 (Figure 4.5) was synthesised 
through coupling 5- (and 6-) carboxyrhodamine succinimidyl ester to an amino 
derivative of B12 PRGLILHGDWWKH¶-OH-ribose position.  
 
Figure 4. 5. Fluorescent conjugate of vitamin B12 [28] . 
 
Vitamin B12 FDQ DOVR EH PRGLILHG DW WKH ¶-ribofuranosyl-OH position to yield a 
carboxylic acid handle in replacement of the aforementioned amino spacer. Such a 
procedure would involve reaction with glycine methyl ester followed by saponification 
[27]. This would permit conjugation to alternative nanoparticles or fluorescent dyes 
with reactive amine groups at their surface. This option of course widens the scope for 
application of B12 as a targeting moiety for the delivery of other components into or 
across cells or mucosal surfaces. Extensive uptake of vitamin B12 is considered to be 
a good marker of fast growing cancer cells. Imaging of tumours with the help of 
derivatives as detailed above, as well as targeted delivery of conjugated drugs is an 
exciting avenue for further B12-related research.  
 
The following list summarises reactions to functionalise B12 and derivatives [30]: 
(i) Reaction of carboxy-VB12 with substituted amines 
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 VB12-COOH + NH2-R Æ VB12-CONH-R + H2O 
(ii) Reaction of carboxy-VB12 with substituted phenols 
VB12-COOH + OH-Ph-R Æ VB12-CO-O-Ph-R + H2O 
(iii) Reaction of amino-VB12 with substituted carboxylates 
VB12-NH2 + COOH-R Æ VB12-NHCO-R + H2O 
 
The work in this chapter describes the synthesis and characterisation of an amino- 
derivative of vitamin B12 ZKLFK ZDV DFWLYDWHG DW WKH ¶-hydroxyl group of the ribose 
PRLHW\XVLQJ¶-carbonyldiimidazole (CDI). The resXOWDQWĮ-Ȧ-aminohexylcarbamate 
B12 derivative was intended to allow reaction with carboxy-functional nanoparticles 
containing fluorescent dyes (as model carriers). In addition, previous studies have 
VKRZQ WKDW WKH Į-Ȧ-aminohexylcarbamate B12 retains its binding activity for 
transcobalamin (II), haptocorrin, and IF [7, 31].The derivative prepared in this chapter 
was designed for transport studies of modified nanoparticles using in vitro cell models 
of the intestinal and bronchial epithelium via specific VB12 receptors found on the 
apical surface.  
4.2 Methods 
4.2.1  Synthesis of Į-Ȧ-aminohexylcarbamate vitamin B12 
¶-Carbonyldiimidazole (CDI, 260 mg, 0.32 mmol) was added to cyanocobalamin 
(1.0 g, 0.74 mmol), previously dissolved in anhydrous dimethyl-sulfoxide (12 ml). The 
PL[WXUHZDVVWLUUHG IRUKUVDWÛ&'U\-hexanediamine (314 mg, 2.7 mmol) 
was added and the mixture stirred at room temperature over 24 hrs. Moisture was 
removed from the reaction mixture through azeotropic distillation with toluene. The 
mixture was then poured into 30 ml ethyl acetate and left to stand. The mixture was 
transferred to glass vials and centrifuged using an MSE Centaur 2 at 14,000 rpm for 
10 min. The supernatant was decanted and the residue sonicated for 5 min in acetone 
(50ml). The resultant supernatant was filtered and the solid washed with acetone. The 
crude product was purified by silica column chromatography (isopropanol 45%, n-
butanol 30%, ammonia 4% and water 21%). Thin layer chromatography (TLC) was 
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carried out on pre-coated aluminium sheets with 0.2 mm silica gel F254 from Fluka 
(Sigma-Aldrich) (iPrOH 30/n-BuOH 45/H2O 21/NH4OH 4/TEA 1 ml). Following TLC 
analysis, the relevant fractions were pooled and the solvent was removed using rotary 
evaporation. The remaining derivative in its solid form was flushed with N2 before 
being stored at -Û&IRUIXWXUHXVH$OOYLWDPLQ%12 and its analogues were treated as 
photo-sensitive. Reactions were therefore carried out in the dark and reagents and 
products were stored in aluminium foil. 
4.2.2  Analytical purification and characterisation 
Preparative high performance liquid chromatography (HPLC) of the product was 
carried out using a Waters Associates system using a Waters X-Bridge C18 column 
(100 x 19 mm). The vitamin B12 product was eluted with 100% water containing 10 
mM ammonium formate and 0.1% (v/v) of ammonia solution (pH9.5, solvent A) 
and  95% acetonitrile (Fisher Chemical, HPLC gradient grade) with 5% water and 
0.1% ammonia solution (in water) (solvent B), using a gradient system at 20 mL/min 
comprising linear gradients from 3% solvent B to 10% solvent B at 2 min, 35% solvent 
B at 11.5 min and 95% solvent B at 12 min. Purity (>95%) was determined using a 
Waters analytical HPLC system with a Waters 996 photodiode array detector at 
wavelengths 230-400 nm. NMR spectra of the product and starting material 
(cyanocobalamin) were obtained using a Bruker AV600 spectrometer equipped with a 
5mm TXI (1H, 13C, 15N) cryoprobe running TopSpin v2.1 in deutero-methanol (CD3OD) 
solution. The method was adapted from McEwan et al. [26]. This part of the work was 
carried out by Ian Whitcombe and Adam Hold at UCB (Slough, Berkshire, UK). In 
addition, the 1H-NMR data was interpreted with the assistance of Dr Francisco 
Fernández Trillo (University of Nottingham, UK).  
4.3 Results & Discussion 
4.3.1  Thin layer chromatography analysis 
From the preparative silica column, 100 fractions of 12 ml were collected and all even 
number fractions (2-80 inclusive) were subjected to TLC analysis and compared 
against crude product and unmodified VB12 (cyanocobalamin) (Figure 4.6). 
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Separations proved difficult owing to slow migration behaviour, due to high solvent 
viscosity and the swelling of the silica during elution. 
 
 
Figure 4. 6. TLC analysis comparisons of cyanocobalamin (VB12) and crude product 
fractions. 
(crude product fractions initially comprising multiple species, as shown by separation of a series of 
components with different Rf values). Fractions were collected until a single spot was obtained. Note: the 
product sourced from these fractions had a different Rf value to the starting material (VB12).  
In order to obtain better separations of the product material, the TLC eluent 
composition was altered slightly via the addition of more water. In addition, the TLC 
plate was pre-eluted in the eluent with the aim of neutralising the charges on the silica 
to aid eventual movement of the material. These changes in conditions were not 
effective in improving the separation. For optimised TLC eluent conditions, 
approximately 2 ml of methanol was added to each of the fractions prior to capillary 
spotting. Both crude product and B12 were dissolved in methanol for this experiment. 
In addition TEA (15% v/v) was added to the original eluent. These alterations resulted 
in a better separation, reduced spreading and faster migrations on the TLC plates. 
Fractions 54-64 inclusive were pooled on account of their migration behaviours on the 
TLC plate and their marked difference to Vitamin B12.  
 
Preliminary TLC analysis of the crude product revealed two distinct species according 
to their respective separations; one corresponding to vitamin B12 and another which 
had an Rf (retention factor) value of 0.11 (Figure 4.7), which agreed with the literature 
value quoted for the 1,6-GLDPLQRKH[DQH Į-Ȧ-aminohexylcarbamate) derivative of 
VB12 [26].  
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Figure 4. 7.Calculation of the retention factor value from TLC. 
Following the same TLC procedure and using the same eluent conditions, a larger 
quantity of the crude product was separated via a capillary dragging spotting 
technique (Figure 4.8). This technique is commonly used to obtain small amounts of 
pure product from a crude mixture. The pure sample can be scraped from the plate 
using a scalpel blade - the silica can be removed via simple centrifugation to yield 
sufficient quantities of product for mass spectrometry analysis or associated analytical 
techniques.  
 
Figure 4. 8. Capillary dragging technique for mass spectrometry analysis . 
4.3.2  HPLC purification and TOF-MS analysis 
The SXULW\!RIWKHĮ-Ȧ-aminohexylcarbamate derivative of B12 was confirmed by 
HPLC. Figure 4.9 shows liquid chromatographs of the product both before and after 
SXULILFDWLRQ7KHVSHFLHVRILQWHUHVWLHSXUHĮ-Ȧ-aminohexylcarbamate B12 derivative) 
VB12 Crude 
product 
Crude product 
1 
2 
Band corresponding to VB12 (cyanocobalamin) (1) 
 
 Band corresponding to VB12 derivative (2) 
* Requires characterisation 
 
 
 
 
X 
A B 
Distance from starting point to top of 
spot (A) 
Rf (X) =  
Distance from starting point to top 
of solvent front (B) 
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had a retention time of 2.53 min under the conditions used (see section 4.2.2). It is 
clearly apparent from the chromatographs that a high level of purity had been 
achieved, as depicted by a single clear peak at 2.53 min and a flat baseline (Figure 
4.9, top), as compared with the crude material post silica-column (Figure 4.9, bottom), 
which comprised several peaks (of which the fraction of interest corresponded to the 
largest peak with a retention time of 2.54 min), and had a higher signal to noise ratio.  
 
Figure 4. 9 /LTXLG FKURPDWRJUDSKV RI FUXGH ERWWRP ODEHOOHG µEHIRUH
SXULILFDWLRQ¶ DQG SXULILHG Į-Ȧ-aminohexylcarbamate vitamin B 12  (top; 
ODEHOOHGµDIWHUSXULILFDWLRQ¶  
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TOF-MS  analysis (Figure 4.10) revealed a peak (26% area) for 1500.39 m/z, 
appearing as doubly charged species at 750.19 (M+2H)2+. Despite the later 
identification of peaks resembling product masses, the relative abundances were low. 
It is possible that fragments will vary in ionisation state depending on the matrix 
(protonation possible at the amino group as well as the linking phosphate).  
 
Figure 4. 10.  TOF-06RISXULILHGĮ -Ȧ-aminohexylcarbamate vitamin B 12 .  
&KDUDFWHULVDWLRQRIĮ-Ȧ-aminohexylcarbamate VB12 derivative by 1H-NMR 
While NMR characterisation of the vitamin B12 derivative was of crucial importance to 
confirm identity and to assess purity, full peak assignment of the product was not 
necessary as the compound was not a new chemical entity. Comparison of the 1H-
NMR spectra obtained for the derivative with that of unmodified cyanocobalamin 
required particular attention to the assignment of peaks for the linker (hexanediamine) 
and any changes in coupling patterns on the ribose moiety resulting from modification 
RIWKHULERIXUDQRVH¶-hydroxyl moiety of B12. Thus, the presence of these peaks in the 
product as absent in native B12 would give a good indication, when combined with MS 
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and HPLC analysis, that the desired compound, which has previously been reported 
[26, 27], was successfully synthesised. Careful inspection of the 1H-NMR signals for 
the ribose ring revealed that its signals were significantly shifted after functionalisation, 
HVSHFLDOO\ WKRVHFORVHU WR WKH¶K\GUR[\OJURXS ,QDGGLWLRQQHZUHVRQDQFHVDULVLQJ
from the C6 linker (hexanediamine) could be observed (denoted by the letter e) 
(Figure 4.11). The signals arising from (f) and (g) on the hexanediamine linker remain 
hidden in this 1H NMR spectrum. Therefore, accurate assignments of (f) and (g) 
required COSY experiments (see below).  
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Figure 4. 11. 1H-NMR (MeOD, 400 MHz) of Į-Ȧ-aminohexylcarbamate vitamin B12 (top) and cyanocobalamin (bottom). 
Assignments of (f) and (g) were not possible at this stage of the analysis. 
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In order to assign more accurately the functional groups on the hexanediamine moiety 
of the VB12 derivative, two dimensional NMR spectroscopy experiments were carried 
out in addition to conventional NMR. Two dimensional homonuclear nuclear magnetic 
resonance experiments are recorded through correlation spectroscopy (COSY), of 
which several types include conventional correlation spectroscopy, total correlation 
spectroscopy (TOCSY) and nuclear Overhauser effect spectroscopy (NOESY) [32]. 
The COSY and TOCSY processes transfer magnetisation through the chemical bonds 
between adjacent protons. Because conventional COSY experiments are only capable 
of transferring magnetisation between protons on adjacent atoms (i.e. an alpha proton 
transfers magnetisation to the beta protons, the beta protons transfer to the alpha and 
gamma protons, if any are present, then the gamma proton transfers to the beta and 
delta protons, etc), TOCSY is often used in conjunction. Here, magnetisation is 
relayed through all protons on a portion of the molecule; thereby enabling a direct 
transfer among all the protons that are connected by adjacent atoms (i.e. the alpha 
and all other protons are able to relay magnetisation to the beta, gamma, delta and 
epsilon if they are connected by a continuous chain of protons).  
TOCSY 1H-NMR experiments were therefore used to selectively irradiate at specific 
proton positions to show adjacent coupling. The units of both axes represent chemical 
shifts. Following irradiation of a proton the ribose moiety of native cyanocobalamin 
(Figure 4.12 bottom, as depicted by the letter a), this signal is propagated to reveal 
adjacent coupling protons which can be assigned accordingly to each portion of the 
ribose ring (b, c, d and e). &RPSDULVRQ ZLWK WKH VSHFWUXP RI WKH Į-Ȧ-
aminohexylcarbamate derivative of vitamin B12, i.e. the product (Figure 4.12, top), 
there is an apparent shift in field with a reduction in the number of signals, resulting 
from interference from the presence of the C6 linker. Despite a loss of propagation in 
the signal, making the assignment of (f) and (g) difficult, the comparison of the two 
very different spectra serves to show the marked presence of the C6 linker, giving 
confidence that successful derivatisation has taken place.  
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Figure 4. 12. 1D selective TOCSY 1H-105 VSHFWUXP 0H2'  0+] RI Į-Ȧ-
aminohexylcarbamate vitamin B12  (irradiated at 6.24 ppm with 200 ms TOCSY mixing 
time) (top) and cyanocobalamin (irradiated 1t 4.7 ppm with 60 ms TOCSY mixing time 
(bottom). 
Following ir radiat ion of a proton the ribose moiety of nat ive cyanocobalamin (bottom, as 
depicted by the letter a),  th is signal is propagated, to reveal adjacent coupling protons 
which can be assigned accordingly to each port ion of the ribose ring (b, c,  d and e).  
COSY 1H-NMR was used not only to cross-check previous assignments, but also to 
assign two new signals in the spectra for the derivative which were not found in the 
spectra for cyanocobalamin (starting material). And although these signals could be 
attributed to several regions on the molecule, ie: methyls at a chiral centre (Figure 
4.13 blue/red arrows), it is likely that these arise from two key protons on the C6 linker 
itself (Figure 4.13, f and g SURYLGLQJ IXUWKHU HYLGHQFH IRU LGHQWLW\ RI WKH Į-Ȧ-
aminohexylcarbamate derivative of B12. From this, a sound protocol for the amino-
derivatisation of vitamin B12 with hexane-diamine and similar linkers such as 4,7,10-
trioxa-1,13-tridecanediamine was verified.  
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Figure 4. 13. COSY (MeOD, 300 MHzRIĮ-Ȧ-aminohexylcarbamate vitamin B12 (2 scans 
per increment 2048 x 400 points). 
4.3.4  Evaluation of analytical methods for B12 and B12-conjugate/derivative 
characterisation 
Further analytical methods available for the structural characterisation of vitamin B12 
derivatives include spectrophotometry, chemiluminescence, atomic absorption 
spectrometry, electrochemical analysis, matrix-assisted laser desorption/ionisation 
(MALDI), time-of-flight mass spectrometry (TOF-MS) and high performance liquid 
chromatography (HPLC) amongst others [33]. The MS analysis of large molecules 
such as vitamin B12/vitamin B12 analogues can be problematic owing to poor ionisation 
efficiency. The establishment of a sensitive high performance liquid chromatography-
electrospray ionisation-mass spectrometry (HPLC-ESI-MS) method for B12 in food 
products was made possible through simple preparative processes and application of 
high cone voltages in a study carried out by Luo and co-workers (2006) [33].  
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Kinsel et al. [34] reported that the MALDI-TOF spectra of vitamin B12 resulted in low 
apparent abundances of the protonated molecule. Thus, obtaining sufficient sensitivity 
for detection remains a challenge from an analytical perspective. Despite the issues of 
low sensitivity and poor selectivity associated with structural determination of vitamin 
B12 and its derivatives, such quantitative data is necessary for future work as a means 
of confirming  the precise identity of the synthesised material.  
 
4.3.5  Evaluation of B12-conjugate chemistry and uptake mechanisms 
Initial studies focused on the design of  uptake systems based on a simple covalent 
linkage to the modified B12 molecule [5, 17, 35]. However, it was soon evident that 
potential utility of such an uptake system was severely handicapped by the low 
absorption capacity (1 µg/dose in man); the difficulties in covalent attachment to B12 
and exposure to proteolytic enzymes. With reference to the bioconjugation of B12 and 
the resulting biological efficacy of these systems, in one such study [3], the in vitro and 
in vivo potency of LHRH antagonists were found to be greatly reduced following direct 
conjugation to B12, which the authors attributed to steric hindrance following the 
binding of the conjugate to the pituitary receptor for LHRH by the bulky B12 molecule 
being in close proximity to the peptide. In an attempt to overcome this problem, spacer 
groups attached by non-cleavable linkers were used to produce conjugates between 
the (2-aminoethyl) amido eVB12 and the ANTIDE analogues, thereby separating the 
bulky B12 group from the peptide. B12 conjugates formed with either, an anilido-
(PA)/EGS-derived spacer, or a DSS-derived spacer, had an in vitro activity similar to 
that of the native peptide, suggesting that placing the B12 group at some distance from 
the ANTIDE restored the affinity of ANTIDE for its receptor. It was found that these 
conjugates had very low activities in vivo, possibly due to the removal of the 
conjugates from the circulation by the B12-binding proteins (TCI and TCII). In order to 
minimise the possibility of steric hindrance produced by the presence of B12 in the 
conjugates, or reduced systemic bioavailability of the conjugates as a result of 
clearance by B12-binding proteins, B12-peptide conjugates were prepared using linkers 
which are potentially biodegradable in vivo. The disulphide-linked B12-ANTIDE 
&KDSWHU7KHV\QWKHVLVFKDUDFWHULVDWLRQDQGGUXJGHOLYHU\DSSOLFDWLRQRIWKHĮ-Ȧ-
aminohexylcarbamate derivative of Vitamin B12 
125 
 
conjugates were found to have a slightly reduced in vitro potency in comparison to 
ANTIDE or the anilido and EGS-linked B12-ANTIDE conjugates. In contrast, the 
disulphide-linked conjugates showed a dramatic increase in their in vivo potencies 
when compared to the non-cleavable, extended spacer conjugates. A conjugate 
containing a spacer of similar length, including a non-cleavable thioether bond in place 
of the disulphide bond, showed greatly reduced in vivo activity, suggesting that the 
increased activity of the disulphide-linked conjugate was due its ability to be cleaved in 
vivo.  
 
Russell-Jones and colleagues worked on amplifying the uptake capacity of the system 
by incorporating the therapeutic within biodegradable nanoparticles and then targeting 
them using B12 decoration on the surface [36]. To this end, a comparison study [26], 
tested the biological application of twelve biologically active ribose-¶-carbamate 
derivatives of vitamin B12. The ribose-5¶-hydroxyl group of vitamin B12 was activated 
WKURXJK WKH XVH RI ¶-FDUERQ\OGLLPLGD]ROH &', ¶-carbonyldi- (1,2,4-triazole) 
(CDT), or di(1-benzotriazolyl) carbonate (DBTC). Subsequent addition of an 
aminoalkane, diaminoalkane, or alkane diacid dihydrazide gave rise to vitamin B12 
derivatives suitable for attachment to various proteins, peptides, or nanospheres to 
enable oral delivery utilising the vitamin B12 uptake system. The ribose-5¶-carbamate 
derivatives were found to possess similar affinity for IF as that of the e-monocarboxylic 
acid of vitamin B12. The affinity for HC was similar to cyanocobalamin or even greater 
for some of the smaller derivatives. Polystyrene nanoparticles derivatised with vitamin 
B12 ¶-carbamate adipic dihydrazide into Caco-2 cells showed significantly higher 
levels of transport of the particles, when compared to unmodified particles. 
 
Chasalani et al. [13], evaluated the effect of cross-linking and the nature of the B12-
derivative on the biological effectiveness of B12-conjugated dextran nanoparticles for 
delivery of insulin in animal models. In this study, amino alkyl B12 derivatives suitable 
IRURUDOGHOLYHU\ZHUHV\QWKHVLVHGDW WKH¶-hydroxy ribose and e-propionamide sites 
via carbamate and ester/amide linkages, and were coupled to succinic acid modified 
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dextran nanoparticles of varied cross-linking. The vitamin B12 e-monoacid, which 
possesses ten-fold higher affinity for IF and for TCII compared to other isomers [37], 
was coupled with diamines. Low yields (19-20%) were obtained for both the amino 
ethyl e¶9%12 DQGDPLQRKH[\OH¶9%12 derivatives, compared to native B12. Amino hexyl 
¶29%12 DQGDPLQRGRGHF\O¶29%12 prepared in a related study were found to have 
45-65% yields [38]. Despite the high yields (85-90%) obtained for additional acid 
GHULYDWLYHVVXFKDV¶2VXFFLQR\O- DQG¶2JOXWUR\O9%12, the highly labile ester bond 
renders these derivatives inappropriate for drug delivery. Regarding the nanoparticle 
surface coverage by B12WKHELQGLQJRI¶2VXFFLQR\O- DQG¶2JOXWUR\OGHULYDWLYHVZDV
DOVRKLJKHUFRPSDUHGWRWKH¶2+DQG¶2'GHULYDWLYHVWR Vs 4.0 to 4.4% 
w/w particles). Thus, the results from this particular study revealed that B12 derivatives 
comprising an amide linkage and a long spacer were more efficacious in binding to 
nanoparticles compared with carbamate derivatives. Results from the in vivo studies 
showed that the hypoglycaemic action of the NP conjugates containing carbamate-
linked B12 was higher compared to ester/amide linked VB12. Moreover, the 
hypoglycaemic action was significantly higher with hexyl conjugates (initial phase) and 
the glutaroyl conjugates (secondary phase), compared to the control group. The 
authors postulated that the delayed action of the glutaroyl conjugates resulted from 
hydrolysis of the ester linkages in the gut and the cleaved ligand may compete for 
DEVRUSWLRQZLWKWKH13¶VFRQMXJDWH$OWHUQDWLYHO\WKH\UHDVRQHGWKDWWKH,)DIILQLW\IRU
the glutaroyl derivative may be low. Overall, the authors affirmed that dextran NP 
conjugates comprising low levels of cross linking and coated with a carbamate 
derivative of B12 showed promise for the effective oral delivery of insulin in animal 
models.  
4.4 Conclusion 
In order to exploit the potential of the vitamin B12 transport system in the oral delivery 
of proteins, peptides and immunogens, the ligand itself requires manipulation to permit 
its attachment to the carrier system in question. Vitamin B12, was therefore derivatised 
DW WKH ¶-ribose position by an DZ-aminohexylcarbamate group, as it has been 
suggested that these vitamin B12- derivatives can maintain their binding affinity for IF 
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[26] and other B12-binding proteins, while providing functionality to attach to carrier 
particles (Chapters 5-7).  Furthermore, the carbamate link is stable under the acidic 
conditions of the stomach, [26] an absolute requirement for an intended oral delivery 
system6HOHFWLRQRIWKHĮ-Ȧ-aminohexylcarbamate derivative of B12 was based on a 
sought compromise between its slightly reduced affinities for the B12 binding proteins 
(compared to the e-mono acid of VB12); with provision of better synthetic yield, 
enhanced stability (without hydrolysable bonds) and reduced steric hindrance of 
nanoparticles on B12 by the presence of a six carbon linker. Activation of WKH ¶-
hydroxyl group in the cyanocobalamin ribose ring with CDI followed by derivatisation 
with a slight excess of 1,6-hexanediamine proceeded successfully as shown by TLC 
analysis. Separated fractions from column chromatography were shown by 1H-NMR 
and TOCSY and COSY experiments to contain the desired B12 derivative.  
 
In a complementary procedure, the crude product was purified by HPLC and analysed 
by mass spectrometry. The spectrum obtained was consistent with ion fragments of 
the product although yields of the pure adduct were low. TOF-MS  analysis revealed a 
peak (26% area) for 1500.39 m/z, appearing as doubly charged species at 750.19 
(M+2H)2+. Moreover, further smaller fragments were detected bearing closer 
resemblance to the expected molecular weight of the derivative (1498.61). The 
combined analyses gave sufficient indication of successful synthesis to allow 
exploration of the biological applications of this derivative following its conjugation to 
carboxylate PS nanoparticles.  
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Chapter 5: Epithelial transport of nanoparticles: pathway 
switching through bioconjugation 
5.1 Introduction 
Synthetic drug carriers that exploit natural cellular transport pathways are highly 
desirable for diagnostic and therapeutic applications [1, 2]. Of particular interest are 
nanoparticulate carriers that resemble viruses in their ability to target and be 
internalised by cells, but which are not infective or toxic. Features of viruses important 
in their cellular trafficking are their size (50-150 nm range) and their functional surface 
ligands, especially for cellular and sub-cellular receptors. It is not surprising therefore 
that many synthetic drug delivery systems for intracellular delivery have been based 
on virus-inspired designs [3, 4]. These typically involve a therapeutic compound 
LQFRUSRUDWHG LQWR D QDQRVFDOH FDUULHU µFRUH¶ ZKLFK LV FRDWHG ZLWK OLJDQGV DLPHG WR
specifically guide the carrier towards a particular intracellular pathway, enabling 
delivery of the incorporated therapeutic to a desired intracellular location [5]. However, 
the conjugated-carrier may not adopt the assumed ligand-directed pathway, as 
demonstrated by a recent landmark paper [6],  which indicated that some trafficking 
pathways can be perturbed by synthetic nanoparticles in ways that differ from the 
transport activated by the ligand functionality alone.  
In this chapter, the work set out to probe whether a ligand-mediated pathway, well-
characterised for transport of molecules into and through the epithelial cells of the gut, 
could be exploited by model nanoparticle drug carriers for effective systemic delivery 
of biotherapeutics via mucosal surfaces. Vitamin B12 was selected as the ligand, as its 
intestinal uptake has already been considered for oral delivery of biotherapeutics [7-
10]. Previous attempts to deliver biotherapeutics directly conjugated to vitamin B12 
resulted in loss of therapeutic activity due to digestion of the labile biotherapeutic in 
the gastrointestinal tract [11, 12]. More recently, vitamin B12-conjugated 
nanoparticulate carriers have been evaluated in order to incorporate and protect the 
biotherapeutic [10, 13] (as discussed in Chapter 4). 
Chapter 5: Epithelial transport of nanoparticles: pathway switching through 
bioconjugation 
131 
 
Importantly however, the use of B12-conjugated nanocarriers to deliver biotherapeutics 
across the intestinal surface assumes that the B12-nanoparticles traverse the 
epithelium in a manner that follows the soluble vitamin B12 pathway (Chapter 1, section 
1.5.2.3), i.e. the attached nanoparticle does not perturb the transport pathway. This 
assumes cellular internalisation of the entire cubilin receptor-intrinsic factor-B12-
nanoparticle complex bound to megalin via clathrin-coated vesicles (Figure 5.1) [14, 
15], followed by an endosomal stage where the cubilin and megalin receptors 
dissociate from the complex and recycle to the epithelial cell surface. The remaining 
intrinsic factor (IF)-B12-nanoparticle complex would then be transported to the 
lysosome where, in the case of soluble B12, IF protein is degraded to release free B12 
[16]. The vitamin B12-nanoparticles would then be transported out of the lysosome by 
an as yet unidentified mechanism, as B12 is assumed to do  [17]. Of key significance is 
that, at the start of this study, the mechanism of cellular internalisation and intracellular 
trafficking of B12-conjugated nanoparticles had not been documented.  
 
Figure 5. 1. Schematic representation of VB12-cellular internalisation and trafficking, in 
vivo.  
Note that for the sake of simplicity, megalin was in this instance, not depicted in the figure.  
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The principal aim of this work, therefore, was to probe the mechanisms of entry and 
transport across the cells of nanoparticles conjugated to vitamin B12, and so 
demonstrate a model system that might have wider implications for delivery of 
therapeutic and/or diagnostic nanoparticles in general [18-20]. The model carrier was 
prepared from functionalised polystyrene (PS) nanoparticles spanning the 50-200 nm 
size range, covering viral dimensions as well as sizes reported optimal for endocytotic 
processes [21]. In order to display vitamin B12 as a ligand on the nanoparticle surface 
IUHH IURP VWHULF KLQGUDQFH DQ Į-Ȧ-aminohexylcarbamate derivative of B12 was 
prepared (Chapter 4) and conjugated to carboxylated PS nanoparticles by standard 
carbodiimide chemistries. For the cell studies, a cell culture model of the intestinal 
epithelium was utilised; the Caco-2 (human intestinal) cell line when cultured on 
permeable membrane supports, is the most extensively used model for vitamin B12-
mediated drug delivery [8, 22, 23]. These cell cultures exhibit unidirectional transport 
of vitamin B12 in the apical-to-basolateral direction [8], and also in an IF dependent 
and IF-independent fashion. The latter is likely due to the expression of the 
Transcobalamin II receptor (responsible for the internalisation of transcobalamin II in 
vivo) on their apical surface [24]. The suitability of the Caco-2 cell culture as an 
epithelial model was verified by confirming the expression of cubilin receptor (a 
prerequisite for a functioning vitamin B12 transport pathway, see chapter 3) as well as 
the presence of functioning caveolae and clathrin mediated endocytic pathways.  
The purpose of this work was to assess the cellular uptake, transport and intracellular 
trafficking behaviours of B12-conjugated nanoparticles in Caco-2 monolayers. In this 
respect, transport studies were conducted in the presence of chemical inhibitors of 
clathrin and caveolae-mediated endocytosis. Furthermore, lysosomal markers were 
used to identify the sub-cellular localisation of these nanoparticles. Importantly, 
comparisons of the pathways for cell uptake and transport were made between B12-
bearing nanoparticles and their unmodified counterparts, in addition to the soluble 
vitamin B12 ligand. Overall, this study aimed to assess whether the attachment of 
nanoscale carriers to natural ligands can alter their cellular trafficking behaviour in a 
way that can be exploited for the delivery of biotherapeutics.  
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5.2 Methods 
5.2.1  Preparation and charaFWHULVDWLRQRIWKHĮ-Ȧ-aminohexylcarbamate 
derivative of vitamin B12 
The chemical synthesis and characterisation of the VB12 Į-Ȧ-aminohexylcarbamate 
derivative was described in chapter 4 (sections 4.2.1 and 4.2.2). 
5.2.2  Preparation of vitamin B12-conjugated nanoparticles 
Fluorescent carboxylate Yellow Orange nanoparticles (YO, fluorescence spectrum 
equivalent to rhodamine, PolySciences Inc) of 50 nm, 100 nm and 200 nm (1 ml of 
 DQGDTXHRXVVXVSHQVLRQ UHVSHFWLYHO\ ZHUHPRGLILHG ZLWK WKHĮ-Ȧ
aminohexylcarbamate vitamin B12 derivative (10 mg) by activation with 1-ethyl-3-[3-
Dimethylaminopropyl]carbodiimide (EDAC), in the presence of N-hydroxy-succinimide 
(NHS). The reaction was left to proceed for 5 hrs followed by incubation with glycine 
(100 mg/ml) in 50 mM carbonate buffer, pH 9.5. The nanoparticles were dialysed 
extensively against distilled water over 24 hrs, with the water exchanged at regular 
intervals.  
5.2.3  B12-conjugated nanoparticle characterisation 
The mean diameter of both B12-cRQMXJDWHG QDQRSDUWLFOHV DQG µXQPRGLILHG¶
nanoparticles (50, 100 and 200 nm nominal diameter) was determined by Dynamic 
Light Scattering (DLS) using a Viskotec 802 system. The nanoparticles (all 400 µg/ml), 
suspended in HBSS at pH 7.4 (to replicate the conditions in which the nanoparticles 
were applied to cells) were then analysed using the default programme setting, 
wherein the optimal intensity count was 300 k counts and the temperature was 25°C. 
Omnisize software was used to calculate the particle size.  The experimental values 
obtained were then exported and plotted in Microsoft Excel. The zeta potential of the 
nanoparticles (suspended in HBSS, pH 7.4) was measured using a Zetasizer ZS 
(Malvern Instruments, UK). The reported value represents the mean of 3 
measurements.  
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Fluorescence emission spectra of both vitamin B12-conjugated and unmodified 
nanoparticle suspensions in HBSS (400 µg/ml) were recorded on a Cary Eclipse 
IOXRULPHWHUȜex = 529 nm). The unmodified nanoparticle suspensions were titrated with 
increasing volumes of soluble cyanocobalamin (present in nanoparticle suspensions in 
order to prevent dilution of nanoparticles upon titration). 200 µg of vitamin B12 was 
added to 500 µl of 400 µg/ml nanoparticle suspensions. This was then used to titrate 
the unmodified nanoparticles, with the suspension added to unmodified nanoparticles 
in steps of 5-20 µl. Spectra were recorded after each addition and calibration curves 
were generated based on percent weight vitamin B12 against fluorescence intensity. 
The concentration of carboxyl groups on unmodified YO-NP was calculated by 
potentiometric titration. Experiments were conducted with unmodified nanoparticles 
(50, 100, 200 nm), using a Fisher brand® Hydrus 600 pH meter and a Thermo fisher 
orion 911 pH electrode at room temperature (23 °C). Unmodified nanoparticles were 
diluted 1:5 using distilled water obtained from an ELGA purification system (resistivity 
0ȍFP7KHS+RI WKHQDQRSDUWLFOHVXVSHQVLRQVZDV ORZHUHG WRXVLQJ0
HCl. Stepwise additions of 0.1M NaOH were made until neutral pH was attained. The 
concentration of carboxyl groups was calculated from the difference between the 
number of moles of HCl originally added and those of NaOH used for neutralisation. 
The density of the carboxylic acids on the surface (da) expressed in number per nm2 
was calculated using the equation below:  
 ?ൌ ?ൈ  ? ൈ   
 
Where: 
x mola is the calculated moles of acid 
x NA is Avogadro's number 
x NP is the number of particles (calculated from the density provided by the 
manufacturer and corrected for dilution). 
x SA is the surface area of the particle expressed in nm2.  
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5.2.4  Cell Culture 
The protocols for routine culture of Caco-2 cells are described in Chapter 2 (sections 
2.1 and 2.2).  
5.2.5  Cellular uptake and transport studies of B12-conjugated nanoparticles 
Culture medium was removed from filter-cultured Caco-2 cells and replaced with 
+DQN¶V%DODQFHG6DOW6ROXWLRQ+%66EXIIHUHGZLWK2-[4-(2-hydroxyethyl)piperazin-1-
yl]ethanesulfonic acid (HEPES, 20mM) and cell monolayers incubated for 45 min. 
Unmodified YO nanoparticles (50, 100, 200nm) and vitamin B12-conjugated 
nanoparticles were suspended in HBSS/HEPES to achieve a final concentration of 
400 µg/ml. 3 µg of recombinant human intrinsic factor (rHUIF, Autogen Bioclear Ltd) 
was added per 1 ml of 400 µg/ml suspension of B12-conjugated nanoparticles. This 
amounted to 5.6, 45.1 and 360.9 molecules of IF per one nanoparticle for 50, 100 and 
QPQDQRSDUWLFOHVUHVSHFWLYHO\7KHVROXWLRQZDVLQFXEDWHGDWÛ&SULRUWRWKHLU
application to cells. Following a routine assessment of TEER (as described in chapter 
2, section 2.2.2), nanoparticle suspensions (0.5 ml) were applied to the apical 
chamber of triplicate wells and the Caco-FXOWXUHVLQFXEDWHGDWÛ&RYHUKUV$W
minute sampling intervals, 100 µl was removed from the basolateral side and analysed 
for fluorescence. Sample volumes were replaced with 100 µl of HEPES/HBSS to 
maintain a constant basal volume. Internalised fluorescence (indicating nanoparticle 
uptake) was determined by cell lysis using 0.2% Triton X-100 (Fluka) (10 min 
incubation). Cell uptake of nanoparticles was quantified by fluorescence (Dynex, 
microplate reader, 529 nm/546 nm) using calibration curves. The effect of a 
µFRPSHWLWRU¶ RQ UHFHSWRU-mediated uptake of nanoparticles was assessed in the 
presence of excess cyanocobalamin (500 µg per 0.5 ml of vitamin B12-conjugated 
nanoparticles). Soluble vitamin B12 transport studies were conducted in a similar 
manner to nanoparticle transport experiments, but instead of fluorescence detection, 
vitamin B12 was quantified by UV absorbance (350 nm, Beckman Coultier DU 800 UV 
spectrophotometer).  
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5.2.6  Immunostaining for clathrin and caveolin-1  
Immunostaining for clathrin and caveolin-1 in Caco-2 monolayers was conducted in 
the manner described in Chapter 2, section 2.2.5.5.  
5.2.7  mRNA expression of Caveolin-1  
mRNA was isolated from filter-cultured Caco-2 cells on day 7, day 14 and day 21 of 
transwell® culture using the method described in section 2.2.6.1.1.  cDNA was 
synthesised using the protocol described in section 2.2.6.1.2. A conventional PCR 
was performed on the PTC-200 Thermal Cycler to amplify the cDNA which was then 
visualised using gel electrophoresis (section 2.2.6.2). The expected size of the 
amplified cDNA fragment was 361bp (see section 2.2.6.2.1 for primer details).  
5.2.8  Lysosomal cell trafficking studies 
Caco-2 cells were cultured as polarised monolayers in the manner described 
previously (chapter 2, section 2.2.1). /\VRWUDFNHU *UHHQ '1'-26 (Invitrogen) was 
GLOXWHG DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V LQVWUXFWLRQV LQ +%66 DQG QDQRSDUWLFOHV
(unmodified and vitamin B12-conjugated) were suspended in this solution to achieve a 
final incubation concentration of 250 µg/ml. The lysotracker-containing nanoparticle 
suspensions (0.5 ml) were applied to the apical side of the cell monolayers and 
LQFXEDWHG DW Û& IRU  KUV 7KH ,)-B12-nanoparticle composites were prepared as 
described above. For anti-LAMP 1 immunostaining studies, nanoparticles (unmodified 
and B12-conjugated) were applied (in HEPES-buffered HBSS) to the apical side and 
the cells incubated at 37°C over 2 hrs. The reader is referred to Chapter 2, section 
2.2.5.3 for further experimental details of sample preparation for confocal microscopy. 
5.2.9  Clathrin and caveolae inhibition studies 
Caco-2 cell monolayers were treated with inhibitors of specific endocytic pathways, 
genistein (200 µM), filipin (5 µg/ml) or chlorpromazine (10 µg/ml), dissolved in 
HBSS/HEPES for 1hr at 37°C prior to the addition of nanoparticles [25]. Unmodified 
and vitamin B12-conjugated nanoparticles (in the presence of IF) were applied 
suspended in HBSS/HEPES (400 µg/ml) containing one of the above inhibitors and 
incubated for 3 hrs. At 30-min sampling intervals, 100 µl samples were removed from 
Chapter 5: Epithelial transport of nanoparticles: pathway switching through 
bioconjugation 
137 
 
the basolateral side for fluorescence determination in order to quantify the transport of 
the nanoparticles (as described in section 5.2.5). At the final time point, nanoparticle 
internalisation was determined by cell lysis also described in section 5.2.5. For the 
potassium depletion study, conducted to perturb clathrin-mediated endocytosis [25, 
26], Caco-2 cells were washed once with potassium free buffer (pH 7.4), containing 
140 mM NaCl (BDH, Analar®), 20 mM HEPES, 1 mM CaCl2, 1 mM MgCl2 and 1 mg/ml 
D-JOXFRVH *,%&2 IROORZHG E\ D ZDVK ZLWK D K\SRWRQLF EXIIHU SRWDVVLXP IUHH
buffer diluted 1:1 with water). The cells were then washed again twice with potassium 
free buffer. Control wells were treated with buffer (pH 7.4), containing 140 mM NaCl, 
20 mM HEPES, 1 mM CaCl2, 1 mM MgCl2, 1 mg/ml D-glucose and 10 mM KCl. 
Vitamin B12-conjugated nanoparticles were incubated with the cells in potassium free 
or potassium containing buffer as indicated. Subsequently, nanoparticle uptake and 
transport was determined by fluorescence. As a control for clathrin-mediated uptake 
[25], FITC-transferrin (Autogen Bioclear, LTD) (dissolved in HBSS to a final incubation 
concentration of 100 µg/ml), was applied to the apical chambers in the presence or 
absence of chlorpromazine (10 µg/ml), a specific inhibitor of clathrin-mediated 
endocytosis. In addition, native cyanocobalamin (vitamin B12), in the presence of IF 
was also applied in conjunction with the same inhibitor, to confirm the route of 
internalisation of the soluble ligand and cell uptake and transport was determined via 
UV-absorbance at 350 nm. To assess the specificity of filipin as an inhibitor of 
caveolae-mediated uptake [27, 28], transport of Alexa Fluor 488-labelled cholera toxin 
subunit B (Invitrogen, applied at 5 µg/ml) was determined following its application with 
or without filipin (5 µg/ml).  
Importantly, in order to verify that there were no adverse of toxic effects on cell 
monolayer by treatment with these agents, TEER reversibility measurements were 
carried out in a separate series of experiments. Cell monolayers were incubated with 
chlorpromazine (1.25-10 µg/ml), filipin (1.25-5 µg/ml), K+ depleting medium and 
Genistein (at a fixed concentration of 200 µM) and TEER was measured every 30 min 
over 3 hours in HEPES/HBSS in the presence of the inhibitors. In addition TEER 
measurements were recorded in culture medium before incubation with the inhibitor 
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and 24 hours after incubation to assess for permanent damage to the cell monolayer 
(note: after 3 hours, the chemical agents were removed and culture medium 
replaced).  
5.3 Results & Discussion 
5.3.1  Characterisation and conjugation of Į-Ȧ-aminohexylcarbamate vitamin 
B12 to functionalised nanoparticles 
)OXRUHVFHQW<236QDQRSDUWLFOHVZHUHVHOHFWHGIRUVXUIDFHPRGLILFDWLRQZLWKWKHĮ-Ȧ-
aminohexylcarbamate vitamin B12 derivative. These nanoparticles not only have 
surface carboxylic acid groups, permitting attachment of derivatised vitamin B12 but 
also contain a rhodamine-like fluorophore, allowing easy quantitation. In order to 
functionalise the surface of YO nanoparticles, vitamin B12 was amino derivatised using 
D¶-ribose carbamate linkage (Chapter 4), as it has been suggested that these vitamin 
B12-carbamate derivatives provide an increased yield and affinity towards intrinsic 
factor [29]. Furthermore, the carbamate should be stable under the acidic conditions of 
the stomach [29]DQDEVROXWHUHTXLUHPHQWIRURUDOGHOLYHU\7KHUHIRUHWKH¶-hydroxyl 
JURXS LQ F\DQRFREDODPLQ¶V ULERVH ULQJ ZDV DFWLYDWHG ZLWK &', WR EH LPPHGLDWHO\
derivatised with a slight excess of 1,6-hexanediamine (Figure 5.2a). Successful 
derivatisation of cyanocobalamin was confirmed by means of NMR, MS and HPLC 
VHH&KDSWHUVHFWLRQ7KHV\QWKHVLVHGĮ-Ȧ-aminohexylcarbamate-vitamin B12 
derivative was reacted with carboxylated functionalised YO polystyrene nanoparticles 
in the presence of 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDAC) and N-
hydroxy-succinimide (NHS) and purified by dialysis to yield  the desired vitamin B12-
conjugated nanoparticles (Figure 5.2c).  
 
In addition, it was observed that the fluorescence intensity of nanoparticles decreased 
following the conjugation process. This fluorescence quenching property of vitamin B12 
has been previously reported [30, 31]. It was therefore decided to attempt to exploit 
this phenomenon in order to establish the presence of vitamin B12 on the surface of 
nanoparticles. Based on this fluorescence quenching effect, the comparison of 
fluorescence intensity of the vitamin B12-conjugated to that of unmodified YO 
Chapter 5: Epithelial transport of nanoparticles: pathway switching through 
bioconjugation 
139 
 
nanoparticles showed a markedly lower fluorescence for the nanoparticles with 
surface conjugated vitamin B12 (Figure 5.2d and further details provided in section 
5.3.3).  
 
 
Figure 5. 26\QWKHVLVDQGFKDUDFWHULVDWLRQRIĮ-Ȧ-aminohexylcarbamate-vitamin B12  
D5HDFWLRQVFKHPHIRUV\QWKHVLVRIĮ-Ȧ-aminohexylcarbamate-vitamin B12 b) 1H-NMR (expanded region) of 
SXULILHGF\DQRFREDODPLQDQGĮ-Ȧ-aminohexylcarbamate-vitamin B12, c) Schematic of WKHFRQMXJDWLRQRIĮ-
Ȧ-aminohexylcarbamate-vitamin B12 to fluorescent YO nanoparticles, d) Comparison of the fluorescent 
spectra of YO (50 nm) nanoparticles; and in the presence of free vitamin B12 (unmodified + 22% w/w VB12) 
and vitamin B12-conjugated YO (50 nm) nanoparticles. 
5.3.2 B12-conjugated nanoparticle characterisation 
To confirm that following conjugation, nanoparticle size distribution did not significantly 
change, or that aggregation did not occur to a significant extent, particle size 
distribution was assessed via dynamic light scattering (Figure 5.3 and table 5.3c). The 
results indicate that the diameters determined experimentally are slightly smaller than 
the nominal diameters provided by the manufacturer (Polysciences, Inc): 42 nm, ~80 
nm and ~140 nm for 50, 100 and 200 nm sized unmodified nanoparticles respectively. 
Data demonstrates the somewhat increased hydrodynamic diameter of the B12-
conjugated nanoparticles relative to their unmodified counterparts with an increase in 
their respective particle size to 78 nm, 200 nm and 280 nm, for B12-conjugated 
nanoparticles of nominal 50, 100 and 200 nm size, respectively, which is indicative of 
a degree of nanoparticle aggregation. However, the increased particle size remained 
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within the accepted limits for cellular internalisation by endocytosis [25]. For ease of 
data comparison between B12-conjugated and unmodified nanoparticles, B12-
conjugated nanoparticles of 50, 100 and 200 nm are hereafter referred to as their 
LQLWLDO µSUH-FRQMXJDWHG¶ QRPLQDO GLDPHWHU %12 conjugation to nanoparticles was also 
indicated by a change in nanoparticle surface charge (zeta potential) post conjugation. 
The data overall demonstrates that unmodified nanoparticles of all sizes display a 
higher negative surface potential than their B12-conjugated analogues (Figure 5.3d), 
due to surface charge shielding by B12 on the surface of the conjugated nanoparticles.  
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Sample Peak % Area Rh (nm) % RSD 
NP50 1 99.3 21.22 15.5 
2 0.7 2.41e+6 16.9 
NP100 1 0.6 1.24 5.2 
2 99.4 39.95 28.6 
NP200 1 81.5 69.86 18.5 
2 18.5 5798.35 18.4 
B12-conjugated  
(50 nm) 
1 0.3 0.86 0.0 
2 99.7 39.32 22.1 
B12-conjugated  
(100 nm) 
1 11.4 17.64 8.7 
2 79.4 100.06 21.4 
3 9.2 7990.49 14.6 
B12-conjugated  
(200 nm) 
1 3.0 7.73 15.8 
2 97.0 139.84 48.9 
 
 
Unmodified 
nanoparticles 
(50 nm) 
B12-
conjugated 
(50 nm) 
Unmodified 
nanoparticles 
(100 nm) 
B12-
conjugated 
(100 nm) 
Unmodified 
nanoparticles 
(200 nm) 
B12-
conjugated 
(200 nm) 
Zeta 
Potential 
(mV) 
-34.6 -26.3 -32.1 -27.8 -33.1 -27.4 
Zeta 
deviation 
(mV) 
0.06 1.67 0.61 0.64 0.17 2.55 
 
Figure 5. 3. Size and surface characterisation of B12-conjugated nanoparticles. 
 DLS measurements for a) unmodified polystyrene Polysciences nanoparticles and b) B12-conjugated PS 
nanoparticles, c) a tabulated summary of DLS data showing Rh (hydrodynamic radii, nm), % occupied by 
peak and % relative standard deviation (RSD), d) Zeta potential of unconjugated and vitamin B12-conjugated 
nanoparticles. The data represent a mean of 10 measurements for DLS. Measurements were recorded at 
&LQ+DQN¶V%DODQFHG6Dlt Solution (HBSS, biological solution in which nanoparticles were applied to the 
cells). 
5.3.3  Quantitative analysis of B12 attachment 
In order to obtain quantitative information on nanoparticle surface coverage by B12, an 
option to quantify ligand loading would be to analyse the remaining ligand in the 
supernatants/dialysates after particle purification, as conducted by Chalasani et al. 
[13]. However, this method offers uncertainties as to the efficiency of ligand recovery 
during washing steps/dialysis.  Other options open to consideration were analytical 
techniques based on NMR, UV/Vis and infra-red spectrophotometry. Experimentally, 
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all of these techniques display limitations. Nuclear magnetic resonance techniques 
require swelling of the polystyrene nanoparticles prior to analysis of molecular B12. 
Even then, the presence of B12 peaks would be masked by the signals generated from 
the polystyrene. 
It was therefore opted to explore the fluorescence quenching properties of vitamin B12 
[30], as indicated in Figure 5.2d and Figure 5.4, not only to confirm successful 
conjugation, but to attempt to quantify the amount of B12-ligand attached to the surface 
of the nanoparticles.  When the unmodified nanoparticles were exposed to free 
vitamin B12 in solution; this produced a decrease in nanoparticle-associated 
fluorescence intensity as the amount of free vitamin B12 was increased (Figure 5.4a), 
but was restored after removal of free vitamin B12 by dialysis (Figure 5.4d). On the 
contrary, for vitamin B12 conjugated nanoparticles the fluorescence intensity did not 
increase following dialysis (Figure 5.4d). Taken together, this data confirms successful 
B12 conjugation to the nanoparticles. To quantify B12 attachment, emission of YO-
polystyrene nanoparticles was measured in the presence of increasing amounts of B12 
(shown for 50 nm nanoparticles in Figure 5.4a) and the maximal emission peaks 
plotted as a function of the weight percentage of free B12 added (Figure 5.4a). Fitting 
this data to an exponential decay model (Figure 5.4b) (R2   DOORZHG
determination of the weight percentage of B12 in B12-conjugated particles. This way, 
B12 loading for 50, 100 and 200 nm nanoparticles was estimated to be 24%, 28% and 
20% w/w, respectively. However, these values are above those calculated for 
shoulder-to-shoulder conjugation and thus this data cannot be used to accurately 
quantify the level of B12 on the particle surface. This is because the fluorescence 
quenching effect of free vitamin B12 would be expected to differ somewhat to that of 
B12 covalently bound to nanoparticles. In fact, a red shift in fluorescence was observed 
for the YO nanoparticles in the presence of free B12, that was not detected in PS 
nanoparticles with B12 covalently bound to their surfaces (Figure 5.4c). This could be 
explained by the dependence of quenching effect on diffusion and the distance 
between the two species [32], a scenario where covalently immobilised B12 will be 
different to free B12.  
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Figure 5. 4. Fluorescence characterisation of YO Polysciences, Inc. 
nanoparticles.   
a) Wavelength scan (530-650 nm) of 50 nm unmodified nanoparticles with increasing percentage amounts 
(w/w) of soluble B12 and of B12-conjugated nanoparticles (shown in black) b) Exponential decay model (R2 
0.997) for determination of the weight percentage of B12 in B12-conjugated particles (Data was fitted using 
Prism5 v 5.0 from GraphPad Software, Inc, using an in built model)  c) Wavelength scan showing 
unmodified nanoparticles and B12-conjugated nanoparticles for 50, 100 and 200 nm particle sizes. d) 
Dialysis experiment showing restored fluorescence intensity of unmodified nanoparticles following removal 
of free B12 and comparison with B12-conjugated nanoparticles.   
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Theoretically, the maximum shoulder-to-shoulder conjugation of B12 to nanoparticles 
(whereby B12 covers nanoparticle surface completely) yields a loading of 6.6%, 3.4% 
and 1.7% (w/w) for 50 nm, 100 nm and 200 nm nanoparticles (or 0.25 groups per nm2 
for all three particle sizes), respectively, assuming 4 nm2 for vitamin B12 ligand (as 
modelled from the chemical structure of vitamin B12).  On the other hand, the extent of 
B12 loading on nanoparticle surface depends on the number of functional carboxylic 
acid groups available. To investigate this, potentiometric titration experiments were 
conducted with unmodified nanoparticles. From this data (Figure 5.5) the density of 
carboxyl groups on the nanoparticles was calculated, obtaining values of 2.23, 8.86 
and 20.8 groups per nm2 of 50 nm, 100 nm and 200 nm particles, respectively.  
 
Figure 5. 5. Potentiometric titration of unmodified YO carboxy polystyrene nanoparticles 
(50, 100, 200 nm) with 0.05M NaOH.  
 
Although it was not possible to confirm this data with the manufacturer (Polysciences, 
Inc), this high level of acidic functional groups per nanoparticle area, also documented 
for Polysciences nanoparticles in other works [33], actually exceeds the number of 
groups required for shoulder-to-shoulder conjugation of B12 (considering the 
approximate 4 nm2 area of B12). Therefore, the high density of the surface acid groups 
on the nanoparticle surface (for all sizes) indicates that the level of B12 conjugation to 
nanoparticles is not limited by the availability of acidic groups, but by the conjugation 
efficiency. 'Shoulder-to-shoulder' conjugation would require 1.85 mg B12 for 50 nm, 
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0.92 mg for 100 nm and 0.46 mg for 200 nm nanoparticle suspensions used (with 
equal volumes of nanoparticle suspensions used in each conjugation reaction), whilst 
an excess of 10 mg of B12 was employed. As it is not expected that the conjugation 
efficiency would be greatly affected by the size of nanoparticles, and with excess of 
both charged groups and vitamin B12 derivative for shoulder-to-shoulder conjugation, 
one would expect similar surface conjugation per surface area on the three different 
sized nanoparticles, hence the spatial distribution of vitamin B12 ligand is likely to be 
similar for all nanoparticle sizes. The ligand surface density has been shown to play 
an important role in cellular interaction and uptake; however a significant effect is seen 
at the lower levels of surface modification with a plateau after which there is no further 
effect of increasing ligand density on nanoparticle uptake [34-38]. Taken together, this 
suggests that the ligand distribution on the nanoparticle surface, and their presentation 
to the cells, would be similar (assuming a statistical distribution), hence minimising any 
biological effects relating to ligand surface coverage. 
5.3.4  Cell uptake and transport of vitamin B12-conjugated nanoparticles  
Cell uptake studies (Figure 5.6a) demonstrated that internalisation of 50 nm vitamin 
B12-conjugated nanoparticles occurred to a significantly greater extent (28 Pg/cm2 of 
cell monolayer area over the 3 hr experiment) as compared to unmodified 
nanoparticles of the same size (1.5 Pg/cm2 per cell monolayer). This demonstrates 
that conjugation of vitamin B12 to nanoparticles enhances their endocytosis. It should 
be noted that although intrinsic factor (IF) binds to cyanocobalamin in a 1:1 molar ratio 
[39], the amount of IF (1.5 µg) added to the cell monolayers in combination with the 
B12-conjugated nanoparticles is likely to be significantly lower than the amount of 
particle-conjugated vitamin B12. However, considering its notably larger molecular 
mass (55000 Da versus 1497 Da for Į-Ȧ-aminohexylcarbamate-vitamin B12), one IF 
molecule is expected to occupy a significantly larger area on the nanoparticle surface. 
Furthermore, cell uptake of the nanoparticle-bound vitamin B12-IF is likely to result 
from binding of one such complex to the cell surface cubilin receptor, as reported for 
soluble B12-IF [40]. The amount of IF added to the nanoparticle systems (expressed as 
the number of molecules) exceeded the number of particles for all the particle sizes 
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employed, with approximately 6, 45 and 361 molecules of IF per particle for 50, 100 
and 200 nm nanoparticles, respectively. Provided that IF localisation on the 
nanoparticle surface is a random event (based on random vitamin B12 functionalisation 
of nanoparticles), and with multiple molecules of IF on the nanoparticle surface, 
nanoparticles are 'statistically likely' to approach the cell surface receptors in the 
µFRUUHFWSRVLWLRQ¶ 
 
The competitive inhibition study demonstrated that cellular uptake of vitamin B12-
conjugated nanoparticles was significantly inhibited by the presence of excess free 
vitamin B12, from 28 µg/cm2 to 1.7 µg/cm2 (Figure 5.6a). Regarding transcellular 
transport of nanoparticles, the experiments (Figure 5.6b) demonstrate an increased 
translocation of B12-conjugated nanoparticles relative to the unmodified counterparts, 
with the level of transport amounting to 7.3 µg/cm2 and 1.3 µg/cm2 in a 3 hr 
experiment, respectively. The transport of B12-conjugated nanoparticles was reduced 
in the competitive experiment with free B12 to 1.3 µg/cm2. 500 µg of cyanocobalamin 
per 0.5 ml of B12-conjugated nanoparticles was considered a sufficient excess 
considering the maximum theoretical (shoulder-to-shoulder) conjugation of 6.6% w/w 
which equates to 13.2 µg of conjugated B12 per 0.5 ml of 50 nm nanoparticles).  The 
suppression of cell uptake and transport of B12-conjugated nanoparticles by excess of 
free vitamin B12 (Figures 5.6a and b), implies that these processes are indeed 
dependent on binding of the conjugated ligand (with IF) to vitamin B12-receptor 
(cubilin). It should be noted that data on nanoparticle transport across the cell 
monolayers probably underestimates the transport capacity of vitamin B12-conjugated 
nanoparticles, due to the previously reported hindered translocation of the 
nanoparticles through the pores in the filters used to culture the cells [8, 41].  
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a)              b) 
 
 
 
 
 
 
Figure 5. 6. Cell uptake and transport of unmodified and vitamin B12-conjugated 
nanoparticles in Caco-2 monolayers.
  
a) cell uptake b) transport of B12-conjugated nanoparticles per se or in competition experiment with excess 
free vitamin B12 in solution, compared with unmodified nanoparticles. 50 nm YO fluorescent nanoparticles 
were used and the experiments conducted in the presence of intrinsic factor (IF) in all cases. Data 
represents the mean ± SD (n=3).Statistical comparison (ANOVA) performed EHWZHHQµ%-FRQMXJDWHG¶DQG
B12-conjXJDWHGH[FHVVIUHH%¶DQGµ%-FRQMXJDWHGH[FHVVIUHH%¶DQGµXQPRGLILHGQDQRSDUWLFOHV¶, 
where **** denotes p>0.0001 and 'ns' denotes 'not signficant' 
5.3.5  Effect of nanoparticle size on cell uptake and transport of vitamin B12-
conjugated nanoparticles 
There have been numerous studies assessing the impact of particle size on uptake by 
epithelial cells in vitro, [42, 43] but rather fewer studies [8, 44] have been conducted 
with systems where ligand-modified nanoparticles of specific size ranges were utilised 
to target particular epithelial transport pathways. Ligand B12 modified nanoparticles of 
three different (nominal) sizes (50, 100 and 200 nm polystyrene lattices with narrow 
size distribution) were therefore created, encompassing the generally accepted size 
range for endocytosis in epithelial cells and cellular uptake, as well as translocation 
across, the polarised cell monolayers was studied (Figure 5.7). Data was calculated 
and analysed in terms of mass of nanoparticles (important from drug delivery 
perspective). However, further analysis of the number of nanoparticles internalised 
and transported by the cells (important for understanding the number of events 
occurring) was conducted. The data together highlights the influence of particle size 
on both of these parameters.  
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In terms of mass of nanoparticles, vitamin B12-conjugation promoted greater 
(statistically significant) internalisation of nanoparticles of 50 and 100 nm, compared to 
unmodified nanoparticles (Figure 5.7a), with the level of internalisation of 39 µg/cell 
layer for 100 nm (conjugated), in comparison to 32 µg/cell layer for 50 nm 
nanoparticles (unmodified). Cell uptake of B12-conjugated nanoparticles of 200 nm 
(approximately 8 µg/cell layer) was, however, similar to the unmodified nanoparticles 
of the same size (approximately 6 µg/cell layer) (Figure 5.7a). Considering the same 
data in terms of number of uptake events occurring, it is apparent that 50 nm B12-
conjugated nanoparticles were taken up by the cells in the greatest number 
(4.7x1011/cell layer), followed by 100 nm B12-conjugated nanoparticles (7.1x1010), 
followed by 200 nm B12-conjugated nanoparticles (1.7x109). The observed trend 
follows an approximate 6.6-fold decrease in the number of internalised nanoparticles 
from 50 to 100 nm and a 40.9-fold reduction from 100 to 200 nm.  
 
The transport of vitamin B12-conjugated nanoparticles across the cell monolayers 
(Figure 5.7b) mirrored the general trends in cell uptake (Figure 5.7a). As nanoparticle 
size increased from 50 to 100 nm, the mass of nanoparticles that translocated across 
the cells during the experiment increased from 5.8 µg to 14 µg respectively, but was 
reduced to 1.4 µg for 200 nm nanoparticles. Considering the number of nanoparticles 
transported across the cell monolayers, there was a decrease from 8.5x1010 to 
2.6x1010 to 3.2x108 as nanoparticle size increased from 50 nm to 100 nm to 200 nm, 
respectively, indicating a 3.3-fold reduction in transport when nanoparticle diameter 
increased from 50 to 100 nm and 81.1-fold reduction for the size increase from 100 to 
200 nm. Expressing the number of transported nanoparticles as a ratio of internalised 
nanoparticles, indicates that 50 nm and 200 nm nanoparticles were in fact least 
efficiently translocated, with 1 in 5.5 of internalized nanoparticles traversing into the 
basal medium in both cases, whereas 1 in 2.8 of internalised 100 nm nanoparticles 
translocated across the cell monolayer. However a potential underestimation due to 
issues of nanoparticles diffusion though pores of the supporting membrane, as 
mentioned above, should be taken into account, particularly as particle size increases. 
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Of importance for transmucosal delivery of biologicals, is the maximum amount of 
translocation of the therapeutic from the luminal to the basal side of the epithelium, 
which is dependent on both maximal therapeutic loading capacity and a high number 
of receptor-governed events. This data indicates that a nominal particle size of 100 nm 
would yield optimal delivery capacities for a vitamin B12-mediated drug delivery 
system.  
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Figure 5. 7. Effect of particle size on cell uptake and transport of vitamin B12-conjugated 
nanoparticles in Caco-2 monolayers.  
a) Cell uptake and b) transport across the cell monolayers. Vitamin B12-conjugated nanoparticles of 50nm, 
100nm and 200nm were used and nanoparticles were quantified in terms of mass (per surface area of the 
cell monolayer) and number. Bars denote nanoparticle amount (primary axis), whereas lines represent 
nanoparticle number (secondary Yaxis). Data represents the mean ± SD (n=3). Statistical comparison 
between amount data related to the uptake and transport of B12-conjugated nanoparticles (100 nm vs 50 nm 
and 200 nm vs 100 nm shown in black) and B12-conjugated nanoparticles vs. unmodified nanoparticles of 
the same nominal size (shown in red).  
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5.3.6  Cell uptake and trafficking of vitamin B12-conjugated nanoparticles 
In the mechanism of soluble vitamin B12 absorption across the epithelium in vivo, the 
IF-B12 complex is believed to traffic into the lysosome, where IF protein is degraded to 
release B12 [17]. From the perspective of transmucosal delivery of biologicals, this 
would mean that the internalised carrier and the incorporated biologic are reaching the 
highly degradative lysosomal compartment, seriously undermining their delivery 
potentials. A series of studies were conducted to establish whether the vitamin B12-
conjugated nanoparticles also reach the lysosomal compartment following cell 
LQWHUQDOLVDWLRQ 7KH UDWLRQDOH IRU /\VRWUDFNHU VWDLQLQJ DQG /$03 LPPXQRVWDLQLQJ
was discussed in Chapter 2 (section 2.2.5.3). These studies were conducted on 50 nm 
(B12-conjugated and unmodified) nanoparticles, as this particle size is amenable to all 
the different cellular internalisation pathways possible. Control experiments in the 
absence of nanoparticles established that the /\VRWUDFNHU probe is undetectable 
(Figure 5.8a) and that LAMP1 is only observed at a very low level (Figure 5.8b), both 
LQGLFDWLQJ WKDW WKH O\VRVRPDO FRPSDUWPHQW LV RQO\ µDFWLYH¶ ZKHQ HQGRF\WRVLV RFFXUV
When unmodified nanoparticles were applied to the cells, the images indicate their co-
ORFDOLVDWLRQ ZLWK WKH/\VRWUDFNHUPDUNHU )LJXUHF), suggesting the presence of 
unmodified nanoparticles in the lysosomal compartments. This in turn indicates that 
the intracellular trafficking of unmodified nanoparticles largely IROORZVWKHµGHJUDGDWLYH
URXWH¶UHDFKLQJO\VRVRPHV)XUWKHUPRUHVWDLQLQJIRr LAMP1 after cell incubation with 
unmodified nanoparticles shows intensive punctate staining of this lysosomal protein 
within the cytosol (Figure 5.8d), suggesting the presence of lysosomal structures.  
Following cell layer incubation with vitamin B12-conjugated nanoparticles (Figure 5.8e), 
lysosomal compartments were not detected by the /\VRWUDFNHU probe, while LAMP1 
staining revealed protein distribution that was diffuse throughout the cytoplasm of the 
cells (Figure 5.8f) rather than clustered as punctate regions, as in the case with 
unmodified nanoparticles (Figure 5.8d).  
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Taken together, this data indicates that the unmodified nanoparticles are trafficked to 
the lysosomes, but the B12-conjugated nanoparticles circumnavigate lysosomal 
compartmentalisation.
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Figure 5. 8. Characterisation of Caco-2 cell layer uptake of 50 nm vitamin B12-conjugated nanoparticles by confocal microscopy.  
a) Cell staining with Lysotracker Green DND-26 in the absence of nanoparticles b) immunostaining for lysosomal associated-membrane protein 1 (LAMP1) in the absence of nanoparticles, c) Co-
localisation of unmodified nanoparticles with lysosomal compartments, d) Immunostaining for LAMP1 protein following cell incubation with unmodified nanoparticles, e) Staining with Lysotracker 
Green DND-26 after cell incubation with vitamin B12-conjugated nanoparticles (red), f) Immunostaining for LAMP1 following exposure of cells to vitamin B12-conjugated nanoparticles. Lysotracker 
Green DND-26 excitation 504, emission 511 nm; YO nanoparticle excitation 529, emission 546 nm.
a) b) c) 
d) e) f) 
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)XUWKHUPRUHDVHULHVRIFRQWURO/\VRWUDFNHUH[SHULPHQWVZHUHFRQGXFWHGWRHQVXUH
that the imaged pattern (in Figure 5.8) did not result from fluorophore cross emission. 
The reader is referred to Chapter 2, section 2.2.5.3 (Table 2.1) for further experimental 
details. In experiment A (Figure 5.9, sub-figures Ai-iii), cells were incubated with both 
YO nanoparticles and unlabelled non-fluorescent nanoparticles and imaged under the 
settings for /\VRWUDFNHU.  The generated green signal has a weak intensity (Aii), 
showing that cross emission between the YO nanoparticle fluorescence and the green 
/\VRWUDFNHU IOXRUHVFHQFH LV PLQLPDO In a separate experiment, where cells were 
stained with the LysoWUDFNHUSUREH LQ WKHDEVHQFHRI<2 nanoparticles, but in the 
presence of unlabelled non-fluorescent nanoparticles (Figure 5.9B) the sample was 
imaged under the YO nanoparticle emission settings. In this case, a weak red signal 
was observed (Bii), confirming minimal red-green cross-emission. The presence of the 
unlabelled nanoparticles in the latter experiment ZDVLPSRUWDQWDVWKH/\VRWUDFNHU
probe was not detected in the absence of nanoparticles following HBSS-induced 
serum starve (Figure 5.8a).  
In a similar series of experiments (C-E in Figure 5.9 and in Table 2.1, Chapter 2), cells 
were treated with the YO nanoparticles and imaged XQGHUWKH/\VRWUDFNHUVHWWLQJV
ZKLOH /\VRWUDFNHU VWDLQLQJ ZDV RPLWWHG 8QGHU WKHVH FRQGLWLRQV a green signal  
was not observed (Figure 5.9Cii). Conversely, applying the /\VRWUDFNHU SUREH (in 
the absence of the YO nanoparticles) and imaging the cells under the YO nanoparticle 
settings does not result in a significant red signal (Figure 5.9Dii). Lastly, cells imaged 
with unlabelled (non-IOXRUHVFHQW QDQRSDUWLFOHV XQGHU WKH /\VRWUDFNHU VHWWLQJV
(Table 2.1, experiment E, Figure 5.9Eii) displayed a similar punctate staining pattern 
to cells imaged with unmodified YO fluorescent nanoparticles (Figure 5.8c), which 
serves to verify that the pattern seen is not a result of cross-emission between the YO 
IOXRURSKRUH DQG WKH /\VRWUDFNHU IOXRURSKRUH LQ WKH RWKHU VHTXHQWLDO VFDQ RYHUOD\
H[SHULPHQWV )LJXUH )XUWKHUPRUH LW FRQFOXGHV WKHSRLQW WKDW WKH/\VRWUDFNHU
probe is only detectable in the presence of nanoparticles. Taken together, these 
control experiments confirm that the Lysotracker-nanoparticle co-localisation data 
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shown in Figure 5.8 results from true fluorescence from both species as opposed to 
experimental artefact from cross-emission between the fluorophores.  
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Figure 5. 9.  Control Lysosomal studies using LysotrackHU *UHHQ '1'-26 with 
unmodified nanoparticles (50 nm) in Caco-2 monolayers.  
A) Cells treated with both unlabelled (non-fluorescent) 50 nm nanoparticles and YO fluorescent 50 nm 
nanoparticles and LPDJHGXQGHU /\VRWUDFNHUVHWWLQJV L blue channel (Hoechst stain) for cell nuclei; ii) 
green channel, iii) overlay image of blue and green channels. B) Cells treated with unlabelled nanoparticles 
DQGWKH/\VRWUDFNHUSUREHDQGLmaged under YO nanoparticle settings: i) blue channel (Hoechst stain) for 
cell nuclei; ii) red channel, iii) overlay image of blue and red channels. C) Cells treated with YO 50 nm 
nanoparticles and LPDJHGXQGHU /\VRWUDFNHUVHWWLQJV L blue channel (Hoechst stain) for cell nuclei, ii) 
green channel, iii) overlay image of blue and green channels. D) Cells treated with the /\VRWUDFNHUSUREH 
and imaged under YO nanoparticle settings: i) blue channel (Hoechst stain) for cell nuclei, ii) red channel, iii) 
overlay image of blue and red channels. E) Cells treated with unlabelled (non-fluorescent) 50 nm 
nanoparticles and Lysotracker probe and imaged under LysotUDFNHUVHWWLQJVLblue channel (Hoechst 
stain) for cell nuclei, ii) green channel, iii) overlay image of blue and green channels. 
A  i. ii. iii. 
B  i. ii. iii. 
C  i. ii. iii. 
D  i. ii. iii. 
E  i. ii. iii. 
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In summary, the cell uptake and trafficking data suggests that surface decoration of 
nanoparticles with vitamin B12 has a profound effect on intracellular trafficking, giving 
rise to lysosomal bypass ± a phenomenon that has not been demonstrated to occur in 
the process of cell uptake of soluble vitamin B12. Adoption of an intracellular pathway 
that is different to both soluble vitamin B12 and unmodified nanoparticles, indicates a 
switch in intracellular trafficking of the B12 ligand, as a direct consequence of its 
attachment to a nanoparticle surface.  
5.3.7  Cubilin, caveolin-1 and clathrin expression in Caco-2 cells 
In order to further investigate the internalisation and cellular trafficking of B12-
conjugated nanoparticles, it was initially confirmed that the Caco-2 cultures employed 
in this study as a model of the intestinal epithelium express the appropriate structural 
components implicated in the vitamin B12 uptake and transport pathway (Figure 5.1). 
In Chapter 3 (section 3.3.4), the data demonstrated an abundant expression of the 
vitamin B12 cell surface receptor, cubilin (and also gene and protein expression of TCII 
receptor and the TCII carrier protein, respectively). The expression of cubilin is 
relevant to the ligand-receptor binding stage of endocytosis, while other components 
of the cell machinery are responsible for subsequent trafficking of vitamin B12. Further 
work was therefore conducted to determine whether Caco-2 cultures express relevant 
components of specific endocytic pathways. This includes the presence of essential 
components of clathrin-coated pits, implicated in the internalisation of the soluble B12-
IF complex, as well as caveolae, another possible route for material internalisation by 
cells. Caco-2 cell monolayers immunostained for clathrin, the protein responsible for 
WKH IRUPDWLRQ RI FODWKULQ µFRDWHG-SLWV¶ FOHDUO\ VKRZ WKH SUHVHQFH RI IOXRUHVFHQFH
indicative of clathrin expression (Figure 5.10 ai), in contrast to the control experiment 
(Figure 5.10 aii).   
Unlike clathrin expression, there are contradictory reports regarding the presence of 
caveolin-1 in Caco-2 cells and the resulting ability of Caco-2 cells to internalise 
material via caveolae-like domains [27, 45-47].  Expression of caveolin-1 protein in 
Chapter 5: Epithelial transport of nanoparticles: pathway switching through 
bioconjugation 
158 
 
cells is generally considered sufficient and necessary to drive the formation of 
morphologically identifiable caveolae [48-50], and immunostaining of Caco-2 
monolayers (Figure 5.9 bi) revealed its clear expression and presence at cell-cell 
boundaries. It should be noted that cellular permeabilisation (with Triton X-100) in this 
experiment was necessary, based on the generally accepted view that both the NH2- 
and the COOH- termini of caveolin-1 face the cytoplasm and that no portion of the 
protein is extracellular [51, 52]. The lack of fluorescence in the control overlay image 
rules out experimental artifacts possibly resulting from non-specific antibody binding 
(Figure 5.10 bii). The data hence indicate that Caco-2 monolayers are capable of 
undertaking both, clathrin and caveolin-mediated endocytosis.  
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Figure 5. 10. Expression of select endocytic components by immunohistochemistry in Caco-2 monolayer model.  
a) i. Expression of caveolin-1, shown by treating cells with anti-human caveolin 1 H-97, followed by goat, anti-rabbit IgG-Rhodamine, and ii. Control monolayer, incubated with goat, anti-rabbit IgG-
Rhodamine only. b) i. Expression of clathrin, as demonstrated by cell incubation with rabbit anti-clathrin primary antibody and goat, anti-rabbit IgG-FITC, and ii. Control monolayer treated with the 
secondary, goat, anti-rabbit IgG-FITC only. Cell nuclei were labelled with Hoechst 33342 (blue) in all cases.
a) i 
 b)    i ii ii 
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5.3.8 mRNA expression of Caveolin-1 in Caco-2 monolayers 
Further to immunostaining (section 5.3.7) which revealed expression of the caveolin-1 
protein in Caco-2 cells, the presence of caveolin-1 in differentiated Caco-2 cell 
cultures was confirmed at mRNA level. Figure 5.11 shows caveolin-1 mRNA 
expression on day 7, 14 and 21 of Transwell® culture, with an amplified cDNA product 
of 362bp. These results (both immunostaining and PCR) are in agreement with 
published data from Mayor et al. [53], who demonstrated expression of caveolin in 
Caco-2 cells using immunofluorescence techniques and Field et al. [47] who found 
expression of caveolin-1 at the mRNA level. In contrast to these findings, Mirre et al. 
[54] and Vogel et al. [55] failed to detect expression of caveolin-1 at either mRNA or 
protein level. These conflicting findings are likely to be a result of variability among 
Caco-2 cell lines and the heterogeneity of protein expression from the same Caco-2 
cell clone [47, 56, 57]. 
 
Figure 5. 11. mRNA expression of caveolin-1 in Caco-2 cell monolayers on day 7 (D7), 
day 14 (D14) and day 21 (D21) of culture. 
 
5.3.9 Cellular trafficking of free vitamin B12  
The cell trafficking pathway of native, soluble vitamin B12 in vivo is well established, as 
discussed in section 5.1. As a starting point to decipher the uptake and intracellular 
trafficking pathways of B12-conjugated nanoparticles, it was aimed to confirm the 
previously documented cell uptake and transport mechanism of vitamin B12-IF. To this 
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end, the effect of clathrin and caveolae inhibitors on cell uptake and transport of 
vitamin B12 (cyanocobalamin), in the presence of IF, was assessed.  
The cell trafficking inhibitors used in this study, namely chlorpromazine and filipin, 
have been used extensively as specific inhibitors of clathrin- and caveolae-mediated 
endocytosis, respectively [25, 27, 58]. The pathway-inhibiting effects of 
chlorpromazine and filipin in Caco-2 layers were confirmed by testing the uptake and 
transport of pathway-selective ligands, transferrin [59, 60] and cholera toxin B-subunit 
[27, 58] (section 5.3.10). The results revealed that vitamin B12 internalisation (Figure 
5.12a) and transport (Figure 5.12b) were sensitive to the effects of chlorpromazine, 
with a 4-fold decrease in both uptake into and transport across the cells. Vitamin B12 
trafficking, on the other hand, remained largely unaffected by the action of caveolae 
inhibitor, filipin. This data, therefore, agrees with the previous reports that vitamin B12 
(in the presence of IF) exploits the clathrin-mediated route in the process of 
internalisation in Caco-2 cells. However, it must be noted that other vitamin B12 
transport pathways are operating in conjunction with the IF-mediated pathway (as 
discussed in Chapter 6).  
In the above experiments, vitamin B12 was applied at a high (non-physiological) 
concentration as these studies were designed not to assess its permeation capacity 
by the intestinal epithelium but to investigate the cellular trafficking pathway of vitamin 
B12 and to enable quantitation by UV absorbance, as opposed to detection by radio-
labelling.  
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Figure 5. 12. Effect of endocytic pathway-specific inhibitors on cell uptake and transport 
of soluble vitamin B12.  
a) Effect of chlorpromazine and filipin on cell uptake of vitamin B12, b) Effect of chlorpromazine and filipin on 
transport of vitamin B12 across Caco-2 monolayers. Vitamin B12 was applied in combination with IF and 
quantified by
 
UVAbs (350nm). Data represents the mean ± SD (n=3). Statistical comparison with the 
SUHFHGLQJGDWDVHWµns¶ = non significant and ** denotes p<0.01. 
5.3.10  Cell trafficking of vitamin B12-conjugated nanoparticles  
Earlier experiments (Figure 5.6) showed that vitamin B12-conjugated nanoparticles are 
both internalised and transported across the Caco-2 cell monolayers in a notably more 
efficient manner than unmodified nanoparticles. Data also provided evidence of 
involvement of the vitamin B12 transport pathway in cell uptake and transport of 
vitamin B12-bearing nanoparticles (Figure 5.6). Whilst the biological pathway of free 
(i.e. non-particle immobilised) vitamin B12 is well established, the cell trafficking routes 
of vitamin B12-conjugated nanoparticles have not been demonstrated, despite their 
investigation and suggested use for oral delivery of biologicals [10, 13]. It was 
therefore sought to establish this by assessing the effect of inhibitors of specific cell 
entry pathways on the uptake and transport of vitamin B12-conjugated nanoparticles. 
In addition to using chlorpromazine and filipin, the clathrin- or caveolae-mediated 
pathways were also inhibited, by the way of potassium depletion and the use of 
genistein, respectively. Previous studies have shown that depletion of intracellular 
potassium inhibits clathrin-mediated endocytosis [25, 61], whilst genistein, a known 
0 
2 
4 
6 
8 
10 
12 
14 
0 50 100 150 200 
Am
o
u
n
t t
ra
n
sp
or
te
d 
(µg
 p
er
 
cm
2 ) 
Time (min) 
untreated 'free' B12 
Filipin (5µg/ml) treated 
Chlorpromazine (10µg/ml) treated 
a) b) 
0 
5 
10 
15 
20 
25 
30 
35 
untreated 'free' 
B12 
Filipin (5µg/ml) 
treated 
Chlorpromazine 
(10µg/ml) 
treated 
Ce
llu
la
r 
u
pt
ak
e 
(µg
 p
er
 
cm
2 ) ns 
** 
Chapter 5: Epithelial transport of nanoparticles: pathway switching through 
bioconjugation 
163 
 
inhibitor of the tyrosine kinases involved in caveolae-mediated endocytosis [62, 63], 
was used to suppress caveolae-mediated pathways. 
The data shows that cell uptake of vitamin B12-conjugated nanoparticles was 
unaffected by chlorpromazine treatment, which produced a statistically insignificant 
reduction in the extent of nanoparticle uptake (Figure 5.13a). Considering the effect of 
chlorpromazine on nanoparticle transport across the cells (Figure 5.13b), although an 
inhibitory effect on the level of transport was seen in the initial phase of the experiment 
(the first two hours), the amount of vitamin B12-conjugated nanoparticles transported to 
the basolateral side (across the cell layers) at 3hrs measurement point reached the 
values seen in untreated cells. It is not entirely clear why an initial inhibitory effect on 
transport was apparent, though it may have resulted from chlorpromazine interference 
with cytoskeletal function and consequent decreased transport of material towards the 
basolateral membrane  [64, 65]. These trends therefore suggest that cell uptake and 
transport of vitamin B12-conjugated nanoparticles was largely unaffected by the 
inhibition of clathrin. To confirm this, the cell uptake and transport behaviours of B12-
bearing nanoparticles were determined using an alternative clathrin pathway inhibiting 
approach. The data from experiments conducted in potassium-depleted medium  
(Figure 5.13c) indicated no effect on cell uptake of vitamin B12-conjugated 
nanoparticles, as there was no significant difference between the level of cell uptake in 
potassium-deprived conditions and controls (potassium supplemented medium). A 
lack of inhibitory effect was also seen in transport experiments, where the absence of 
potassium did not affect the extent of B12-conjugated nanoparticle transport across the 
Caco-2 cell monolayers (Figure 5.13d). It must be noted however that in the latter 
experiment, the extent of nanoparticle transport for both potassium depleted and 
control conditions were markedly lower (by more than 2-fold) compared to the 
previous studies, which were conducted in HBSS buffer, suggesting that the overall 
nanoparticle transport partially depends on the type of cell medium. Overall, inhibition 
of the clathrin endocytic pathway in two different ways did not suppress the cell uptake 
or transport of vitamin B12-conjugated nanoparticles, therefore excluding a role of this 
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pathway in the uptake and cellular transport of this ligand-bearing nanoparticulate 
system.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 13. Effect of clathrin inhibition on cell uptake and transport of vitamin B12-
conjugated nanoparticles.  
a) Effect of chlorpromazine on cell uptake and b) transport of nanoparticles. c) Effect of potassium depletion 
on cell uptake and d) transport of nanoparticles. Cell uptake and transport studies were conducted with B12-
conjugated nanoparticles of 50nm nominal diameter and in the presence of IF. Data represents the mean ± 
SD (n=3).  
Following the demonstration that the clathrin pathway is not involved in cell processes 
responsible for trafficking vitamin B12-conjugated nanoparticles, the subsequent focus 
was on determining whether inhibiting the caveolae-dependent pathway would exhibit 
any effect. Indeed, treatment by filipin gave rise to a pronounced reduction of cell 
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uptake of vitamin B12-conjugated nanoparticles by approximately 5-fold (Figure 5.14a). 
The effect is mirrored in the data depicting the transport of vitamin B12-linked 
nanoparticles in the presence of the same agent  (Figure 5.14b), where the transport 
of nanoparticles was suppressed by nearly 6-IROG  ȝJ vs  ȝJ DW KUV
measurement point for filipin treated and control cells, respectively). It should be noted 
that, for the purpose of comparison, the data for the control experiment depicting 
transport of B12-conjugated nanoparticles across untreated cells, presented in Figure 
5.14b, was also used in the clathrin inhibition experiment (Figure 5.13b). As in the 
case of the clathrin inhibition studies, the definitive role of caveolae in the 
internalisation and transport of vitamin B12-conjugated nanoparticles was confirmed by 
employing a second inhibitory agent specific to the caveolae endocytic pathway. In the 
presence of this agent, genistein, cell uptake of vitamin B12-conjugated nanoparticles 
was significantly reduced (5-fold, Figure 5.14c). The effect was largely reproduced in 
the transport experiment (Figure 5.14d), where genistein dramatically suppressed the 
transport of vitamin B12-bearing nanoparticles across Caco-2 monolayers, with the 
extent of inhibition amounting to 29-fold at the 3hr measurement point.  
Taken together, the data from inhibition of specific endocytic pathways suggests that 
the caveolae-mediated route is predominantly implicated in the cell uptake and 
transport of this vitamin B12-conjugated nanosystem. The fact that soluble vitamin B12 
(complexed with IF) trafficking is mediated by clathrin, whilst vitamin B12-bearing 
nanoparticles exploit caveolae-mediated route(s), is interesting.  
7KH µVZLWFK¶ LQ FHOO HQWU\ DQG LQWUDFHOOXODU WUDIILFNLQJ SDWKZD\ FRXOG UHVXOW IURP WKH
nature of nanoparticle-bound vitamin B12 ligand interaction with its receptor (cubilin) 
being different to free vitamin B12. The close proximity of multiple nanoparticle-
immobilised ligands may result in multivalent binding (simultaneous interaction of 
multiple ligands with multiple receptors) of nanoparticle-associated vitamin B12-IF 
complexes WR FXELOLQ ,W LV SRVVLEOH WKDW WKLV µXQQDWXUDO¶ YLWDPLQ %12 ligand-cubilin 
interaction may trigger a cell uptake and intracellular trafficking mechanism that is 
entirely different to that of free vitamin B12. Indeed, the profound effect of ligand 
presentation on the cell uptake pathway was recently shown in a study from our group 
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by Moradi et al. [38]. In this work the effect of nanoparticle-bound ligand distribution on 
cellular internalisation was explored using folate-decorated nanoparticles. The results 
indicated that both the ligand density and µFOXVWHULQJ¶LHSUHVHQWDWLRQRIWKHOLJDQGDV
µSDWFKHV¶RQQDQRSDUWLFOHVXUIDFHRQWKHQDQRSDUWLFOHVXUIDFHSOD\DSURIRXQGUROHLQ
the biological mechanism of nanoparticle internalisation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 14. Effect of caveolae inhibition on the uptake and transport of vitamin B12-
conjugated nanoparticles. 
Effect of filipin on a) cell uptake and b) transport of nanoparticles, Effect of genistein on c) cell uptake and d) 
transport of nanoparticles. 50nm vitamin B12-conjugated nanoparticles were applied in combination with IF. 
Data represents the mean ± SD (n=3).  
The specificity of chlorpromazine and filipin inhibitors was determined by testing their 
effect on cell uptake and transport of pathway-selective ligands. These ligands 
included transferrin [59, 60] and cholera toxin B-subunit [27, 58], which are known to 
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internalise preferentially either by clathrin- or by caveolae-mediated endocytosis, 
respectively. In the presence of chlorpromazine (10 µg/ml), internalisation of FITC-
transferrin was inhibited by approximately 9-fold (Figure 5.15a) and transport reduced 
8-fold (Figure 5.15b). When incubated in combination with filipin (5 µg/ml), cell 
internalisation (Figure 5.15c) and transport (Figure 5.15d) of cholera-toxin B subunit 
was reduced by 2.5-fold. These studies thus revealed that at the concentrations used 
in this work, both chlorpromazine and filipin were effectively inhibiting clathrin- and 
caveolae-mediated pathways, respectively, in Caco-2 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. 15. Inhibition of cell uptake (a) and transport (b) of FITC-transferrin and Cholera-
toxin B subunit (c, d) by chlorpromazine (10 µg/ml) and filipin (5 µg/ml). Data represents 
the mean ± SD (n=3). 
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TEER studies conducted during and following incubation with chlorpromazine, filipin, 
genistein and K+ depleting medium revealed no apparent adverse effects on the cell 
monolayers (Figure 5.16). Specifically, incubation with chlorpromazine over a 
concentration range of 1.25-10 µg/ml for 3 hours (5.16a), resulted in an initial drop in 
TEER over the first 30 min, followed by a steady recovery over 2.5 hours. This initial 
decrease in TEER is common following replacement of extracellular medium and 
results from cell acclimatisation to the change of conditions. Importantly, there was no 
concentration-dependent TEER response to chlorpromazine, with no difference in 
monolayers incubated with 1.25 µg/ml chlorpromazine and those incubated with the 
highest concentration (10 µg/ml).  Furthermore, TEER reversibility, as measured 
following incubation and subsequent removal of chlorpromazine resulted in complete 
TEER recovery after 24 hours, regardless of the concentration used (Figure 5.16b).  
The dose-dependent TEER profile with filipin (1.25-5 µg/ml) revealed an apparent 
increase in TEER following the zero minute time point, with an eventual plateau after 1 
hour incubation (Figure 5.16c). Although the reasons for TEER increase are not clear, 
the data shows that there was no apparent concentration-dependent long term TEER 
decrease, suggesting that within this concentration range, filipin did not cause any cell 
toxicity. The TEER reversibility experiment showed that after 24 hours, TEER was 
restored to levels similar to the baseline value (Figure 5.16d). For genistein, the TEER 
was measured at a single concentration of genistein (200 µM) as these were 
optimised conditions for the inhibition experiments (Figure 5.16e). After an initial drop 
between 0 and 30 min, the resistance remained constant over the 3 hour period (~500 
ȍFP2). TEER measurements taken at the 24 hour time point (Figure 5.16f) in 
supplemented medium revealed that although complete baseline recovery was not 
DFKLHYHG YDOXHV ! ȍFP2 indicated that at this concentration, genistein had 
caused no significant adverse effects to the cell monolayers. As mentioned previously, 
cell incubation in a potassium depleted medium altered the transport profile 
considerably. This too was reflected in the TEER profile (Figure 5.16e) as initial 
readings (at t=0), were ~450 ȍFP2, suggesting that the cells were sensitive to the 
change. However, despite an initial further drop in TEER to >200 ȍFP2 after 150 min, 
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a slight TEER recovery was noticed. Similarly, although TEER recovery was poor after 
KRXUVaȍFP2, Figure 5.16f), the incremental rise following replacement in cell 
culture medium, was significant (as TEER had increased to greater than the baseline 
value in potassium depleted medium), indicating that although these conditions were 
not optimal for long-term cell incubation, the adverse effects were reversible. 
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Figure 5. 16. Measurement of TEER on Caco-2 monolayers after treatment with inhibitors 
of clathrin and caveolae-mediated endocytosis. 
a) treatment with chlorpromazine (1.25-10µg/ml) with TEER measurements over 3 hours, b) TEER recovery 
after 24 hr following treatment with chlorpromazine, c) treatment with filipin (1.25-5µg/ml) with TEER 
measurements over 3 hours, d) TEER recovery after 24 hr following treatment with filipin, e) treatment with 
genistein (200µM) and potassium depleted medium with TEER measurements over 3 hours, f) TEER 
recovery after 24 hr following treatment with genistein and after incubation of cells in a potassium depleted 
medium. 
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Having established that vitamin B12-conjugated nanoparticles exploit a different cell 
trafficking pathway to soluble vitamin B12, the next experimental step sought to 
determine whether this phenomenon was intrinsically due to nanoparticles. Inhibition 
of either clathrin or caveolae trafficking pathways, with chlorpromazine and filipin, 
respectively, did not demonstrate any remarkable effect on the uptake and transport of 
unmodified nonoparticles (of 50 nm in diameter as used throughout the study), 
suggesting a dominance of alternative (i.e. non-clathrin and non-caveolae) cell 
trafficking routes in their cell uptake and transport (Figure 5.17 a and b, respectively).  
  
 
 
 
 
 
 
 
 
 
Figure 5. 17. Inhibition of a) cell uptake and b) transport of unmodified 50 nm PS 
nanoparticles by chlorpromazine (10 µg/ml) and filipin (5 µg/ml).  
Data represents the meaQ6'Q µns¶ = non significant. 
Literature reports on the cell uptake pathways of unmodified polystyrene nanoparticles 
are rather inconsistent. A study by Dausend et al. [66] demonstrated no inhibitory 
effect by chlorpromazine on the uptake of 120 nm negatively charged polystyrene 
nanoparticles by HeLa cells. On the other hand, dos Santos et al. [67] showed that 
chlorpromazine inhibited the internalisation of (carboxylated polystyrene) 
nanoparticles, with the extent of inhibition depending on the particle size (greater for 
200 nm, as compared to smaller 40 nm sized nanoparticles). The authors also 
reported that genistein exerted minimal effect on the internalisation of 40 nm 
nanoparticles in 3 independent cell lines, which is in agreement with the data for 50 
nm particles in this thesis (Figure 5.17). Work by Rejman et al. [21] also investigated 
the uptake pathway of similar systems, namely negatively charged polystyrene 
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nanoparticles, with sizes between 50 and 1000 nm in B16 cells (mouse melanoma cell 
line). The authors reported that treatment with inhibitors of caveolae-mediated 
endocytosis (filpin and genistein) did not affect the uptake of nanoparticles <200 nm in 
size, but inhibition with chlorpromazine treatment and potassium depletion elicited a 
greater effect for these particles (with the inhibitory effect diminishing as the size of the 
particle increased). The published work on the biological pathways of particle uptake 
hence suggests that both particle size and the cell line(s) employed in the study 
greatly influence the route of nanoparticle internalisation. A comparison between this 
thesis and the literature is hence problematic for unmodified nanoparticles and in the 
case of B12-conjugated particles the comparison is not possible at all considering that 
the cell uptake mechanisms for B12-decorated particle systems have not been 
reported. The data on the uptake of B12-conjugated particles by intestinal Caco-2 cells 
reported here indicate that the involvement of the caveolar route is specific to the B12-
conjugate nanosystem (and not unmodified nanoparticles), where surface decoration 
of particles with vitamin B12 ligand is presumably essential for the shift in biological 
pathway of cell entry and intracellular transport. 
 
5.4 Conclusions 
 
The work detailed in this chapter demonstrated that surface-conjugation of vitamin B12 
ligand to nanoparticles results in an unexpected intracellular trafficking behaviour in 
HSLWKHOLDOFHOOOD\HUVZLWKDµVZLWFK¶WRDQRQ-degradative caveolae pathway ± a finding 
that may have important implications for oral delivery of nanoscale therapeutics and 
diagnostics. Although in the process of vitamin B12 uptake in vivo, lysosomal function 
is essential to degrade the associated IF [17], further studies are necessary to 
ascertain whether vitamin B12-conjugated nanoparticles retain IF on exit from the cells 
and if so, what are the consequences in a therapeutic context. However, the ligand 
decoration effects observed in epithelial cell cultures on the intracellular trafficking of 
B12-conjugated PS nanoparticles is, to the best of our knowledge, a previously 
unreported example of controlled pathway switching in this way. These findings may 
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SURYLGH VLJQLILFDQW QHZ LQVLJKWV DQG FKHPLFDO µGHVLJQ UXOHV¶ IRU QDQRSDUWLFXODWH
systems, which could enable their practical use in delivery of therapeutic and 
diagnostic macromolecules across the intestinal epithelium.  
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Chapter 6: The role of intrinsic factor on cellular 
trafficking of vitamin B12-conjugated nanoparticles 
6.1 Introduction 
The clear involvement of intrinsic factor (IF) in the intestinal absorption of vitamin B12, 
together with the associated molecular mechanism, has been depicted in earlier 
sections of this thesis (Chapters 1, 4 &5). The trafficking (binding, internalisation and 
transcytosis) of soluble vitamin B12, has been shown to be an IF-dependent 
phenomenon in several cell lines [1-8]. However, studies have also demonstrated the 
transport of vitamin B12 across epithelial cells in the absence of IF [9, 10].  This 
transport is thought to occur either paracellularly [11] (indeed with a molecular weight 
of 1356 Da, the paracellular route is expected to contribute to overall transport of 
vitamin B12), as has been suggested for other subtypes within the vitamin B family 
(thiamin, riboflavin and pyridoxine) [12] or due to the complexation of vitamin B12 with 
apically localised-TCII, followed by recognition and endocytosis by the TCII-receptor 
(Chapter 1, section 1.5.2.3).  
 
Whether the presence of IF is a crucial parameter influencing the uptake and transport 
of B12-bearing nanoparticles is not clear. Similarly to soluble vitamin B12, routes other 
than the cubilin-mediated pathway (which binds to the IF-vitamin B12 complex) could 
contribute to the uptake and transport of vitamin B12-conjugated nanoparticles. This 
chapter details work conducted to consider the role of IF on the uptake and transport 
of B12-conjugated nanoparticles in Caco-2 cells. The effect of IF on the trafficking 
pathways of B12-nanoparticles was determined to establish whether IF dictates the cell 
trafficking of B12-bearing nanoparticles. 
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6.2 Methods 
6.2.1  Effect of IF on cell uptake and transport of B12-conjugated nanoparticles  
The chemical synthesis and characterisation of the vitamin B12 Į-Ȧ-
aminohexylcarbamate derivative is described in Chapter 4 (sections 4.2.1 and 4.2.2). 
Methods for the preparation and characterisation of the B12-conjugated nanoparticles 
are described in Chapter 5, sections 5.5.2-5.2.3. 
For the cell uptake and transport studies, culture medium was removed from filter-
cultured Caco-2 cells and replaced with HEPES (20mM) buffered HBSS and cell 
monolayers were incubated for 45 min. Unmodified YO nanoparticles  and vitamin B12-
conjugated nanoparticles (50, 100, 200 nm) were suspended in HBSS/HEPES to 
achieve a final concentration of 400 µg/ml. B12-conjugated nanoparticles were applied 
to the cells in the presence or absence of IF. Regarding the former, 3 µg of 
recombinant human IF (rHUIF, Autogen Bioclear Ltd) was added per 1 ml of 400 µg/ml 
suspension of B12-conjugated nanoparticles (as discussed in Chapter 5, sections 5.2.5 
DQG  DQG WKH VROXWLRQ ZDV LQFXEDWHG DW Û& SULRU WR DSSOLFDWLRQ WR FHlls. 
Following TEER measurement (as described in chapter 2, section 2.2.2), nanoparticle 
suspensions (0.5ml) were applied to the apical chamber of triplicate wells and the 
Caco-FXOWXUHVLQFXEDWHGDWÛ&RYHUKUV$WPLQXWHVDPSOLQJLQWHUYDOVl 
was removed from the basolateral side and analysed for fluorescence. Sample 
volumes were replaced with 100 µl of HEPES/HBSS to maintain the same basal 
volume. Internalised fluorescence (signifying nanoparticle uptake) was determined 
following cell lysis using 0.2% v/v Triton X-100 (Fluka) (10 min incubation). Cell uptake 
of nanoparticles was quantified by fluorescence (Dynex, microplate reader, 529 
nm/546 nm) using calibration curves (as in Chapter 5, section 5.2.5).  
6.2.2  Effect of IF on cell uptake and transport of soluble B12  
In addition to nanoparticle studies, the effect of IF on cell uptake and transport was 
also determined for soluble vitamin B12. Vitamin B12 (cyanocobalamin, 1 mg/ml) was 
applied (0.5 ml) to the Caco-2 cell monolayers (in HEPES-buffered HBSS, with or 
without IF (rHUIF), which was used at 3 µg/ml. It must be noted that application of IF 
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at a 1:1 molar ratio to vitamin B12 was not feasible due to the high applied 
concentration of vitamin B12. Soluble vitamin B12 uptake and transport studies were 
analysed in a similar manner to the nanoparticle transport experiments, but instead 
vitamin B12 was quantified by UV absorbance (350 nm, Beckman Coultier DU 800 UV 
spectrophotometer), using a pre-constructed calibration curve. In addition, soluble B12 
transport studies were conducted using different applied amounts (5 µg, 50 µg and 
500 µg) at 37 °C and 4 °C. These were carried out to determine whether soluble 
vitamin B12 transport is saturable and to assess the contribution of the paracellular 
(passive transport) route to overall transepithelial translocation of soluble B12. 
6.2.3 Effect of IF on cell uptake and transport pathways of B12-conjugated 
nanoparticles  
B12-conjugated nanoparticles of 50 nm in size were applied to Caco-2 cell monolayers 
as a 400 µg/ml suspension (in HEPES:HBSS buffer), with or without IF (as in section 
6.2.1) and in combination with inhibitors of clathrin and caveolae endocytosis. Caco-2 
cell monolayers were treated with filipin (5 µg/ml) or chlorpromazine (10 µg/ml), diluted 
in HBSS/HEPES buffer for 1hr at 37°C prior to the addition of  nanoparticles (as 
detailed in Chapter 5, section 5.2.9). Vitamin B12-conjugated nanoparticles (in either 
the presence or absence of IF) were applied suspended in HBSS/HEPES buffer (400 
µg/ml) containing one of the above inhibitors at the appropriate concentration and 
incubated for 3 hrs. At 30 min sampling intervals, 100 µl samples were removed from 
the basolateral side for fluorescence determination in order to quantify the transport of 
the nanoparticles. At the final time point, nanoparticle internalisation was determined 
by cell lysis as described in Chapter 5, section 5.2.5.  
6.3 Results and Discussion 
6.3.1  Effect of IF on cell uptake and transport of B12-conjugated nanoparticles  
Assuming that B12-conjugated nanoparticles cross the epithelial barrier in the manner 
mirroring that of soluble vitamin B12, would suggest that the entire cubilin receptor-IF-
B12-nanoparticle complex would be internalised bound to megalin and via clathrin-
coated vesicles [13, 14]. However, in chapter 5, it was shown clearly that the 
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trafficking of B12-conjugated nanoparticles (in the presence of IF) in Caco-2 cells 
occurs in a way that is different to both soluble vitamin B12 and unmodified 
nanoparticles, hence further studies were needed to ascertain whether IF itself is 
important for the cell uptake and transport of B12-bearing nanoparticles. Furthermore, 
there is evidence of transport of soluble vitamin B12 across epithelial cells in IF-free 
conditions [9, 10], which may arise from non-cubilin mediated pathways, such as 
through the paracellular route and via the TCII receptor.  
 
Initial work in this chapter investigated whether the presence of IF influences the level 
of cell uptake of B12-conjugated nanoparticles. In this regard, Figure 6.1a compares 
cellular internalisation of B12-conjugated nanoparticles (50, 100 nm and 200 nm 
nominal diameter) in Caco-2 cells in the presence or absence of IF. The data shows 
that the effect of IF on the cell uptake of B12-conjugated nanoparticles appears to be 
dependent on the nanoparticle size. Specifically, there was a 2.5-fold lower level of 
cell internalisation for 50 nm nanoparticles in the absence of IF (13 µg per cell layer 
vs. 32 µg in the presence of IF). However for the larger nanoparticles of 100 nm and 
200 nm, a reduction in cell uptake in IF-free conditions was not statistically significant 
compared to conditions with added IF.  
 
Regarding the apical-to-basolateral transport of B12-conjugated nanoparticles between 
30 min and 3 hrs (Figure 6.1b) for the 100 nm system, the rate of transport across the 
cell monolayers was higher in the presence of IF (as indicated by a higher slope 
gradient of 0.0318, compared to 0.022 in IF-free conditions, which amounts to a 1.45-
fold increase), while the rate of transport for 50 nm B12-conjugated nanoparticles 
during this period  was not significantly affected by the presence of IF (gradients of 
0.098 and 0.095 in the presence and absence of IF, respectively). For 200 nm B12-
conjugated nanoparticles, the presence of IF appeared to somewhat enhance the rate 
of transport (1.3-fold increase, indicated by in the change in slope gradient from 0.066 
to 0.086).  
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In terms of comparison of transport rate in IF-free conditions for different particle sizes, 
50 nm B12-conjugated nanoparticles were transported at a lower rate compared to 100 
nm sized counterparts, with 200 nm B12-conjugated nanoparticles exhibiting the lowest 
rate of transport. This mirrors the trend observed for IF-supplemented conditions.  
 
It is however important to note that the rate of transport appears to be at its highest 
during the first 30 minutes of the experiment (no intermediate measurements were 
made between 0 and 30 minutes), as shown by a large increment in transport amount 
from 0 minutes to 30 minutes. This pattern, shown in Figure 6.1b, may be expected for 
a receptor-mediated system, whereby following ligand application, receptors are 
rapidly occupied, leading to a net loss of receptors at the apical cell surface before 
they are able to recycle back to engage with more ligand [15]. During this time, ligands 
bound to the receptors move through a series of endocytic vesicles. This results in a 
IOX[RI WUDQVSRUWHGFDUJR µDOODWRQFH¶&RQWLQXHGH[SRVXUHRI WKHFHOOV WR WKHYLWDPLQ
B12 ligand-bound nanoparticles then results in a sustained, but considerably slower 
rate of uptake and transport. Similar observations were reported by Paulos et al. [16] 
on the ligand binding and kinetics of folate receptor recycling.  
 
IF elicited a more notable effect on the cumulative amount of B12-conjugated 
nanoparticles transported over the three hour experiment for both 50 nm and 100 nm 
sized nanoparticles. This effect was more prominent for the transport of 50 nm B12-
conjugated nanoparticles, where IF enhanced the overall transport from 3.05 µg to 
5.81 µg per cell layer, while for 100 nm sized B12-nanoparticles, transported amounts 
reached 10.14 µg per cell layer in the absence of IF compared with 14.1 µg in the 
presence of IF. Addition of IF to 200 nm B12-conjugated nanoparticles did not appear 
to significantly affect the overall amount transported (1.39 µg versus 1.34 µg in IF-
containing and IF-absent conditions, respectively). 
 
Overall, this data suggests that in the absence of IF, B12-conjugated nanoparticles are 
still internalised and transported across intestinal Caco-2 monolayers, but the level of 
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this trafficking is of a reduced capacity compared to that occurring by cells in the 
presence of IF. Interestingly, in some instances (e.g. for 100 nm B12-conjugated 
nanoparticles) IF appears to influence the extent of nanoparticle transport (in terms of 
both rate and amount), but appears not to affect their uptake by the cells. The reason 
for this is presently unclear, but it may be related to an effect on intracellular events 
occurring post particle uptake. 
 
 
 
Figure 6. 1. Cell uptake and transport of B12-conjugated nanoparticles in Caco-2 
monolayers. 
a) Cell uptake of B12-conjugated nanoparticles of  50, 100 and 200 nm size in the presence and absence of 
intrinsic factor (IF), b) transport of B12-conjugated nanoparticles of 50, 100 and 200 nm size in the presence 
and absence of IF. Data represents the mean ±SD (n=3). Data fitted with a linear trend line and the equation 
of the line is displayed for each data set. 
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Studies examining the role of IF on epithelial uptake and transport of B12-bearing 
nanoparticles are rare. One such study investigated the effect of IF on the uptake and 
transport of vitamin B12-conjugated nanoparticles of the same nominal size as those 
employed in this work (i.e. 50 nm, 100 nm and 200 nm) [10]. The authors reported that 
the addition of IF enhanced the uptake of vitamin B12-bearing nanoparticles by only a 
small degree (likely to be statistically insignificant, though the authors did not provide a 
statistical comparison) and did not affect the level of transport ± a trend that was 
apparent for all three particle sizes tested. This finding prompted the authors of the 
study to conclude that Caco-2 cells are able to internalise and transport B12-
nanoparticles in both an IF-independent and IF-dependent manner, without further 
explanation for the discrete role of IF on their system.  
It must be noted that in the present study, the uptake and transport of B12-conjugated 
nanoparticles in the absence of IF occurs to a notably greater extent compared to 
unmodified nanoparticles (Chapter 5, Figure 5.8). This would suggest that an 
additional, IF-independent vitamin-B12 pathway is operating in Caco-2 cells, which is in 
agreement with work by Russell-Jones et al. [10]. At this stage, one can only 
speculate that this secondary pathway is occurring via the TCII receptor. The 
expression of this receptor has previously been found in both the basolateral and 
apical membranes of Caco-2 cells in an apparent ratio of 6:1 and TCII was shown to 
mediate vitamin B12 endocytosis from both directions with a capacity proportionate to 
the extent of expression on basolateral and apical membranes [17]. The expression of 
the both TCII and the TCII receptor is also shown in this thesis (Chapter 3, sections 
3.3.4.1 and 3.3.4.2, respectively).  
The apical pathway for TCII-B12 endocytosis also appears to be functional in intact rat 
intestine [9]. Importantly however, the relevance of this pathway in vivo is not clear, as 
the presence of TCII carrier protein (a crucial component for the functioning of this 
pathway) in the intestinal lumen has not been demonstrated. Furthermore, patients 
with IF or cubilin defects, develop vitamin B12 deficiency [17, 18], highlighting that the 
TCII pathway may not be important for physiological absorption of vitamin B12 in man. 
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6.3.2  Effect of IF on cell uptake and transport of soluble B12  
Following studies that assessed the role of IF on cell internalisation and transport of 
B12-conjugated nanoparticles, further experiments were conducted to establish 
whether IF contributes to the cell uptake and transport of soluble vitamin B12. Data 
comparing the uptake of soluble vitamin B12 in culture conditions with added IF and 
those without IF (Figure 6.2a) shows a larger extent of uptake (2.3-fold higher) in the 
presence of IF. The data depicting the transport of soluble vitamin B12 across the cell 
layer in IF-containing or IF-free medium (Figure 6.2b), on the other hand, illustrates 
that the effect of IF on transport is not as apparent as its influence on the uptake. To 
this end, soluble vitamin B12 transported at a similar rate (amount transported over 
time) with or without IF. The cumulative amount of vitamin B12 transported across the 
cell monolayers in the experiment was somewhat higher when vitamin B12 was co-
administered with IF in comparison to IF-free conditions, again dominated by the initial 
transport occurring between 0 and 30 minutes.   
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a) 
 
b) 
 
Figure 6. 2. Effect of intrinsic factor on the uptake and transport of soluble vitamin B12.  
Effect of IF on a) cell uptake and b) transport of nanoparticles, Soluble vitamin B12 (500 µg) was applied to 
the cell monolayers either in the presence or absence of IF. Data represents the mean ± SD (n=3).  
It is rather difficult to compare our data on the role of IF on cell uptake and transport of 
(soluble) vitamin B12 with the literature. For example, in the aforementioned study by 
Russell-Jones and colleagues [10], the presence of IF was found to either inhibit or 
promote the uptake of soluble vitamin B12, depending on cell passage number, whilst 
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transport was generally found to be facilitated by the presence of IF, although again, 
this was highly dependent on cell passage number, which  adds  complexity and 
makes the comparison between this work and studies by others (e.g. the publication 
by Russell-Jones et al. [10]) problematic. Furthermore, numerous studies [19-21] 
investigating vitamin B12 transport do not specify whether B12 was applied in 
combination with IF, making appropriate comparisons difficult.  
 
An important difference between this work and some of the previous studies 
examining the uptake and trafficking of soluble vitamin B12 lies in the applied dose of 
vitamin B12. The amount of vitamin B12 applied to Caco-2 monolayers in this work (500 
µg per cell layer) were considerably higher compared to those used in some studies 
[22] where vitamin B12 was applied at more physiologically relevant amounts (e.g. 100 
fmoles/well or 1.36 ng/well), while another study from the same group [10] fails to 
specify applied amounts of vitamin B12. On the other hand, a group of studies from 
other authors have employed similar concentrations of soluble vitamin B12 to this work, 
with Sarti et al. [20] applying  50 µg/ml, Tronde et al. [21] using 10 µM (1.36 µg/ml) 
(both in Caco-2 monolayers) and Schanker et al. [11], measuring soluble vitamin B12 
transport across rat lung following its application over a 100-fold range of 
concentrations from 0.01 to 1 mM, which was reported to be non-saturable. Non-
saturable transport of soluble vitamin B12 across a 100-fold range of applied amounts 
(in the presence of IF) is also observed in the present work. The data in Figure 6.3 
shows no plateau in the level of transport as the applied dose increased from 5 µg-
500 µg at 37 °C.  
 
It should be noted that in the literature reports discussed above, the apparent 
permeability of soluble vitamin B12 across the mucosal models (i.e. Caco-2 cells or 
lung tissue) amounted to 1.8x10-7 cm/s [20], 1x10-7 cm/s [21] and 8x10-7 cm/s [11, 19], 
which are similar values to that reported in this chapter (7.54x10-7 cm/s, when 
expressing soluble vitamin B12 transport as an apparent permeability coefficient, 
calculated from Figure 6.2b according to the equation described in Chapter 2) and 
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indeed in other sections in this thesis. The conditions (higher than the physiological 
dose of soluble vitamin B12) employed in this study were not used to predict the 
absorption capacity of the vitamin B12 by the intestinal epithelium; but to assess 
whether the additional effect of IF on cell uptake and transport of soluble vitamin B12 is 
similar to that seen for vitamin B12±conjugated nanoparticles.  
 
Figure 6.3 also depicts transport of soluble vitamin B12 across Caco-2 monolayers at 4 
°C ± conditions where energy-requiring cell processes are inhibited. The data 
indicates that in this scenario, the transport of soluble vitamin B12 across the cells is 
suppressed over all the applied concentrations.This data implies that at the 
concentration applied, a considerable proportion (up to 41%) of the transported 
soluble B12 traverses the Caco-2 monolayers passively, most likely through the 
paracellular corridor. This is perhaps not surprising considering the molecular weight 
of soluble vitamin B12 (1356 Da), as discussed in section 6.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. 3. Transport of soluble vitamin B12 (applied with IF in all cases) across Caco-2 
cell monolayers, following different applied amounts (apically) at 37°C and 4°C.  
Data represents the mean ± SD (n=3). 
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6.3.3  Effect of IF on cell trafficking of soluble vitamin B12 
The role of clathrin-mediated uptake in cell trafficking pathway of native soluble 
vitamin B12 in vivo is well established [23]. The literature documented cell uptake and 
transport mechanisms of vitamin B12 in the presence of IF were confirmed in Chapter 
5, where the results suggested that vitamin B12-IF internalisation and transport were 
sensitive to the effects of chlorpromazine inhibition of the clathrin pathway, but 
remained insensitive to the effects of caveolae inhibition using filipin. Work presented 
in this section aimed to evaluate the cell uptake and trafficking of soluble vitamin B12 in 
the absence of IF.  
In the presence of chlorpromazine, cell internalisation of soluble vitamin B12 in the 
absence of IF (Figure 6.4a) was inhibited by approximately 2.7-fold and reduced to a 
somewhat lower extent (~2.1-fold) in the presence of filipin (with a statistically 
significant more prominent effect by chlorpromazine). This suggests a role for both 
clathrin- and caveolae-mediated pathways in the process of cell trafficking of soluble 
B12 ligand in the absence of IF. Similarly, transport of B12 across Caco-2 cell 
monolayers was inhibited by both agents (Figure 6.4b), where the data revealed a 3.8-
fold decrease following treatment by chlorpromazine, as compared to a 3.2-fold 
decrease in the presence of filipin. It is therefore likely that vitamin B12 trafficking in the 
absence of IF explores other cellular uptake and trafficking pathways, potentially 
implicating the role of the TCII receptor-mediated pathway.  
In the current model of vitamin B12 trafficking, the TCII-B12 complex that is bound to 
the TCII-receptor is internalised via clathrin-coated pits, as in the case of the IF-B12 
complex bound to cubilin [23]. In one experimental study [24], the TCII receptor was 
detected in the apically derived clathrin-coated vesicles and intermicrovillar clefts of 
the rat kidney, and although no further evidence was provided for its sub-cellular 
location within the intestine (or in Caco-2 cells), these findings nonetheless implicated 
a role for clathrin in the internalisation of the TCII receptor. 
Contrary to literature reports [23, 24], the data presented in this section indicates that 
soluble B12 uptake in the absence of IF is dependent on both caveolae- and clathrin-
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mediated endocytosis events. Therefore, unlike vitamin B12 uptake in the presence of 
IF (i.e. most likely in the form of the B12-IF complex), which is governed by the clathrin 
pathway (as results suggested in Chapter 5, Figure 5.12), it appears that soluble 
vitamin B12 in the absence of IF may (also) exploit alternative routes, with one 
possibility being the TC-II receptor-mediated pathway.  
The joint contribution of cellular pathways (i.e. both clathrin and caveolae) has also 
been implicated in the endocytosis of insulin [25]. Evidence indicates that in the 
endothelium, it can be endocytosed by both clathrin-coated and non-coated vesicular 
pathways [26, 27], consistent with the proposed idea that coated pits internalise insulin 
for degradative purposes and that in the endothelium, insulin can be internalised not 
only for degradation but for other purposes, such as transcytosis. Therefore, the 
association of receptors either within clathrin-coated pits or within caveolar structures 
per se does not necessarily limit them to adopting a single pathway when bound to 
ligand. Likewise and as partly demonstrated in Chapter 5, the highly complex cell 
trafficking pathways are not controlled by the ligand-receptor interaction alone and in 
vitro data may not necessarily reflect the in vivo situation (there may also be tissue-
specific differences).  
The finding therefore that soluble vitamin B12 uptake and transport in intestinal 
epithelial Caco-2 cells in the absence of IF utilise route(s) that do not follow those 
observed in the literature and do not display the same pattern of sensitivity to 
endocytosis inhibitors as the trafficking route in the presence of IF is therefore not 
entirely unexpected. 
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Figure 6. 4. Effect of endocytic pathway-specific inhibitors on cell uptake and transport 
of soluble vitamin B12 (applied at 1 mg/ml) in the absence of intrinsic factor. 
a) Effect of chlorpromazine and filipin on cell uptake of vitamin B12, and b) Effect of chlorpromazine and 
filipin on transport of vitamin B12 across Caco-2 monolayers. Vitamin B12 was applied in the absence of IF 
and quantified by
 
UVAbs (350 nm). Data represents the mean ± SD (n=3).  
 
In the studies examining the role of IF on the cell uptake and transport of soluble of 
vitamin B12 (Figures 6.2 and 6.3), together with the associated mechanisms, IF was 
a) 
0 
2 
4 
6 
8 
10 
12 
0 50 100 150 200 
Am
o
un
t t
ra
ns
po
rte
d 
(µg
 p
er
 
cm
2 ) 
Time (min) 
Chlorpromazine treated (10µg/ml) 
Filipin treated (5µg/ml) 
Untreated (HBSS) 
0 
2 
4 
6 
8 
10 
12 
Chlorpromazine 10 
µg/ml 
Filipin 5 µg/ml Untreated HBSS 
Ce
llu
la
r 
u
pt
ak
e 
(µg
 p
er
 
cm
2 ) 
**** **** 
* 
b) 
Chapter 6: The role of intrinsic factor on cellular trafficking of vitamin B12-conjugated 
nanoparticles 
192 
 
applied at a dose notably lower than a 1:1 molar ratio to vitamin B12 (with the latter 
applied at high doses). Importantly, the presence of IF is only essential for the cubilin-
mediated pathway of vitamin B12 uptake and transport route. To this end, the overall 
cell uptake and transport of vitamin B12  is likely to occur through multiple pathways, 
including the TCII receptor and the paracellular route (which would contribute to 
transport rather than cell uptake), as shown in Figure 6.3. 
 
6.3.4  Effect of IF on cell trafficking of B12-conjugated nanoparticles 
The cell internalisation route of vitamin B12-conjugated nanoparticles (50 nm) under IF-
free conditions was established using the pathway-specific cell trafficking inhibitors 
employed in the section above (and in Chapter 5). The concentrations of inhibitors 
employed to induce uptake inhibition without causing cell toxicity have been described 
elsewhere (Chapter 5, section 5.3.10). In addition, the uptake inhibition activity of 
these materials was tested on ligands known to internalise specifically via either 
clathrin- or caveolae-mediated routes (Chapter 5, Figure 5.15). Figure 6.5 reveals cell 
uptake and transport of B12-conjugated nanoparticles in the presence of either 
chlorpromazine or filipin, and in the absence of IF (cell uptake data for B12-conjugated 
nanoparticle uptake in the presence of IF, shown in Chapter 5, has been included for 
the purpose of comparison). Figure 6.5ai shows that in IF-free conditions, the cell 
uptake of B12-conjugated nanoparticles is reduced 3.3-fold in the presence of 
chlorpromazine ± a phenomenon that was not observed in the case of B12-conjugated 
nanoparticles in the presence of IF (instead, chlorpromazine treatment exhibited no 
significant effect on particle internalisation amount). Filipin treatment somewhat 
inhibited the cellular uptake of B12-conjugated nanoparticles in the absence of IF 
(approximately 1.4-fold reduction); this effect was less marked compared with B12-
conjugated nanoparticle uptake in the presence of IF (Figure 6.5aii).  
Transport data in the absence of IF appears to follow a similar trend. Chlorpromazine 
treatment (Figure 6.5bi) resulted in a 1.8-fold reduction for B12-conjugated nanoparticle 
transport, relative to the untreated control. Following filipin treatment B12-conjugated 
nanoparticle transport across the cells (Figure 6.5bii) was inhibited during the initial 
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phase of the experiment (over 2 hr), but the amount of nanoparticles transported to 
the basolateral side at the 3 hr measurement point reached the values seen in the 
untreated cells. The reason for this apparent trend is not entirely clear as filipin, a 
known sterol-binding agent is shown to severely disrupt caveolae and caveolae-
mediated endocytosis by way of removing cholesterol from the cell membranes 
causing vesicle flattening and disassembly [28, 29] , but it is also a used as a selective 
inhibitor for non-coated vesicular transcytosis [25], the effects of which are irreversible 
with time. To further investigate this phenomenon, uptake studies conducted at 
intermediate time points (between 0-3 hr) are required to determine whether filipin acts 
as an inhibitor in the early uptake phase. Indeed, if this proved to be the case, this 
may serve to account for the observed transport trends of B12-conjugated 
QDQRSDUWLFOHVDQGWKLV³ORVVRIHIIHFW´E\ILOLSLQRYHUWLPH 
Overall, the data suggests that the transport of vitamin B12-conjugated nanoparticles in 
the absence of IF was predominantly influenced by inhibition of the clathrin pathway. 
Although further studies using alternative inhibitors are needed to confirm these 
findings,this study suggests that IF plays an important additional role in dictating the 
internalisation and subsequent trafficking of both soluble vitamin B12 and B12-
conjugated nanoparticles. Under IF-free conditions, internalisation of vitamin B12 (or 
B12-conjugated nanoparticles) by cubilin is not possible.  The cubilin receptor needs to 
recognise and engage with the IF-B12 complex in order to trigger its endocytosis [30]. 
This infers the distinct involvement of a secondary receptor-mediated pathway. Thus it 
seems highly probable that the way in which B12-conjugated nanoparticles are 
µSURFHVVHG¶E\HSLWKHOLDOFHOOV LVJRYHUQHGE\DGLIIHUHQW LQLtial receptor-binding event 
(e.g. complexing to TCII and undergoing TCII receptor-mediated endocytosis) under 
IF-free conditions. Further mechanistic studies are needed in order to fully 
characterise this secondary (receptor-mediated) pathway and to delineate its 
involvement in the uptake and transport of B12-conjugated nanoparticles. It must be 
noted that a comparison of our findings related to the role of IF on the trafficking of 
B12-conjugated nanoparticles and existing literature is not possible due to the lack of 
such published studies. 
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Figure 6. 5. Effect of clathrin and caveolae inhibition on cell uptake and transport of 
vitamin B12-conjugated nanoparticles in the absence of IF. 
a) Effect of chlorpromazine (i) and filipin (ii) on cell uptake of nanoparticles. Experiments where IF is added 
UHIHUUHG WR DV µ,)¶ ([SHULPHQWV FRQGXFWHG LQ WKH DEVHQFH RI ,) UHIHUUHG WR DV µ-,)¶  E (IIHFW RI
chlorpromazine (i)  and filipin (ii) on the transport of nanoparticles. Cell uptake and transport studies were 
conducted with B12-conjugated nanoparticles of 50nm diameter. Data represents the mean ± SD (n=3).  
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6.3.5 Cell trafficking summary of soluble B12 and B12-conjugated nanoparticles 
in Caco-2 cells 
The trafficking behaviours of soluble B12 and B12-conjugated nanoparticles in intestinal 
Caco-2 monolayers, as suggested by data from experiments employing 
pharmacological inhibitors, are summarised in Table 6.1.  
 
Cell trafficking in Caco-2 cells occurring via 
 
Clathrin Caveolae Both 
Soluble B12 (with 
IF) see chapter 5 + -  
Soluble B12 (without 
IF)   + 
B12-conjugated 
nanoparticles (50 
nm, with IF) see 
chapter 5 
- +  
B12-conjugated 
nanoparticles (50 
nm, without IF) 
+ (-) (+) 
 
Table 6. 1. Summary table showing observed cell  trafficking behaviours of soluble 
B12  and B1 2-conjugated nanoparticles (of 50 nm pre -conjugation diameter) across 
Caco-2 cells. '+' denotes positive involvement of pathway, ' - '  denotes no 
involvement of pathway. Brackets indicate some/minor involvement of pathway.  
 
 
6.4 Conclusion 
Previous reports have shown that IF adopts a crucial role in the internalisation of 
vitamin B12 through enabling recognition and internalisation via the cubilin receptor. In 
its absence, the B12 ligand is shuttled along a different pathway, likely involving 
recognition by TCII and subsequent internalisation via the TCII receptor.  
In this chapter it was sought to determine whether IF is important for the cell uptake, 
transport and cell trafficking pathway of soluble vitamin B12 and B12-conjugated 
nanoparticles in Caco-2 cells. Overall, the data suggests that in the absence of IF, B12-
conjugated nanoparticles are internalised and transported by cells to a lesser extent 
than when co-administered with IF, although the magnitude of this reduction was not 
substantial. The findings also demonstrate that soluble vitamin B12 trafficking (without 
IF) occurs via a different route to that used by vitamin B12-IF (i.e. cubilin mediated). 
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Unlike B12-nanoparticle uptake behaviours under IF-containing conditions, which were 
found to exploit a caveolae-mediated route, the cellular internalisation and transport of 
B12-conjugated nanoparticles in the absence of IF were instead predominantly affected 
by inhibition of the clathrin pathway. As in the case of soluble VB12 trafficking, this 
further suggests the involvement of an uptake and trafficking route which is different to 
that in the presence of IF, indirectly implicating a role for the TCII receptor-mediated 
pathway in the endocytosis and transport of B12-conjugated nanoparticles, a 
phenomenon which may be exploited in parallel to the conventional B12 pathway for 
vitamin B12-mediated drug delivery. 
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Chapter 7: The vitamin B12 transport pathway in airway 
Calu-3 cells 
7.1 Introduction 
The receptor-mediated endocytosis pathway of B12 has shown potential for oral 
delivery of peptides and proteins [1-5], in addition to nanoparticulate carriers 
(conjugated to B12), offering the possibility of enhanced drug delivery [4, 6]. Published 
work assessing  the  potential of the B12 pathway for delivery of protein therapeutics 
has focused on oral delivery, with studies being conducted either in vivo in rats [4] or 
in vitro using the intestinally-derived cell lines, Caco-2 [7, 8] and HT29 [9, 10]. In 
intestinal Caco-2 cells, the B12 pathway has been shown to transport nanoparticles, in 
addition to soluble protein therapeutics, modified with B12 [2]. This was covered in 
detail in chapter 5, where the previously unreported mechanism of cell internalisation 
and intracellular trafficking of B12-conjugated nanoparticles, was explored.  
 
This chapter describes work investigating whether the B12 endocytosis pathway is 
present and operates in bronchial Calu-3 cells. This objective is partly a result of 
earlier observations within our group, which showed that the Calu-3 cell line expresses 
folate receptors [11]. To the best of our knowledge, cubilin expression in epithelial cell 
lines originating from the airways has not previously been demonstrated and the B12 
pathway not investigated. Initial experiments were conducted to determine whether 
Calu-3 cells express cubilin, the TCII receptor and the TCII carrier protein. This was 
followed by assessment of cell uptake and transcellular transport of B12-conjugated 
nanoparticles and a delineation of the mechanisms involved, providing a comparison 
with the cell uptake and transport of B12-bearing nanoparticles in Caco-2 cells. 
 
7.2 Methods 
7.2.1  3UHSDUDWLRQRIWKHĮ-Ȧ-aminohexylcarbamate derivative of 
cyanocobalamin 
'HWDLOV RQ WKH FKHPLFDO V\QWKHVLV DQG FKDUDFWHULVDWLRQ RI WKH Į-Ȧ-
aminohexylcarbamate derivative of vitamin B12 are described in Chapter 4.  
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7.2.2  Preparation and surface characterisation of vitamin B12-conjugated 
nanoparticles 
Fluorescent carboxylate Yellow Orange (YO) nanoparticles of 50 nm and 100 nm 
3RO\6FLHQFHV ,QF ZHUH PRGLILHG ZLWK WKH Į-Ȧ DPLQRKH[\OFDUEDPDWH YLWDPLQ %12 
derivative by activation with 1-ethyl-3-[3-Dimethylaminopropyl]carbodiimide (EDAC), in 
the presence of N-hydroxy-succinimide (NHS). See Chapter 5 (5.2.2) for further 
experimental details. The presence of the B12 ligand on the surface of the 
nanoparticles was established using fluorescence quenching experiments (Chapter 5; 
section 5.2.3).  
7.2.3  Cell Culture  
The protocols for routine culture of Calu-3 cells are described in Chapter 2, section 
2.2. Calu-3 cells were cultured for 21 days and under liquid-covered culture (LCC) 
conditions for all experiments detailed in this chapter. Culturing cells over the full 21 
day period was considered important to ensure complete cell differentiation.   
7.2.4  Barrier and morphological characterisation of Calu-3 cell layers 
Calu-3 cells were cultured on filters following the methods detailed previously (section 
2.2.1). TEER measurements were conducted (in the manner described in section 
2.2.2) every 2 or 3 days, starting from day 2 to day 15-21 of culture. Calu-3 TEER 
profiling experiments were carried out by Dr Driton Vllasaliu (University of 
Nottingham).  
 
The barrier capacity of polarised Calu-3 cell layers was confirmed by determining the 
permeability of FITC-dextrans (FD) of varying molar mass after 21 days in LCC 
culture. Culture medium of polarised cell layers was initially replaced with warmed (37 
°C) HBSS (transport medium) and cells were allowed to equilibrate for approximately 
30 min. TEER measurements were taken to confirm cell layer intactness (refer to 
sections 2.2.2 and 2.2.3). HBSS was then removed from the apical side and replaced 
with FD solutions, comprising of FD4, FD10, FD20, FD40, FD70 or FD150 dissolved in 
HBSS (37 °C) at 500 µg/ml. Cells were placed in the incubator at 37 °C in between 
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sampling intervals. FD permeability was determined as detailed in Chapter 2, section 
2.2.3.  
In a separate experiment, Calu-3 cells were imaged using SEM and TEM following 21-
day culture on filters. Polarised Calu-3 cells were also stained for Zonula Occludens-1 
(ZO-1) in the manner described in Chapter 2, section 2.2.5. 
7.2.5  Immunohistochemical analysis of cubilin and TCII 
Filter-cultured Calu-3 cells were selected for immunostaining experiments on day 21 
of culture. The culture medium was replaced with HBSS and following a 45 min 
incubation period, TEER measurements were taken to ensure cell layer intactness. 
Cells were then fixed with 4% paraformaldehyde (in PBS) for 10 min. For TCII 
staining, cells were permeabilised with 0.2% (v/v) Triton X-100 for 10 min. Cells were 
then washed with PBS and incubated with 1% w/v BSA/PBS (for 1 hr). Antibodies to 
cubilin and TCII (cubilin H-300; Transcobalamin II H-260; both rabbit, anti-human; 
Santa Cruz Biotechnology, Inc.) were added to the cell samples diluted 1:50 in 1% 
BSA/PBS; cells were incubated for 30 min. Primary antibodies were then removed and 
cells washed 3 times with PBS, followed by incubation with the secondary antibody 
(goat, anti-rabbit IgG-rhodamine) diluted 1:100 (in 1% BSA/PBS) for another 30 min. A 
control experiment was conducted where polarised cells were incubated with the 
secondary antibody only. Following a final extensive washing step, the cell nuclei were 
stained with Hoechst 33342 (0.1 mg/ml) and the filter membranes excised from the 
inserts. Cells were mounted on glass slides using 1,4-diazabicyclo[2.2.2]octane 
(DABCO) (1%, diluted in 9:1 glycerol:PBS) and covered with glass cover slips. 
Confocal imaging was carried out using a Leica SP2 CLSM confocal microscope. 
 
7.2.6  mRNA expression of cubilin and Transcobalamin II receptor 
mRNA was isolated from filter-cultured Calu-3 cells on day 21 of culture on Transwell® 
inserts, using the method described in section 2.2.6.1.1. cDNA was synthesised using 
the protocol described in section 2.2.6.1.2. A conventional PCR was performed on the 
PTC-200 Thermal Cycler to amplify the cDNA, which was then visualised using gel 
electrophoresis (section 2.2.6.2). The expected size of the amplified cDNA fragments 
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was 602bp for cubilin and 343bp for CD320 (encoding Transcobalamin II receptor). 
The reader is referred to section 2.2.6.2.1 for primer details.  
7.2.7  Immunostaining for clathrin and caveolin-1  
Immunostaining for clathrin and caveolin-1 in polarised Calu-3 cells was carried out in 
a manner described previously (Chapter 2, section 2.2.5.5).  
 
7.2.8  mRNA expression of caveolin-1  
mRNA was isolated from polarised Calu-3 cells (cultured on Transwell® supports for 
21 days using the method described in section 2.2.6.1.1). cDNA was synthesised 
using the protocol described in section 2.2.6.1.2. A conventional PCR was performed 
on the PTC-200 Thermal Cycler to amplify the cDNA, which was then visualised using 
gel electrophoresis (section 2.2.6.2). The expected size of the amplified cDNA 
fragment was 362bp (see section 2.2.6.2.1 for primer details).  
 
7.2.9  Cellular uptake and transport of B12-conjugated nanoparticles  
Calu-3 cells were cultured on Transwell® supports over 21 days (as described in 
VHFWLRQ &XOWXUHPHGLXPZDV UHPRYHG IURP WKHFHOOVDQG UHSODFHG ZLWK +DQN¶V
Balanced Salt Solution (HBSS), buffered with 2-[4-(2-hydroxyethyl)piperazin-1-
yl]ethanesulfonic acid (HEPES, 20mM) and cell monolayers incubated for 45 min. 
Unmodified YO nanoparticles (50 and 100 nm) and vitamin B12-conjugated 
nanoparticles were suspended in HBSS/HEPES to achieve a final concentration of 
400 µg/ml. Recombinant human intrinsic factor (rHUIF, Autogen Bioclear Ltd) was 
added (3 µg per 1 ml of 400 µg/ml nanoparticle suspension) and the solution was 
LQFXEDWHG DW Û& SULRU WR DSSOLFDWLRQ WR FHOOV )ROORZLQJ D URXWLQH DVVHVVPHQW RI
TEER (as described in chapter 2, section 2.2.2), nanoparticle suspensions (0.5 ml) 
were applied to the apical chamber of triplicate wells and the Calu-3 cultures 
LQFXEDWHGDWÛ&RYHUKUV$WPLQXWHVDPSOLQJ LQWHUYDOVOZDV UHPRYHG
from the basolateral side and analysed for fluorescence. Sample volumes were 
replaced with 100 µl of HEPES/HBSS to maintain sink conditions. Internalised 
fluorescence (indicating nanoparticle uptake) was determined by cell lysis using 0.2% 
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Triton X-100 (Fluka) (10 min incubation). Cell uptake of nanoparticles was quantified 
by fluorescence (Dynex, microplate reader, 529 nm/546 nm) using calibration curves. 
Soluble vitamin B12 transport studies were conducted as described in Chapter 5, 
section 5.2.5. 
7.2.10  Lysosomal cell trafficking studies  
/\VRVRPDOFHOO WUDIILFNLQJVWXGLHVXVLQJPDUNHUVIRU O\VRVRPHV/\VRWUDFNHU*UHHQ
DND-26 and anti-LAMP1 antibody, were carried out in the same manner as for Caco-2 
cells, described in section 5.2.8.  
 
7.2.11 Clathrin and caveolae inhibition studies  
Cell trafficking inhibitory studies were conducted in the same way as for Caco-2 cells, 
detailed in section 5.2.9. Calu-3 cell layers (on day 21 of culture) were treated with 
inhibitors of specific endocytic pathways, filipin (5 µg/ml) or chlorpromazine (10 µg/ml), 
in HBSS/HEPES for 1 hr at 37°C prior to the addition of nanoparticles [12]. Unmodified 
and vitamin B12-conjugated nanoparticles of 100 nm in diameter (400 µg/ml in 
HBSS/HEPES) in the presence or absence of IF were applied in combination with one 
of the above inhibitors for 3 hrs. It should be noted that 100 nm B12-conjugated 
nanoparticles were used in the trafficking experiments in work described in this 
chapter (particle trafficking work in Caco-2 cells was conducted with 50 nm sized B12-
conjugated nanoparticles). Control experiments with known ligands for the clathrin- 
and caveolae-mediated pathways (FITC-transferrin at 100 µg/ml and cholera toxin-B-
subunit at 5 µg/ml, respectively) were performed as described previously. In addition, 
native cyanocobalamin (vitamin B12) in the presence of IF was also applied in 
conjunction with filipin or chlorpromazine to confirm the route of internalisation of the 
soluble ligand and quantified by UV-absorbance at 350 nm.  
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7.3 Results and Discussion 
 &KDUDFWHULVDWLRQ RI WKH Į-Ȧ-aminohexylcarbamate derivative of 
cyanocobalamin and vitamin B12-conjugated nanoparticles 
&KDUDFWHULVDWLRQRI WKHĮ-Ȧ-aminohexylcarbamate derivative of cyanocobalamin was 
described in Chapter 4, section 4.3. Likewise, characterisation of vitamin B12-
conjugated nanoparticles was detailed earlier (Chapter 5, sections 5.3.1-5.3.3). 
 
7.3.2  Barrier and morphological characterisation of Calu-3 cell layers 
In culture, the Calu-3 cell line produces features of differentiated, functional human 
airway epithelial cells [13], including the formation of the tight junctions [14-24]. The 
Calu-3 cell line as a model of the airways has demonstrated good in vitro±in vivo 
correlation in terms of drug permeation. This section shows data related to barrier and 
morphological characterisation of Calu-3 cells, cultured as polarised cell layers. Figure 
7.1a depicts the development of TEER over time in culture. No significant increase in 
TEER was observed until day 7 of culture. Thereafter, TEER increased sharply, but 
subsequently reached a plateau after day 16 in culture. Immunostaining of polarised 
Calu-3 cells with an antibody to ZO-1 protein on day 21 (Figure 7.1b) revealed a 
typical distribution pattern of this protein as continuous 'belts' at cell-cell contacts. 
Figure 7.1c shows an SEM micrograph revealing closely packed cells, with distinct 
cell-cell boundaries and microvilli on the apical surface. The TEM micrograph (Figure 
7.1d) highlights that Calu-3 cells also express a number of apically-located electron-
translucent round granules of approximately 1 ȝm diameter, with some of these 
exhibiting an electron dense core. These resemble mucin granules of airway goblet 
cells in organisation and size [25], and their expression in Calu-3 cells has also been 
reported by other groups [13, 26, 27]. 
 
Finally, Figure 7.1e compares the permeability of FITC-dextrans of varying molecular 
mass across Calu-3 layers with Caco-2 cells. Apical-to-basolateral permeability 
decreased with increasing molecular mass of the solute (from 4 kDa to 150 kDa) in 
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Calu-3 cells, which is similar to the trend observed for Caco-2 cells. For example, the 
largest macromolecule, FD150 (150 kDa), exhibited a 34-fold lower permeability than 
the solute with the lowest molecular mass, FD4 (4 kDa). Comparing the permeability 
data in Calu-3 cell layers with that obtained in Caco-2 monolayers, it is clear that Calu-
3 layers present a considerably greater barrier to the permeability of dextrans 
compared to Caco-2 monolayers. It is interesting to note that whilst the difference in 
permeability between FD4 and FD10 was not statistically significant in Caco-2 cells 
(Chapter 3, Figure 3.5), this difference in permeability in Calu-3 layers was notable 
(more than 2-fold). Furthermore, whilst FD4 exhibited a 5.3-fold higher permeability 
than FD40 in Calu-3 cells, this difference in Caco-2 cells amounted to only 2.5-fold. 
These observations hence indicate that the paracellular route in Caco-2 cells is able to 
accommodate the passage of macromolecular solutes of larger molar mass compared 
to Calu-3 cells. A detailed discussion related to the differences between Calu-3 and 
Caco-2 cell lines in terms of their morphology and barrier characteristics falls beyond 
the scope of this thesis and the reader is referred to a recent publication by our group 
[28].  
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a)      b) 
  
c)           d) 
 
 
 
 
e) 
e)  
 
Figure 7. 1. Characterisation of Calu-3 cells, cultured on permeable supports as polarised 
cell layers.  
a) TEER profile; expressed as the measured resistance per area (cm2) of the cell layer. Background TEER 
due to the filter was subtracted from the reported values. Data presented as the mean ± SD (n=5). b) 
Staining for Zonula Occludens-1 (ZO-1) tight junction protein. Micrograph presented as an overlay image 
showing DAPI-labelled cell nuclei (blue) and ZO-1 distribution (red). c) SEM micrograph showing closely 
SDFNHGFHOOVZLWKPLFURYLOOLZKLWHOLQHUHSUHVHQWVDVFDOHEDURIȝP7KHREVHUYHGFUDFNVDUHDUWLIDFWV
resulting from sample processing for imaging. d) TEM micrograph showing a cell expressing microvilli (Mv) 
on the apical membrane and secretory granules (Sg). Scale bar=2 µm. e) Permeability of FITC-dextrans of 
approximate molecular weight of 4 kDa (FD4), 10 kDa (FD10), 20 kDa (FD20), 40kDa (FD40), 70 kDa 
(FD70) and 150 kDa (FD150) across Caco-2 and Calu-3 cell layers. Permeability expressed as apparent 
permeability coefficient (Papp), plotted against a logarithmic scale of the molecular weight of each FD. Data 
presented as the mean ± SD (n=4). 
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7.3.3  Immunohistochemical analysis of cubilin and TCII 
Confocal micrographs of polarised Calu-3 cells, treated with the relevant antibodies 
reveal expression of cubilin (Figure 7.2a i). The control experiment, where the 
incubation step with the primary antibody was omitted, shows minimal fluorescence 
signal, excluding the possibility of non-specific antibody binding (Figure 7.2a ii).  
 
In addition to confirming the presence of cubilin, further experiments were conducted 
to establish whether Calu-3 cells (cultured as polarised layers) express another 
relevant component of the vitamin B12 transport pathway. The role of transcobalamin II 
(TCII) in the transport of B12 was described earlier (Chapter 3, section 3.3.4.1). 
Immunostaining for this protein indicated its presence in Calu-3 cells (Figure 7.2b i). 
The pattern of fluorescence signal indicates a non-polar distribution of TCII (i.e. not 
confined to apical or basal side of the cells), consistent with its function of binding to 
vitamin B12 upon exit from the lysosomes for transport out of the cell. Again, the 
control experiment comprising cell treatment with the secondary antibody 
demonstrates absence of fluorescence signal (Figure 7.2b ii), indicating that the 
observed fluorescence is not due to non-specific binding of the secondary antibody. 
Immunostaining for TCII receptor ± another component involved in the trafficking of 
vitamin B12 in vivo (internalisation in the absence of IF) ± was not conducted due to 
the lack of commercially-available primary antibodies.  
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a) i              ii 
 
 
 
 
 
 
 
b)  i              ii 
 
 
 
 
 
 
 
Figure 7. 2. Immunostaining for cubilin (VB12-IF receptor) and transcobalamin II (TCII) in 
polarised Calu-3 cells.  
a) Expression of cubilin receptor. i) Cells treated with anti-human cubilin H300 antibody, followed by goat, 
anti-rabbit IgG-Rhodamine. ii) Control experiment depicting cells treated only with the secondary antibody 
(goat, anti-rabbit IgG-Rhodamine). b) Expression of TCII. i) Cells treated with anti-human TCII H-260 
antibody, followed by goat, anti-rabbit IgG-Rhodamine, ii) Control experiment where cells were treated with 
goat, anti-rabbit IgG-Rhodamine only. Blue=cell nuclei; Red=anti-rabbit IgG-Rhodamine. 
 
7.3.4  mRNA expression of Cubilin and Transcobalamin II receptor  
Calu-3 cells were also analysed for mRNA expression of cubilin and CD320 (encoding 
the transcobalamin II receptor). Total mRNA of Calu-3 cells was isolated following cell 
culture on filters under the conditions described earlier. Figure 7.3 reveals the 
expression of both cubilin (602 bp) and CD320 (343 bp) in Calu-3 cells. A secondary 
fragment (~260 bp) with weak intensity in addition to the band detected at 343 bp (for 
CD320) was noticed, apparent also in Caco-2 cell experiments (section 3.3.4.2).  
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Figure 7. 3. mRNA expression of (A) cubilin (lanes 1 and 2) and (B) CD320 (TCII Receptor) 
in Calu-3 cells (lanes 3 and 4) on day 21 of culture. 
 *Ctrl denotes PCR product obtained from Caco-2 cell monolayer. 
 
7.3.5  Clathrin and Caveolin-1 expression  
Before attempting to unravel the biological mechanisms involved in the cellular 
trafficking of B12-conjugated nanoparticles, it was first confirmed that the Calu-3 cells 
employed in this study as a model of the bronchial epithelium express the relevant 
components of relevant endocytic pathways. This includes the presence of essential 
FRQVWLWXHQWV RI FODWKULQ µFRDWHG SLWV¶ LPSOLFDWHG LQ WKH LQWHUQDOLVDWLRQ RI WKH VROXEOH
vitamin B12-IF complex, as well as caveolae (a route found to be involved in the 
trafficking of B12-conjugated nanoparticles in Caco-2 cells, Chapter 5). Immunostaining 
for clathrin, the protein responsible for the formation of clathrin coated pits, resulted in 
detection of fluorescence signal, indicative of clathrin expression (Figure 7.4a i), in 
contrast to the control experiment (Figure 7.4a ii). The expression of caveolin-1 protein 
in cells is essential for the formation of morphologically identifiable caveolae [29-31]. 
Immunostaining for this protein in Calu-3 cells (Figure 7.4b i) revealed its expression. 
(The absence of fluorescence in the control overlay image rules out experimental 
artefacts that may result from non-specific antibody binding, shown in Figure 7.4b ii.) 
The expression of these components was also demonstrated in a study conducted by 
Bradbury et al. [32], where the authors investigated the role of caveolae and clathrin-
mediated pathways in the internalisation of cystic fibrosis transmembrane 
conductance regulator (CFTR) in Calu-3 cells. In a separate study, Moradi et al. [11] 
used inhibitors of clathrin and caveolae uptake pathways in the Calu-3 cell layer model 
A B 
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to delineate their respective roles in the internalisation of folate-decorated 
nanoparticles (showing that altering the density of the folate ligand on nanoparticle 
surface produces a change in the cell uptake pathway from predominantly clathrin to a 
predominantly caveolae-mediated route). Taken together, the data indicates that 
airway Calu-3 cells, cultured as polarised layers, express the relevant protein 
components that render them capable of undertaking both clathrin- and caveolin-
mediated endocytosis, as in the case of intestinal Caco-2 cells.  
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Figure 7. 4. Expression of select endocytic components by immunohistochemistry in 
polarised Calu-3 cells.  
a) Staining for clathrin. i) Cells were incubated with rabbit, anti-human clathrin (primary) antibody and goat, 
anti-rabbit (secondary) IgG-FITC. ii) Control experiment where cells were treated with the secondary, goat, 
anti-rabbit IgG-FITC only. b) Staining for caveolin-1. i) Cells were treated with rabbit, anti-human caveolin 1 
H-97, followed by goat, anti-rabbit IgG-Rhodamine. ii) Control experiment where cells were incubated with 
goat, anti-rabbit IgG-Rhodamine only. Cell nuclei (blue) were labelled with Hoechst 33342 in all cases. 
Immunostaining for all components was performed on day 21 of culture. 
 
a) i 
b) i ii 
ii 
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7.3.6  mRNA expression of caveolin-1  
As mentioned earlier, caveolae are thought to be present in Calu-3 cells when cultured 
to form differentiated cell layers [11, 32, 33]. As cells lacking caveolin-1 do not form 
caveolae [34, 35], and heterologous expression of caveolin-1 induces the formation of 
caveolae in cells lacking these structures [36, 37], both immunohistochemical analysis 
(section 6.3.5) and mRNA expression (below) was used in this work to verify the 
existence of caveolin-1 and hence functioning caveolae in filter-cultured Calu-3 cells. 
Prior optimisation of the caveolin-1 PCR primers for work conducted with Caco-2 
cDNA (Chapter 5, section 5.3.8) enabled assessment, using Calu-3 cDNA as a 
template. Figure 7.5 reveals data indicating caveolin-1 mRNA expression on day 21 of 
culture, with an amplified cDNA product of 362bp. The bright intensity of the bands 
(although not quantitative) serves to show that at the point when nanoparticle 
trafficking studies were conducted (i.e. on day 21 of culture), there is mRNA 
expression. Providing that downstream protein translation occurs, this in turn would 
drive the formation of functional caveolae in polarised airway Calu-3 cells, which may 
have implications for the uptake of B12-conjugated nanoparticles (discussed later in 
this chapter), as also suggested for the uptake of poly(vinyl alcohol) nanoparticles in 
Calu-3 cells [33].  
 
 
Figure 7. 5. mRNA expression of caveolin-1 on day 21 of filter-cultured Calu-3 cells 
(sample lanes 2 and 3, n=2). 
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7.3.7  Cell uptake and transport of B12-conjugated nanoparticles  
Figure 7.6a provides a comparison of cellular uptake of B12-conjugated nanoparticles 
(of 50 nm and 100 nm nominal diameter) with unmodified nanoparticles in Calu-3 
cells. It is clear from the figure that the amount of nanoparticles internalised by cells 
over the three-hour period was larger for B12-conjugated nanoparticles, irrespective of 
their size, compared to unmodified nanoparticles (45 µg versus 31 µg, and 15 µg 
versus 8 µg for nanoparticles of 50 and 100 nm nominal diameter, respectively). B12-
conjugated nanoparticles of 50 nm were internalised to a greater extent than 100 nm 
B12-conjugated nanoparticles (45 µg versus 15 µg). This finding is interesting as a 
similar study carried out in intestinal Caco-2 cells demonstrated the opposite 
phenomenon (Chapter 5, Figure 5.7a), where 100 nm B12-conjugated nanoparticles 
were internalised in greater amount than the smaller 50 nm B12-conjugated 
nanoparticles (39 µg vs. 32 µg, respectively).  
 
Figure 7.6a also shows cell uptake of B12-conjugated nanoparticles in the absence of 
IF. IF promoted a 1.25-fold increase in the uptake of B12-conjugated 50 nm 
nanoparticles (45 µg versus 36 µg); for 100 nm B12-conjugated nanoparticles, the 
difference in uptake in the presence of IF (15 µg) was not statistically significant 
compared to IF-free conditions (13 µg). Taking into account comparisons with Caco-2 
cells (Chapter 6, Figure 6.1) ± where IF promoted a 2.4-fold increase in the uptake of 
B12-conjugated nanoparticles (50 nm diameter), but again elicited no statistically 
significant increase in the uptake of larger B12-bearing particles ± the role of IF seems 
ambiguous. However, a similar unremarkable effect of IF was also reported by 
Russell-Jones et al. [2], where IF induced only a modest effect on the uptake of B12-
modified polystyrene nanoparticles in Caco-2 cells. Furthermore, it seems that the 
influence of IF on the uptake of B12-conjugated nanoparticles is restricted to smaller 
nanoparticles of <100 nm diameter in both cell lines. The largely unaffected uptake of 
B12-conjugated nanoparticles in the absence of IF implies that an IF-independent 
pathway also operates in airway Calu-3 cells as in Caco-2 cells. This pathway may 
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involve the TCII receptor-mediated internalisation of B12-conjugated nanoparticles 
bound to the TCII carrier protein, which has also been presumed by others [2, 38]. 
 
Transport of B12-conjugated nanoparticles across Calu-3 cell layers was markedly 
greater than the unmodified counterparts for particles of both 50 and 100 nm (nominal) 
diameter (Figure 7.6b). To exemplify, whilst the cumulative amount transported within 
a 3-hour experiment reached 0.8 and 0.6 µg and for 50 and 100 nm particles, 
respectively, for B12-conjugated nanoparticles the measured amounts were 
considerably higher, with transported levels amounting to 3.0 and 13.6 µg for 50 and 
100 nm B12-conjugated nanoparticles. The observation that B12-modification of 
nanoparticles significantly influenced their cell uptake and transport behaviours in 
airway Calu-3 cells is important. These findings highlight the drug delivery potential of 
B12 bioconjugation, with regard to enhancing the mucosal transport of therapeutic 
nanocarriers in a different epithelial cell line (previous in vitro work demonstrating this 
potential was conducted solely in Caco-2 cells [2]). Moreover, the data demonstrates 
that it is potentially possible to exploit the vitamin B12 biological transport pathway for 
transmucosal delivery of nanomaterials across the airways, which has not been 
previously reported or suggested.  
 
Comparing the transport of vitamin B12-conjugated nanoparticles of different sizes 
across polarised Calu-3 cells, the data in Figure 7.6b shows a significantly greater 
transport for 100 nm, relative to 50 nm particles (13.6 µg versus 3.0 µg, respectively, 
in the presence of IF). This observation is interesting since it does not follow the trend 
of particle uptake data, where cell uptake was the most prominent for 50 nm B12-
conjugated nanoparticles. Consequently, only 7% of the internalised amount of 50 nm 
nanoparticles transported across the cell layers, compared with 88% for 100 nm B12-
conjugated nanoparticles. In the absence of IF, the extent of transport somewhat 
decreased, but followed a similar trend to nanoparticle transport in the presence of IF. 
Namely, the amounts of particles traversing the cell layers in a 3-hour experiment 
were 10.1 µg and 2.5 µg for 100 nm and 50 nm nanoparticles, respectively, equating 
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to a 1.17- and 1.34-fold reduction in cumulative transport, respectively, in the absence 
of IF. This observation is somewhat similar to the trend seen in Caco-2 cells (Chapter 
6, section 6.3.1), where IF enhanced the cumulative amount of transport for both 50 
nm and 100 nm B12-conjugated nanoparticles.  
 
 
Figure 7. 6. Cell uptake and transport of B12-conjugated nanoparticles in Calu-3 layers. 
a) Cell uptake of B12-conjugated nanoparticles (50 nm and 100 nm) in the presence and absence of intrinsic 
factor (IF) and unmodified NPs, b) transport of B12-conjugated nanoparticles (50 and 100 nm) in the 
presence and absence of IF (3 µg recombinant human IF added per 1ml of nanoparticle suspension) and 
unmodified NPs. Data represents the mean ±SD (n=3). Statistical comparisons between B12-conjugated 
NPs (in the presence of IF) of 50 vs. 100 nm (shown in red) and B12-conjugated NPs (in presence of IF) vs. 
B12-conjugated NPs in the absence of IF and unmodified NPs of 50 and 100 nm, respectively. 
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7.3.8  Cell trafficking of B12-conjugated nanoparticles 
As described in Chapter 5, in the process of cell trafficking of soluble vitamin B12 in 
vivo, the IF-B12 complex is believed to traffic into the lysosomes, where IF protein is 
degraded to release B12 [39]. From the perspective of trans-mucosal delivery of drug-
loaded carriers, this would mean that the systems would localise into the highly 
degradative lysosomal compartment, thus undermining their drug delivery potential. 
Studies in Caco-2 cells revealed data suggesting that, unlike unmodified 
nanoparticles, B12-conjugated nanoparticles may not localise into lysosomes (Chapter 
5). Here it was sought to establish information regarding the cell uptake and 
intracellular processing of B12-conjugated nanoparticles in relation to the involvement 
of lysosomes, in airway Calu- FHOOV $JDLQ WKH /\VRWUDFNHU SUREH [40] and 
immunostaining for lysosomal associated membrane protein (LAMP1) [41-43] were 
used as investigational tools allowing lysosomal staining.  
 
Cells were initially treated with the /\VRWUDFNHU probe and stained for LAMP1 in the 
absence of nanoparticles. This experiment revealed the presence of LAMP1 in cell 
samples (Figure 7.7a), inferring that lysosomes are permanent structures within the 
cell as would be expected for a major cellular organelle. Interestingly, the level of 
expression of LAMP1 in cells without nanoparticle application appears to be much 
higher in Calu-3 cells than that found in Caco-2 cells (Chapter 5, Figure 5.8). On the 
other hand, the fluorescence signal for the /\VRWUDFNHU probe could not be detected 
in the absence of nanoparticles (Figure 7.7b). The group has observed this 
SKHQRPHQRQ LQ D QXPEHU RI FHOO OLQHV DQG DV /\VRWUDFNHU LV D IOXRUHVFHQW SUREH
which accumulates in acidic compartments, this finding infers that the lysosomal 
FRPSDUWPHQW LV RQO\ µDFWLYH¶ ZKHQ HQGRF\WRVLV RFFXUV :KHQ XQPRGLILHG
nanoparticles were applied to the cells, the fluorescence signal for the lysosomal 
marker was clearly apparent (Figure 7.7c). Furthermore, the distribution pattern of this 
marker mirrored that of the nanoparticles. This co-ORFDOLVDWLRQ RI WKH /\VRWUDFNHU
probe with the nanoparticles suggests the presence of unmodified nanoparticles in the 
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lysosomes. This in turn indicates that the intracellular trafficking of unmodified 
QDQRSDUWLFOHV IROORZV WKH µGHJUDGDWLYH URXWH¶ UHDFKLQJ O\VRVRPHV DV LV FRQVLVWHQW
with findings in Caco-2 cells.  
 
Data from LAMP1 staining experiments in Calu-3 cells showed a complex picture of 
fluorescence expression (Figure 7.7d). There were some similarities between the 
patterns of LAMP1 expression and unmodified nanoparticle co-localisation with the 
LysotUDFNHU, resulting in a composite picture showing some areas of segregation 
and some areas of co-localisation of label.    
 
Following cell layer incubation with vitamin B12-conjugated nanoparticles (50 nm 
nominal size), lysosomal compartments were not detected by the /\VRWUDFNHU probe 
(Figure 7.7e), which is consistent with results found for Caco-2 cells. LAMP1 staining 
revealed diffuse cytosolic protein distribution (Figure 7.7f), similar to the control image 
(Figure 7.7a, cell sample in the absence of nanoparticles), but quite dissimilar from the 
distribution of the B12-conjugated nanoparticles within the cell sample. Thus, there 
were few areas of co-localisation between the two labels, as revealed on the 
composite picture.  
 
Drawing conclusions from the /\VRWUDFNHU H[SHULPHQWV WKH UHVXOWV VXJJHVWV WKDW
cell uptake and trafficking of B12-conjugated nanoparticles in the airway Calu-3 cell line 
is similar to Caco-2 cells. Thus, it appears that the surface decoration of nanoparticles 
with vitamin B12 appears to affect their intracellular trafficking in Calu-3 cells. The 
possible avoidance of lysosomal trafficking by nanoparticles following B12-conjugation 
± a phenomenon observed in both the intestinal and airway epithelial cell lines tested 
could indicate a cell line independent phenomenon.  
The observations on LAMP1 as an indicator of lysosomal structures are much more 
difficult to interpret. As LAMP1 is a membrane marker, its use in distinguishing 
between intracellular organelles is much more dependent on effective segregation of 
membrane proteins between different but related organelles. Some groups have been 
Chapter 7: The VB12 transport pathway in airway Calu-3 cells 
218 
 
successful in using LAMP1 as a lysosomal marker in Calu-3 cells; for example, Bivas-
Benita et al. [44] and Figueiredo et al. [45] reported cellular internalisation of PLGA-
PEI nanoparticles of 200-230 nm (for gene delivery) and subsequent co-localisation of 
adsorbed rhodamine-labelled DNA with LAMP1, implying their endo-lysosomal fate.  
These examples all represent instances where an expected lysosomal accumulation 
has occurred and is equivalent to the data presented with the unmodified 
nanoparticles in this work. However, it is clear from the work in this thesis and from 
descriptions of the various intracellular pathways that there must be a number of inter-
connecting membrane-bound intracellular trafficking compartments. There is however, 
no clear data in the literature on how the membranes and membrane proteins from 
these different compartments are trafficked. It must therefore be concluded that 
LAMP1 is a less useful marker for distinguishing these various membrane-bound 
vesicles. 
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Figure 7. 7. Characterisation of Calu-3  cell layer uptake of vitamin B12-conjugated nanoparticles (of 50 nm diameter) by confocal microscopy.  
a) Confocal micrograph showing immunostaining for lysosomal associated-membrane protein 1 (LAMP1, green) in the absence of nanoparticles, b) Cell staining with Lysotracker Green DND-26 in the absence of nanoparticles, 
c) Co-localisation of unmodified nanoparticles (red) with Lysotracker Green DND-26 (green), d) Immunostaining for LAMP1 protein (green) following cell incubation with unmodified nanoparticles (red), e) Staining with 
Lysotracker Green DND-26 (green) after cell incubation with vitamin B12-conjugated nanoparticles (red), f) Immunostaining for LAMP1 (green) following exposure of cells to vitamin B12-conjugated nanoparticles (red). 
Lysotracker Green DND-26 excitation 504, emission 511 nm; YO nanoparticle excitation 529, emission 546nm; cell nuclei stained with Hoechst 33342.  
a) b) c) 
d) e) f) 
Chapter 7: The VB12 transport pathway in airway Calu-3 cells 
220 
 
7.3.9  Cellular trafficking of free vitamin B12  
The results shown in Chapter 5 (section 5.3.9) suggest that the cell uptake and 
transport of soluble vitamin B12 in Caco-2 cells is mediated via clathrin, which is 
consistent with literature reports [39]. This was suggested by the significant effects of 
a chemical inhibitor specific for this endocytic pathway, chlorpromazine. Work 
described in this section examined the mechanism of entry of soluble vitamin B12 in 
the bronchial cell line, Calu-3, by way of comparison.  
 
The action of pathway specific cell trafficking inhibitors, chlorpromazine and filipin, in 
Calu-3 cells was initially confirmed by testing their effect on cell uptake and transport 
of pathway-selective ligands, transferrin [46, 47] and cholera toxin B-subunit [48, 49] 
(Figure 7.8a). Cell uptake of FITC-transferrin in the presence of chlorpromazine was 
inhibited by approximately 2-fold (Figure 7.8a i), which is a similar trend to work 
reported by Bradbury et al. [32], where the authors observed an approximate 4-fold 
reduction in the internalisation rate of 125I-transferrin in the presence of 
chlorpromazine. On the other hand, filipin induced a dramatic, 21-fold decrease, in the 
cellular internalisation of cholera toxin B-subunit (Figure 7.8a ii). Transport 
experiments were also conducted for pathway-selective ligands and revealed notably 
low levels of transport in Calu-3 cells for both of these ligands, making analysis of any 
inhibitory effect in the presence of their respective endocytosis inhibitors problematic 
(the data is therefore not included in this thesis). However, cholera toxin B-subunit is 
known to be degraded intracellularly [50-52], whilst transferrin is in turn recycled with 
its receptor back to the apical domain via the recycling endosome [53]. Therefore, it is 
likely that the observed negligible transport of these ligands results from these 
phenomena.  It is however, accepted that both transferrin and cholera toxin B-subunit 
are used as ligands to assess clathrin and caveolae-mediated uptake pathways [48, 
54].  
 
Vitamin B12 internalisation (Figure 7.8b i) and transport (Figure 7.8b ii) were markedly 
sensitive to the effects of chlorpromazine. Namely, cell uptake was inhibited by 19-
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fold, whilst basolateral levels of soluble B12 reached a 12.8-fold lower amount at the 
terminal measurement point (3 hours) in the presence of chlorpromazine. Conversely, 
the uptake of soluble B12 by Calu-3 cells was only moderately inhibited by the action of 
filipin (1.3-fold decrease). Likewise, the effect of filipin on transport was notably less 
prominent than that of chlorpromazine, with an apparent larger influence on the rate at 
which transport took place rather than the final amount transported (12.7 and 14.9 µg 
in the presence and absence of filipin, respectively). The dramatic effect of 
chlorpromazine and the resulting inhibition of the clathrin pathway on the uptake of 
soluble vitamin B12 and the apparent lack of a significant influence by filipin as an 
inhibitor of caveolae-mediated pathway suggest that soluble vitamin B12 is internalised 
in Calu-3 cells predominantly via a clathrin-mediated route. The finding therefore 
complements the data with Caco-2 cells and previous reports based on in vivo studies 
[39, 55, 56] that vitamin B12 (in the presence of IF), predominantly exploits a clathrin-
mediated route in the process of its internalisation in epithelial cells. However, contrary 
to findings in Caco-2 cells (under identical experimental conditions), where inhibition of 
caveolae-mediated endocytic route had no effect in the internalisation and transport of 
soluble vitamin B12, the data suggests that in Calu-3 cells there might be some (albeit 
minor) involvement of the caveolae pathway in the process of trafficking of soluble 
vitamin B12. 
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Figure 7. 8. Effect of endocytic pathway-specific inhibitors on cell uptake and transport 
of soluble vitamin B12 in Calu-3 cell layers.  
ai) Effect of chlorpromazine on the cell uptake of FITC-transferrin in Calu-3 layers and ii) filipin on cell 
uptake of Cholera toxin B-subunit, and bi) Effect of chlorpromazine and filipin on cell uptake of vitamin B12 
(statistical comparisons between chlorpromazine/filipin treated vs. untreated data), and ii) Effect of 
chlorpromazine and filipin on transport of vitamin B12 across Calu-3 layers. Vitamin B12 was applied in 
combination with IF and quantified by UVAbs (350 nm). Data represents the mean ± SD (n=3).  
 
7.3.10  Cell trafficking of vitamin-B12 conjugated nanoparticles  
Following the demonstration of cell trafficking of soluble vitamin B12, by way of 
assessing sensitivity to pathway-specific inhibitors of endocytosis, the next set of 
experiments were directed towards determining the uptake pathway of B12-conjugated 
nanoparticles (100 nm preconjugation diameter). Data showing the influence of cell 
treatment with chlorpromazine or filipin on internalisation of such particles by Calu-3 
cells is shown in Figure (Figure 7.9a). Both agents were seen to affect the cell uptake 
of vitamin B12-bearing nanoparticles, producing a statistically significant reduction in 
0 
5 
10 
15 
20 
25 
Ce
llu
la
r 
u
pt
ak
e 
(µg
 p
er
 
cm
2 ) 
0 
2 
4 
6 
8 
10 
12 
14 
16 
18 
0 100 200 
Am
o
u
n
t t
ra
n
sp
or
te
d 
(µg
 p
er
 
cm
2 ) 
Time (min) 
Untreated (HBSS) 
Filipin treated 
Chlorpromazine treated 
0 
0.005 
0.01 
0.015 
0.02 
0.025 
Chlorpromazine 
(10 µg/ml) treated 
Untreated (HBSS) 
Ce
llu
la
r 
u
pt
ak
e 
(µg
 p
er
 
cm
2 ) 
** 
**** 
 
a) i ii 
ii b) i 
** 
 
0 
0.05 
0.1 
0.15 
0.2 
0.25 
0.3 
Filipin (5 µg/ml) 
treated 
Untreated (HBSS) 
Ce
llu
la
r 
u
pt
ak
e 
(µg
 p
er
 
cm
2 ) 
** 
Chapter 7: The VB12 transport pathway in airway Calu-3 cells 
223 
 
the extent of particle uptake. Treatment with chlorpromazine induced a 3.4-fold 
decrease in nanoparticle internalisation, whereas with filipin a 2.1-fold reduction in the 
level of uptake was apparent.  
 
Establishing the effect of clathrin and caveolae-mediated pathway inhibitors 
(chlorpromazine and filipin, respectively) on the apical-to-basolateral translocation of 
B12-conjugated nanoparticles in Calu-3 cell layers, the data illustrates a dramatic effect 
for both agents. Following a 3-hour experimental period, cumulative amount of B12-
conjugated nanoparticles traversing the untreated cell layers reached ~17 µg. This 
level was 0.9 and 0.4 µg, in filipin and chlorpromazine treated cells, respectively 
(Figure 7.9b), highlighting a prominent effect.  
 
These trends therefore suggest that cell uptake and transport of B12-conjugated 
nanoparticles was dramatically affected by both clathrin and caveolae inhibition in 
Calu-3 cells. This phenomenon was not observed in Caco-2 cells, where B12-
conjugated nanoparticles (50 nm; in the presence of IF) were unaffected by treatment 
with two separate inhibitors of clathrin-mediated pathway, but their uptake and 
transport were notably sensitive to the effects of inhibitors of caveolae. At this stage, 
one can only speculate whether this is a consequence of a difference in cell uptake 
pathways between the two (intestinal and airway-originating) cell lines. Indeed, there 
is evidence for tissue-specific differences in endocytic mechanisms for a single ligand 
[57]. In one such example, albumin endocytosis (mediated by megalin) is reported to 
occur through a clathrin-dependent mechanism in most tissues [58-60]. However, in 
the choroid plexus a caveolae-dependent mechanism has been proposed [61]. In 
another example based on in vitro nanoparticle-based work, dos Santos et al. [62] 
reported variations in the effect of transport inhibitors (i.e. the different pathways 
involved) on the cellular uptake of carboxylated polystyrene nanoparticles in different 
human cell lines, namely in HeLa (cervical cancer), A549 (lung carcinoma) and 
1321N1 (brain astrocytoma).  
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Thus, it may be possible that the mechanisms involved in vitamin B12 trafficking are 
somewhat different in the intestinal Caco-2 cell line and the airway-derived Calu-3 cell 
line. Another major factor that may account for some degree of difference in the 
pattern of cell uptake of vitamin B12-conjugated nanoparticles is nanoparticle size, with 
50 and 100 nm (nominal pre-conjugation diameter) particles used in Caco-2 and Calu-
3 cells, respectively. The influence of particle size on endocytosis has been previously 
highlighted by several other groups [54, 62, 63], postulating that the particle size itself, 
with or without ligand can affect which endocytic pathways are involved. 
 
  
 
 
 
 
 
 
 
Figure 7. 9. Effect of endocytic pathway-specific inhibitors on cell uptake and transport 
of B12-conjugated nanoparticles of 100 nm in Calu-3 cell layers. 
 
 a) Effect of chlorpromazine and filipin on the cell uptake of B12-conjugated NPs in Calu-3 layers and b) 
Effect of chlorpromazine and filipin on transport of B12-conjugated NPs across Calu-3 layers. Cell uptake 
and transport studies were conducted with B12-conjugated nanoparticles of 100 nm diameter and in the 
presence of IF. Data represents the mean ± SD (n=4). Statistical comparisons between 
chlorpromazine/filipin treated vs. untreated data. 
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7.3.11 Cell trafficking summary of soluble B12 and B12-conjugated nanoparticles 
in Calu-3 cells 
The trafficking behaviours of soluble B12 and B12-conjugated nanoparticles in Calu-3 
layers, representing the airway epithelium, are summarised in Table 7.1. The 
summary data is based on findings from cell uptake and transport experiments in the 
presence of pharmacological inhibitors.  
 
 
Cell trafficking in Calu-3 cells occurring via 
 
Clathrin Caveolae Both 
Soluble B12 (with 
IF)  + (-) (+) 
B12-conjugated 
nanoparticles (100 
nm, with IF) 
  + 
 
Table 7. 1. Summary table showing observed cell  trafficking behaviours of soluble 
B12  and B12-conjugated nanoparticles (of 100 nm pre-conjugation diameter) across 
Calu-3 cells. '+' denotes positive involvement of pathway, ' - '  denotes no 
involvement of pathway. (Brackets) indicate some/minor involvement of pathway.  
 
 
7.4 Conclusions 
The work detailed in this chapter investigated the presence of the vitamin B12-transport 
biological system in bronchial Calu-3 cells DQG LWV FDSDFLW\ WR µVKXWWOH¶ B12-bearing 
nanoparticles across these cells when cultured as polarised layers. Calu-3 cells were 
shown to express cubilin, the TCII receptor and the TCII carrier protein. B12-
conjugated nanoparticles internalised and traversed the Calu-3 cell layers 
considerably more efficiently than unmodified nanoparticles. Uptake and transport of 
B12-conjugated nanoparticles was size-dependent and only modestly affected by the 
presence of IF. Confocal microscopy studies revealed that the cell uptake of B12-
conjugated nanoparticles (as well as unmodified counterparts) in the bronchial Calu-3 
cell line follows a similar trend to uptake by intestinal Caco-2 cells, with the surface 
decoration of nanoparticles with B12 influencing intracellular distribution of 
nanoparticles. Data on the trafficking of soluble vitamin B12 (in the presence of IF) 
showed a predominantly clathrin-mediated route in the process of internalisation in 
Calu-3 cells (complementing findings in Caco-2 cells), with some indication of 
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caveolae involvement, hence suggesting an element of cross-talk between the two 
pathways in Calu-3 cells. Cell uptake and transport of vitamin B12-conjugated 
nanoparticles was dramatically affected by both clathrin and caveolae inhibition in 
Calu-3 cells ± an interesting finding that was not encountered in Caco-2 cells and thus 
warrants further investigation. Overall, the data shows that the components of the 
vitamin B12 trafficking machinery are expressed in airway Calu-3 cells and that vitamin 
B12-conjugated nanoparticles traverse these cell layers. These previously unreported 
findings hence indicate that the vitamin B12 nanoparticle bioconjugation strategy 
shows potential for delivery of nanoparticulates across the airway mucosa, as well as 
the intestinal mucosa.  
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Chapter 8: Insulin nanocrystal formulations and their 
stabilisation by THPP 
8.1 Introduction 
Parenteral administration is currently the only clinically available route of insulin 
delivery. Alternative routes of administration (e.g. oral, nasal, rectal, pulmonary and 
ocular) have been extensively investigated [1]. Among them, the oral route is most 
convenient and most accepted by patients. However, the oral delivery of many 
therapeutic peptides and proteins like insulin remains an unresolved challenge 
because of their large size, hydrophilicity, and relative instability in the physiological 
environment [2]. Insulin is largely degraded by proteolytic enzymes in the 
gastrointestinal tract and is very poorly absorbed after oral administration [3, 4]. In 
order to protect it from biodegradation and to improve its intestinal absorption, insulin 
has been encapsulated in/or associated with polymeric biodegradable nanocapsules, 
nanospheres or microparticles associated or not, to surfactants or antiproteases [5-8], 
or otherwise coated with hydrophilic polymers such as chitosan [9-11]. Chitosan is a 
mucoadhesive, polycationic polymer known to facilitate drug absorption by localising 
drug concentration around absorptive cells [12], and prolonging drug residence time in 
the gut [13]. It is also an effective permeability enhancer because of its depolymerising 
action on cellular F-actin and the tight junction protein ZO-1 [9]. However, there are 
several limitations accompanying the aforementioned approaches for oral insulin 
formulations: carrier systems (ie: microparticles and nanospheres) slowly release 
insulin with small amounts being absorbed  [14]. Furthermore, absorption only occurs 
in the small intestine and over a short time-frame which is not sufficient to achieve 
therapeutic doses of insulin. The drawbacks of penetration enhancers (surfactants and 
mucoadhesives) include: lack of specificity, allowing the content of the intestinal tract 
including toxins and pathogens to gain the same access to the bloodstream [15], and 
risk to mucous membranes by surfactants and damage of cell membrane by chelators. 
Surfactants can cause lysis of mucous membrane and may damage the lining of the 
gastrointestinal tract. Bioadhesive systems may be affected by the mucous turnover of 
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the gastrointestinal tract which varies based on the site of absorption. Moreover, 
directing a delivery system to a particular site of adhesion is yet to be achieved.  
Therapeutic proteins like insulin, present many difficulties for drug delivery and 
formulation (Chapter 1, section 1.6). These macromolecules are quickly broken down 
and processed in vivo both in the gastrointestinal tract and by systemic regulatory 
systems. Therefore, they must be formulated to overcome physicochemical, chemical 
and biological instability during processing, storage and delivery [16]. Recently, the 
use of protein crystals in formulation design has been investigated [16-19]. Protein 
crystals could protect the integrity of the therapeutic agent in a lattice-type structure 
both prior to administration and post delivery. Protein crystals in their highly compact 
arrangement, may allow for sustained release of the therapeutic agent, which provides 
maximum drug loading and removes the need for repetitive dosing [16, 20]. 
 
In this chapter, work detailing the preparation of a heterogeneous population of nano- 
and micron-sized insulin crystals (by employing a modification of batch crystallisation 
protocols [17]LVGHVFULEHG)XUWKHUPRUHWKHHIIHFWVRI7+33ȕ-[Tris(hydroxymethyl) 
phosphino] propionic acid) as a proof-of-concept crystal stabiliser were investigated. 
THPP is a water-soluble, trifunctional crosslinker that reacts with primary and 
secondary amines to produce covalent linkages in the form of P-CH2-NH-R. Previous 
studies have employed THPP as a cross-linking agent to enhance the properties of 
elastin-like polypeptides (ELPs) for tissue engineering purposes [21, 22]. This work 
aimed to address the problem of colloidal instability of insulin in the absence of a 
stabilising crystallisation buffer by cross-linking the surface of newly formed crystals 
and then fine-tuning the extent of this cross-linking to produce stable nano-sized 
protein crystals and at the same time permitting the release of biologically active 
insulin with a slow release profile. The effects of THPP on crystal formation, stability, 
insulin release and bioactivity in mouse 3T3 fibroblasts were investigated. The 
potential toxicity of THPP itself was assessed using cell viability assays. The present 
ZRUN GHVFULEHV WKH GHVLJQ DQG FKDUDFWHULVDWLRQ RI µVWDELOLVHG¶ PLFUR- and nano- 
crystals which show promise for the development of a suitable oral delivery platform 
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for protein bioactives and laying the foundations for subsequent development of 
bioconjugated protein nanocrystals (i.e. surface decorated with vitamin B12), which in 
turn would result in their improved mucosal absorption. 
8.2 Methods 
8.2.1  Preparation and stabilisation of insulin crystals 
Hydrochloric acid (0.02M, 3 ml) was added to weighed aliquots of insulin powder and 
the mixture was swirled until the insulin had dissolved. To prepare the crystallisation 
buffer (previously optimised by the group), the following components were then added 
sequentially to produce a turbid solution: aqueous 12% w/v zinc chloride solution (24 
µl), sodium chloride (0.36 g), sodium citrate solution (0.2M, 2 ml)
. 
The pH was 
adjusted to 6.25 with sodium hydroxide (0.1M). The solutions were then rotated on a 
centrifugal evaporator (Genevac® systems, Aqueous setting, 45°C) for 1.5 hrs until 
approximately half the solution had evaporated.  
 
For experimental design 1, THPP solution (1 mg/ml) in corresponding insulin 
crystallisation buffer was prepared and added (immediately after the evaporation 
stage) in the following Insulin:THPP molar ratios: 3:2, 3:1, 6:1 and 12:1 to separate 
crystal preparations (n=2 for each) to achieve different extents of surface cross-
linking. A control sample was prepared without THPP stabilisation. The samples were 
then placed in isopropanol and stored at -20°C overnight. The following day, samples 
were transferred to 4°C to counteract freeze-thaw shock and stored for up to two 
weeks for analysis.  
 
For experimental design 2, insulin preparations were transferred to -20°C overnight 
before THPP was added and incubated for a further 12-24 hr at 4°C. In both studies, 
the THPP-cross-linked Insulin preparations were extensively dialysed against distilled 
H2O overnight and the distilled H2O was replaced three or four times over the 24 hour 
period. A cellulose-ester membrane was used with a molecular weight cut-off of 
25kDa. 
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8.2.2  Dynamic light scattering and disc centrifuge studies 
For dynamic light scattering (DLS), samples were diluted 1:10 in their respective buffer 
and analysed using a Viscotek 802 system. The programme was run using the default 
mode, wherein the optimal intensity count was 300 k counts and the temperature was 
25°C. Omnisize software was used to calculate the particle size data (which was set to 
an average of 10 readings per sample). Repeated measurements were carried out 
post-dialysis to assess the effects of THPP on crystal stabilisation.  
 
Samples (with Insulin:THPP molar ratios of 3:1) were further analysed using 
centrifugal separation analysis. A sucrose gradient of 4-12% was built up on a CPS 
disc centrifuge (Analytik Ltd). The parameters were set for protein samples with a 1.24 
g/ml density and a refractive index of 1.3. The instrument was calibrated before each 
run using 377 nm poly-(vinyl chloride) (PVC) particle standard followed by injection of 
sample (100 µl). This part of the work was conducted by Rosie Adsley (University of 
Nottingham).  
8.2.3  Transmission Electron Microscopy (TEM) 
100 HEX Copper mesh grids (TAAB) were coated with Formvar and carbon support 
film (3.05mm). Insulin solutions were subsequently diluted 10- to 100-fold, and 
aliquots (3.5 µl) were placed on the grids. After 30 seconds, two drops of 1% 
phosphotungstic acid (Sigma Aldrich) were then placed on the grid and left for 10±15 
seconds. Excess water was removed with filter paper, and the grid was then left to air-
dry for 30 minutes. Imaging was performed using an electron microscope (Tecnai 
BioTWIN, FEI) with an acceleration voltage of 100 kV and magnifications typically 
ranging from 1250-135000. The samples were prepared by Denise Christie (Advanced 
Microscopy Unit, University of Nottingham).  
8.2.4  Insulin Release study 
After dialysis to remove salt from the THPP-cross-linked insulin particle preparations 
(section 8.2.1), the amount of insulin retained was quantified using the commercially 
available BCA assay. This step was important as it enabled quantitation of the starting 
amount of insulin in each sample prior to the release experiment, thus enabling 
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eventual calculation of percent insulin release. Insulin standards (used to construct a 
calibration curve) were prepared in distilled H2O (2M HCl was added drop wise to 
dissolve into solution). Both standard and sample (25 µl) were aliquotted into a 96 well 
plate and working BCA reagent (200 µl) was added (comprising BCA solution and 4% 
cupric sulphate in a 50:1 v/v ratio). The plate was incubated at 37°C for 30 min and 
the absorbance was measured at 562 nm on a Dynex MRX microtiter plate reader.  
 
Each THPP-cross-linked insulin sample (1 ml) (of varying ratios of 3:2, 3:1, 6:1 and 
12:1) was dialysed against 50 ml of 0.05M Trizma® base (pH adjusted to 7.4). A 
cellulose-ester membrane with a 100 kDa cut-off was used and the solutions were 
stirred continuously in a closed vessel using a magnetic stirrer. The samples (300 µl) 
were collected from the dialysate over a 48 hr duration over a series of intermediate 
time points. Sample volumes were replaced with fresh buffer (300 µl). Quantification of 
the amount of insulin released over the 48 hour period was carried out using high-
performance liquid chromatography (HPLC) using an HP 1090 system.  A Discovery® 
&cȝP[PPFROXPQ6XSHOFRLQFRPELQDWLRQZLWKD'LVFRYHU\
C18 Supelguard pre-column was used. Two mobile phases were used: 0.1 % 
trifluoroacetic acid (TFA) in water and 0.1 % TFA in acetonitrile.  The flow gradient 
was from 70 to 60% of the aqueous solution over 15 minutes and the flow rate was 
maintained at 1 ml/min.  UV detection was at 215 and 275 nm and the insulin peak 
eluted at approximately 7 minutes.  
8.2.5  THPP toxicity assays 
Caco-2 (human intestinal) cells (passage 60) were seeded onto a 96-well plate at a 
density of 10,000 cells/cm2. The cells were incubated overnight with supplemented 
EMEM media containing 10% foetal calf serum in an atmosphere of 5% CO2 (37°C). 
The following day, the medium was replaced with HEPES:HBSS buffer (50 mM) and 
cells were left to equilibrate for 30 minutes. To the negative (positive, in the case of 
the LDH assay) control wells, Triton X-100 (0.2% v/v, 100 µl) was added (n=5) and 
fresh HEPES:HBSS was added to the positive (negative, in the case of the LDH 
assay) control wells. Varying concentrations of THPP (in HEPES:HBSS) were applied 
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to the sample wells (with five repeats per concentration) to achieve a final 
concentration range of 15.6-1000 µg/ml. The cells were incubated for 2-3hrs before 
the THPP solution was removed and the cells were washed three times with PBS. For 
the MTS assay, supplemented EMEM (100 µl) was added. CellTiter 96 ® Aqueous 
One solution MTS reagent (20 µl) was added to each well. The cells were incubated 
with the reagent for 3 hrs and the absorbance was measured at 490 nm on a Dynex 
MRX plate reader. For the LDH assay, 50 µl was removed from each well (including 
control wells) after incubation with THPP solution and aliquotted onto a new plate. 
Combined LDH assay reagents (100 µl) (LDH assay substrate solution, LDH assay 
cofactor preparation and LDH assay dye solution were mixed previously in equal 
volumes) were added to the samples and these were incubated for 30 min. The 
reaction was quenched with 1M HCl (15 µl). The absorbance was read at 490 nm on a 
Dynex MRX plate reader. The reader is referred to Chapter 2 (sections 2.2.4.2-
2.2.4.3) for calculations of percent Relative Metabolic Activity and LDH release. 
8.2.6  NIH 3T3 proliferation test for insulin bioactivity 
Mouse NIH-3T3 fibroblasts (passage 45) were seeded onto a 96-well plate at a 
density of 10,000 cells/cm2. They were incubated overnight in supplemented DMEM 
medium (containing 1% FCS) at an atmosphere of 5% CO2 (37°C). A solution of 
insulin in 0.05M Trizma® base was prepared as a positive control and diluted to 100 
nM in DMEM. Insulin samples which were collected from the HPLC release study (i.e. 
free insulin from the dialysate, again of varying THPP-cross-linked ratios) were all 
standardised to the same concentration (100 nM) using dilutions in DMEM medium 
and 100 µl was applied to the cells. Note, that the initial starting concentration of each 
insulin sample was determined from HPLC data. 0.2% Triton X-100 was applied (100 
µl) to negative control wells and DMEM was also applied to reference control wells 
(n=6). The fibroblasts were incubated for 24 hrs with the insulin samples. The 
following day, the cells were washed three times with PBS and 100 µl of fresh 
supplemented DMEM medium was applied to the cells. The MTS reagent was added 
and the experiment followed as detailed in section 8.2.5 and Chapter 2 (section 
2.2.4.2). 
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8.3 Results and Discussion 
8.3.1  Stability of insulin crystals post-dialysis 
The first task in this investigation was to establish and optimise a protocol for the 
development of insulin crystals of sub-micron range. This was achieved by carefully 
adjusting the ratio of components of the crystallisation buffer and experimenting with 
the centrifugal evaporation step until the conditions were optimised.  
The second task was to investigate the use of THPP as proof-of-concept stabiliser for 
the newly formed insulin crystals, considered important to preserve the integrity of the 
small crystals following removal of the crystallisation buffer. To this end, varying the 
time of addition of THPP was one parameter investigated. In one experiment, THPP 
was added (in varying molar ratios) before the crystals were slow-frozen. In the 
complementary experiment, THPP (in varying molar ratios to insulin) was added after 
slow-freezing the crystals.  
Particle size analysis was used to assess the effect that the timing of THPP addition 
has on the subsequent growth and stabilisation of the newly formed crystals. Figure 
8.1 shows particle size distribution profiles for samples where THPP was added prior 
to placing insulin crystals in isopropanol at -20 °C. The data indicate that after 24 
hours of growth in sub zero temperatures, a heterogeneous population of Insulin 
particles had formed. Furthermore, the addition of THPP prior to slow-cooling did not 
reduce crystal formation but rather promoted it (i.e. produced size distributions of near 
optimal sub 500 nm range). Figure 8.1 (i), (ii), (iii), (iv) and (v) (pre-dialysis samples) 
show that regardless of THPP ratio, a range of different sized-insulin species are 
present. In all pre-dialysis samples, the predominant size range of the particles was 
found to be around 100-400 nm (occupying about 30-70% of the sample population), 
but both smaller species (~5-80 nm) and considerably larger particles (>20 µm in size) 
were also produced. The larger size particles were presumed to be insulin aggregates 
which had not undergone crystallisation. After extensive dialysis, the role of THPP 
became apparent. In the absence of THPP (Figure 8.1 post-dialysis (i)), it appeared 
that removal of salt promoted some destabilisation of the Insulin crystals and they 
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started to fall apart and then aggregate (this was also visually noticeable). Most of the 
sample area (59% of the population) had  radii higher than >105 nm in size. Moreover, 
the proportion of crystals of a desirable size (<200 nm) had diminished. When 
compared directly with the data obtained prior to the dialysis procedure, a significant 
difference in both size and stability of the crystals was observed. Increasing the 
amount of THPP (decreasing the molar ratio of insulin to THPP) resulted in a 
VXEVWDQWLDO SURSRUWLRQRI WKHSRSXODWLRQRI ,QVXOLQ FU\VWDOV ³VXUYLYLQJ´DQGSUHVHUYLQJ
resistance to destabilisation in the absence of their crystallisation buffer. For example, 
when the molar ratio of Insulin:THPP was 12:1 (Figure 8.1 post-dialysis (ii)), 78% of 
the sample had a mean radius of ~140nm and 14% was detected as 24 nm, 
compared with 8% which had formed aggregates. When the molar ratio was 
decreased to 6:1 (Figure 8.1 post-dialysis (iii)), 6% represented crystals with average 
mean radii of 9 µm and 9% was detected as aggregates. The remaining sample 
comprised a split population of crystals ~15-360 nm in size.  When the molar ratio was 
decreased further to 3:1 (Figure 8.1 post-dialysis (iv)), no aggregates were detected 
and 43% of the population comprised a mean radius of ~40 nm, the remaining 57% of 
crystals were around 230 nm in size. A ratio of 3:2 (Figure 8.1 post-dialysis (v)) 
produced a largely homogenous population with an average size of 88 nm (95.5%).  
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Figure 8. 1. Dynamic light scattering intensity distributions for experimental design 1 (the 
addition of THPP prior to freezing). 
Pre-dialysis samples on left (blue), Post-dialysis samples on right (red) i) No THPP (ctrl), ii) 12:1 
Insulin:THPP, iii) 6:1 Insulin:THPP, iv) 3:1 Insulin:THPP, v) 3:2 Insulin:THPP. 
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In the second experiment, THPP was added after the slow-freezing process and 
again, particle size analysis was conducted on the samples both pre- and post-dialysis 
(Figure 8.2). In drawing a comparison with the control (no THPP, Figure 8.2(i)) and 
samples prepared with THPP before freezing (Figure 8.1), the data revealed a 
different pattern. For 12:1, 6:1, 3:1 and 3:2 (Figure 8.2 pre-dialysis (ii), (iii), (iv) and (v) 
respectively) we postulate that the addition of THPP after freezing either had a 
detrimental effect on the stabilisation of the newly formed crystals or its absence prior 
to freezing actually hindered heterogeneous crystal growth. This is reflected by both 
the absence of smaller crystals and by the presence of large aggregates. For example 
for 12:1 (Figure 8.2 pre-dialysis (ii)), >59% of the population were greater than 950 nm 
in size and 17% presented an average mean radii of 66 nm. Furthermore, increasing 
the amount of THPP seemed to exacerbate the aggregation problem with 35% of the 
population exceeding 2 µm in size and the majority forming aggregates for 6:1 
Insulin:THPP (Figure 8.2 pre-dialysis (iii)). Again, for 3:1 (Figure 8.2 pre-dialysis (iv)), 
88% of the sample population formed aggregates (although these may well have been 
large crystals). A similar profile was observed for 3:2 samples with 16% bearing an 
average radius of ~770 nm and 65% representative of >4 µm. After these samples 
were dialysed, we observed a huge reduction in yield (data not shown) and a 
significant proportion of the Insulin had formed aggregates.  Of note, however, in the 
presence of THPP, new species were detected in the sample after dialysis. For 
example, for both 3:1 and 3:2 samples (Figure 8.2 post-dialysis (iv), (v) respectively), 
a bimodal distribution was observed with crystals bearing a mean radius of ~15-30 nm 
and ~115-130 nm.  
  
Chapter 8: Insulin nanocrystal formulations and their stabilisation by THPP 
240 
 
 
 
 
 
 
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
         
 
 
 
Figure 8. 2. Dynamic light scattering intensity distributions for experimental design 2  
(the addition of THPP after freezing). 
Pre-dialysis samples on left (blue), post-dialysis samples on right (red) - i) No THPP (ctrl), ii) 12:1 
Insulin:THPP, iii) 6:1 Insulin:THPP, iv) 3:1 Insulin:THPP, v) 3:2 Insulin:THPP.  
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Figure 8.3 shows the visual differences between samples post-dialysis. This was so 
that we could observe changes to the opacity of the samples based on the timing of 
THPP addition. For the design 1 samples, as the amount of THPP was increased, the 
solutions became more transparent (A Æ J), with the exception of those samples that 
were subjected to experimental design 2 (THPP added after freezing). In direct 
comparison with its neighbouring solution (at the same Insulin:THPP ratio), samples 
where THPP was added before freezing appear clearer (Figure 8.3. C, E, G, I), than 
those where THPP was added after freezing (Figure 3. D, F, H, J), which appear 
opaque or cloudy. Furthermore, as the molar ratio of Insulin:THPP increases, this 
marked contrast, decreases. This suggests that when THPP is administered prior to 
freezing it either adds to the colloidal stability of the crystals or promotes the formation 
RIVPDOOHUFU\VWDOVZKLFKLQWXUQLVUHVSRQVLEOHIRUWKHRSDJXHRUµEOXH-LVK¶DSSHDUDQFH
of the solution.  
   
Figure 8. 3. Photograph showing visual appearance of Insulin samples post- dialysis.  
The samples were paired according to Insulin:THPP ratio with experimental design 1 & 2 samples placed 
next to each other (ie: samples I & J correspond to 3:2 Insulin:THPP, experimental design 1 and 2 
respectively). i.e. sample on left of each sub-figure prepared using experimental design 1, sample on right of 
each sub-figure prepared using experimental design 2: i) No THPP (ctrl), ii) 12:1 Insulin:THPP, iii) 6:1 
Insulin:THPP, iv) 3:1 Insulin:THPP, v) 3:2 Insulin:THPP  
 
8.3.2  Disc Centrifuge analysis 
DLS analysis is poor at distinguishing between populations with similar sizes but these 
different populations of samples are however readily separated by centrifugation. CPS 
resolves very close multi-modal particle distributions and distinguishes small shifts in 
particle size. Rather than using a predictive algorithm, the disc centrifuge technique 
i. ii. iii. iv. v. 
A       B C       D E       F G       H I       J 
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physically separates nanoparticles before measurements are recorded. Disc 
centrifuge analysis was carried out on the samples.  In this report, we show only a 
comparison of a single sample pre- and post-dialysis (3:1 Insulin:THPP from 
experimental design 1, see Figure 8.1 (iv)). Owing to the limitations of the technique, it 
was not possible to generate a complete size-range profile ranging from nanometers 
to micrometers. We therefore selected two different centrifugal speeds: the first was 
used to detect particles ranging from 0.01-0.4 microns and the second was used to 
detect particles in the 0.2-0.5 micron range. Therefore, large aggregates of Insulin 
were not detected using this method.  
Disc centrifuge analysis revealed a bimodal distribution of insulin crystals both pre- 
and post-dialysis over a range of 0.01-5 µm (Figure 8.4). The dialysis procedure 
appeared to slightly reduce the nominal sizes of the smaller crystal populations. For 
example, the calculated median for the detected peak over the small size distribution 
was reduced from 0.032 µm to 0.020 µm (Figure 8.4 (i), (iii)). However, an asymmetric 
biomodal distribution of particle sizes was observed for the upper limit of detection 
(Figure 8.4, (iv)) with a median of 0.72 µm following dialysis.  
Referring back to the DLS data for the same Insulin:THPP ratio (Figure 8.1 (iv)), 
approximately 60% of the pre-dialysis sample comprised crystals ranging from 3-190 
nm in size of this 60%, 9.4% were 43 nm and 39% were 190 nm in size. This largely 
supports disc centrifuge data across this particular size range (Figure 8.4 (i)). 
However, DLS data reveals peaks corresponding to an intermediate size range 
(0.19<x>2 µm), which is not detected on the disc centrifuge. This could be as a result 
of aggregation of the sample over time, leading to a corresponding peak on CPS at 
3.55 µm. Post-dialysis samples analysed on the CPS (Figure 8.4 (iii), (iv)) resemble 
more closely corresponding DLS samples (refer to Figure 8.1, (iv, post-dialysis)) with 
peaks on CPS giving a mean value of 0.046 µm and peaks on DLS giving a mean 
value of 0.036 µm. Similarly, a minimal peak on the CPS at ~0.3 µm corresponds with 
a peak on the DLS at ~0.24 µm. Again, aggregation of the sample is likely to precede 
peaks detected at 0.6 µm and 1 µm on the CPS (Figure 8.4 (iv)). DLS data analysis 
should be accompanied with an element of caution as the technique often fails to 
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identify multi-modal particle distributions with small differences in particle size. On the 
other hand, CPS analysis can be used to verify the existence of skewed particle 
distributions, which are separated according to mass. Therefore, the two techniques 
can be used in combination for more accurate particle-size determination. On the 
whole, DLS and CPS data are in close agreement particularly for particles sub-0.2 µm 
in size. 
 
Figure 8. 4. Disc centrifuge analysis on 3:1 Insulin:THPP (experimental design 1). 
i) pre-dialysis (in salt) 0.01-0.4 µm size distribution, ii) pre-dialysis (in salt) 0.2-5 µm size distribution, iii) 
post-dialysis (in water) 0.01-0.4 µm size distribution, iv) post-dialysis (in water) 0.2-5 µm size distribution. 
 
8.3.3  Transmission Electron Microscopy (TEM) 
Electron micrographs confirmed that a heterogeneous population of Insulin crystals 
exist. Furthermore these images reveal that larger crystals (>1 µm) adopt a hexagonal 
configuration (Figure 8.5 (ii)). Figure 8.5 (iii) shows a crystal cluster (each 
approximately 60 nm in size) and these show angular characteristics giving 
confidence that these are not ill-defined insulin aggregates. Interestingly, degradation 
of the crystals is also visible (Figure 8.5 (iv)) where whole hexagonal crystals appear 
to have broken into pieces. This could be as a result of the TEM preparation. 
i. ii. 
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Nevertheless, this serves to show that the insulin in the samples is crystalline in nature 
and not a collection of different sized aggregates which cannot be deduced from either 
of the sizing methods used in this study.  
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Figure 8. 5. Transmission electron microscopy images showing stabilised 3:1 
Insulin:THPP crystals. 
i) x11500 magnification, scale bar 2 µm, ii) x790 magnification, scale bar 20 µm, iii) x105000, scale bar 100 
nm, iv) x790 magification, scale bar 20 µm. 
 
8.3.4  THPP toxicity assays 
Both MTS and LDH toxicity assays showed that regardless of the concentration used, 
THPP presented no significant toxicity towards Caco-2 cells as shown by the relevant 
comparisons with positive and negative controls (Figure 8.6). As shown on the graph, 
there was no apparent trend between an increase in THPP concentration and a 
decrease in the cell viability and at no concentration tested, is there a significant drop 
in the cell viability. These results are mirrored by the LDH data where low values 
indicate that the cell membrane integrity is preserved.  
 
 
 
i. ii. 
iii. iv. 
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Figure 8. 6. Toxicity of THPP in Caco-2 cells. 
Data showing mitochondrial activity (% cell viability) from MTS assay and Lactate dehydrogenase (LDH) 
assay showing % LDH release after two hours incubation with THPP at varying concentrations (16-
1000µg/ml) relative to both Triton X-100 and HBSS controls. Data represents mean (n=6 ± SD). 
 
8.3.5  Insulin release study 
Release profiles from the Insulin:THPP cross-linked crystals prepared at different 
THPP:insulin ratios were compared (Figure 8.7). The data show highly variable 
release profiles which are seemingly dependent on the ratio of Insulin:THPP. The 
optimum ratio for release is illustrated by 3:1 Insulin:THPP crosslinked preparations, 
based on the highest percent released over time. After 3 hours, approximately 20% of 
insulin has been released. After 41 hours, the data reveals >80% release from the 
initial amount of cross-linked crystals dialysed. Furthermore, the release profile is fairly 
slow, which is desirable for protein bioactives with short half-lives.  
Increasing the ratio of Insulin:THPP to 6:1 and 12:1 had a detrimental effect on the 
release properties. This might be attributed to destabilisation and precipitation of the 
insulin inside the dialysis tubing preventing subsequent release - likely a consequence 
of insufficient extents of THPP cross-linking. Furthermore, unlike the control sample 
(whereby insulin was dissolved at acidic pH), these samples were dialysed against 
0.05M Trizma® base (and the pH was adjusted to pH 7.4.) This difference in pH 
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undoubtedly affects the solubility behaviour of insulin, as insulin has low solubility at 
neutral pH with solubilisation (1-10 mg/ml) only achieved under acidic conditions (pH 
2-3) [23]. 
Preparations of 6:1 and 12:1 produced very similar release profiles with the total 
percent release not exceeding 50% of the initial amount. Interestingly, 3:2 
Insulin:THPP also delivers a poor release profile (similar to 6:1 and 12:1). This could 
be as a result of extensive cross-linking of insulin at the surface preventing its release.  
 
Figure 8. 7. Insulin release profile for descending cross-linking ratios of Insulin:THPP. 
(n=2) (Insulin release measured using dialysis through 100kDa membrane). Insulin in solution dialysed and 
quantified by HPLC was used as the control (Ctrl) in this study. 
8.3.6  In vitro bioactivity of insulin - NIH 3T3 proliferation assay 
In this study, the MTS assay was used to measure the proliferative cellular response 
to Insulin (released from crystal preparations), as a marker of its bioactivity. Insulin is a 
well-known inducer of fibroblast and other cell-type proliferation in vitro and in vivo [24-
26]. Growth induction by insulin is concentration dependent, therefore the effective 
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concentration at which insulin caused 3T3 proliferation was optimised initially. The 
amount of FCS supplemented in the medium was reduced 10-fold to detect the effects 
of exogenously added insulin. All samples were then standardised to the same 
concentration as the positive insulin control (insulin dissolved in cell growth medium) 
and applied to mouse 3T3 fibroblasts to assess whether the insulin released still 
retained its bioactivity after cross-linking with THPP and release from crystalline 
insulin.  Insulin (100 nM) significantly increases metabolic activity compared to the 
DMEM control (Figure 8.8). This is suggestive of a proliferative response by the cells. 
Bioactivity of insulin released from cross-linked crystals, and applied to the cells at the 
same concentration as the control sample, shows a clear dependence on the extent of 
THPP cross-linking. For instance, insulin released from a 3:2 Insulin:THPP 
preparation, lost its ability to trigger fibroblast proliferation, relative to the DMEM 
medium. This might be attributed to a loss in the functionality of insulin through 
experimental processing or denaturation by cross-linking. Increasing the ratio to 3:1 
and even 6:1 restores this activity with values close to the positive Insulin control. 
Furthermore, this study shows that minimal cross-linking of the surface of the Insulin 
crystals with THPP does not seem to affect insulin functionality and consequently, 
insulin-receptor interactions.  
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Figure 8. 8. NIH 3T3 proliferation assay by Insulin at varying ratios of THPP cross-linking. 
Insulin dissolved in buffer (100nM) was used as a positive control. All insulin preparations (insulin release 
samples) were standardised to 100nM. Data represents mean (n=6 ± SD). Statistical comparisons with the 
'0(0FRQWUROµQV¶ QRWVLJQLILFDQW 
 
8.4 Conclusion 
Nano-scale based protein formulations offer potential as stand-alone drug delivery 
systems and as such, have highly desirable drug delivery properties [27, 28]. 
Furthermore, protein nanocrystals can be fabricated to display functional ligands on 
their surface, enabling targeted therapy or enhanced absorption across the mucosal 
surfaces. 
In this method-development study, a heterogeneous population of nano- and micron-
sized insulin crystals were prepared using a variation of the batch crystallisation 
approach (the reader is referred to Chapter 1, section 1.6.2 for a more comprehensive 
review).  To this end, the first objective was to establish and optimise a protocol for the 
development of insulin crystals of sub-micron range. The methods for preparation of 
insulin crystals using this approach are well-established [17]. However in addition, we 
incorporated a novel centrifugal evaporative step in order to obtain a supersaturated 
solution of insulin (Chapter 1, section 6.1.1, Figure 1.10) thereby initiating 
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defined crystals ranging from 20 nm-3 µm in size as shown by light scattering and 
centrifugal separation techniques.  
The next objective was to investigate THPP as a proof-of-concept stabiliser by 
partially cross-linking the surface of the crystals. It was sought to determine the 
optimal timing for addition of the stabilising agent, with respect to encouraging crystal 
growth and secondly; to establish the optimal extent of cross-linking allowing the 
eventual controlled release of biologically functional insulin. Interestingly, the timing of 
addition of THPP was important not only for the stabilisation of the crystals but also for 
their apparent formation. The studies revealed that adding THPP before slow-freezing 
the crystal preparations was beneficial for the colloidal stability of the forming crystals. 
Furthermore, an optimum ratio of 3:1 Insulin:THPP was demonstrated, in view of 
sufficient cross-linking to maintain stability of the crystals, but not too extensive in 
preventing release of biologically active insulin. In crystals, protein molecules adopt a 
highly symmetrical arrangement and their native confirmation is stabilised, [29] - it is 
thought that the THPP added preserves this ordered arrangement of molecules. In 
vitro toxicity assays revealed that THPP by itself is not harmful to cells, even at higher 
concentrations. However, further investigations, in particular immunological response 
studies, are needed in order to validate fully the use of this compound as a stabilising 
cross-linker. Of significant importance to pharmaceutical applications, the stabilised 
insulin crystals, were generally stable in the absence of their salt buffer, displayed a 
slow-release profile and the insulin released had retained its biological activity in vitro.  
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Chapter  9: Summary & Future Directions 
9.1 Final Summary 
 
The field of biological therapeutics has recently taken off. However, this has not been 
followed by advances in development of novel delivery routes for this class of 
therapeutics. Perhaps frustratingly, the administration of biologics remains limited to 
the parenteral route. Exploiting the potential of the mucosal surfaces for non-invasive 
delivery of this class of drugs is made difficult by the physiological role of the 
mucosae, which is to restrict the movement of material from the external milieu into 
the systemic circulation.  
 
Mucosally administered biologics such as protein drugs generally produce a low 
(predominantly clinically irrelevant) bioavailability. Drug delivery scientists have 
investigated a range of strategies to overcome the mucosal barrier in an attempt to 
improve the bioavailability of mucosally administered protein drugs. These have been 
reviewed in chapter 1. The ultimate goal being to develop a mucosal delivery strategy 
based on systems that exhibit no toxicity upon repeated administration, preserve the 
biological function of the therapeutic molecule, and achieve adequate bioavailability 
with minimal extra costs to the formulation (compared to parenteral systems) and 
which are amenable to different protein drugs. 
 
This thesis has explored the potential of the vitamin B12 pathway, as one of the few 
known transepithelial biological transport pathways, for the systemic delivery of 
nanoparticles across the epithelium. It must be noted that proof-of-concept work 
demonstrating the potential of the vitamin B12 pathway to deliver nanoparticles (as 
drug carriers) across the intestinal epithelium (Caco-2 cells) has been previously 
published by other groups. This thesis therefore is predominantly focused on 
investigating the cell uptake and transport mechanisms involved in the process of 
nanoparticle delivery via the vitamin B12 pathway. The investigation was conducted in 
vitro using epithelial cell culture models (intestinal Caco-2 cells and bronchial Calu-3 
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cells) since these models allow control of experimental conditions, which is necessary 
for studying drug delivery-relevant biological mechanisms. 
 
Initial work investigated the barrier property of Caco-2 cell monolayers and their 
suitability as a model for the vitamin B12 transport system (Chapter 3). To this end, 
work was conducted to determine mRNA expression, in addition to 
immunohistochemical analyses for the key proteins involved in the internalisation and 
transport of vitamin B12 in vivo, including the B12-IF receptor, cubilin; the secondary 
receptor, transcobalamin II receptor (TCIIR), and the TCII carrier protein. The data 
confirmed that Caco-2 cells (as monolayers) express relevant components of the 
vitamin B12 transport system providing an adequate model to study drug delivery 
strategies exploiting the vitamin B12 trafficking pathway. Additionally, the Caco-2 cell 
line used in this work was also validated as an epithelial barrier suitable for the study 
of macromolecular absorption (by determining cell morphology and testing the 
permeability of model macromolecules). Following appropriate culture, Caco-2 cells 
IRUPHGSRODULVHGPRQROD\HUVH[KLELWLQJ7((5RI!FP2 and presented a barrier 
to the permeability of macromolecules (FITC-dextrans and insulin), with the magnitude 
of the barrier being proportional to the MW of the permeant. Furthermore, Caco-2 
monolayers presented a significant barrier to the movement of nanoparticles. 
Considering their morphology, cells exhibited structural features that resemble the 
native epithelium, including the tight junctions and microvilli.  
 
Subsequent work (Chapter 4-7) investigated the vitamin B12 transport pathway for the 
delivery of nanoparticulate carriers. The vitamin B12 ligand itself requires manipulation 
in the form of chemical modification to permit its attachment to the carrier system. 
Work detailed in chapter 4 describes the synthesis and characterisation of an amino- 
derivative of vitamin B12Į-Ȧ-aminohexylcarbamate B12, ZKLFKZDVDFWLYDWHGDWWKH¶-
K\GUR[\O JURXS RI WKH ULERVH PRLHW\ XVLQJ ¶-carbonyldiimidazole (CDI). This was 
based on SUHYLRXVVWXGLHVVXJJHVWLQJWKDW WKHĮ-Ȧ-aminohexylcarbamate B12 retains 
its binding affinity for transcobalamin (II), haptocorrin (HC) and intrinsic factor (IF). 
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Successful derivatisation of cyanocobalamin was confirmed by means of NMR, MS 
and HPLC. Inspection of the 1H-NMR signals for the ribose ring revealed that its 
signals were significantly shifted after functionalisation, especially those closer to the 
¶ K\GUR[\O JURXS )XUWKHUPRUH QHZ VLJQDOV DULVLQJ IURP WKH & OLQNHU FRXOG EH
observed. The purity of the material was confirmed both by HPLC and MS, with the 
H[SHFWHG0ZREVHUYHG7KHUHVXOWDQWĮ-Ȧ-aminohexylcarbamate VB12 derivative 
was reacted with fluorescently-labelled, carboxy-functionalised polystyrene 
nanoparticles in the presence of 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide 
(EDAC) and N-hydroxy-succinimide (NHS), which following a purification step by 
dialysis,yielded the desired vitamin B12-conjugated nanoparticles (Chapter 5).  
For the cell studies described in Chapter 5, the suitability of the Caco-2 cell line as a 
model to study vitamin B12 epithelial transport pathway was verified not only by 
confirming the expression of cubilin receptor (and other essential components for B12 
transport), but also by examining for the presence of functioning caveolae and clathrin 
mediated endocytic pathways. Further work demonstrated that vitamin B12-conjugated 
nanoparticles were internalised and transported across the cells notably more 
efficiently compared to unmodified nanoparticles. Importantly, vitamin B12-conjugated 
nanoparticles bypassed the lysosomal compartments, unlike unmodified 
nanoparticles. Cell internalisation and transport of vitamin B12-conjugated 
nanoparticles remained largely unaffected by the inhibitors of clathrin-mediated 
endocytosis ± the route governing vitamin B12-IF internalisation in vivo. The cell 
internalisation and transport behaviour of B12-nanoparticles was instead markedly 
impeded by specific inhibitors of caveolae-mediated endocytosis, demonstrating that 
vitamin B12 conjugated nanoparticles were trafficked by a different intracellular 
pathway to both free vitamin B12 as well as unmodified nanoparticles.  
Work detailed in Chapter 6 set out to examine the role of intrinsic factor (IF) on the 
cellular uptake and transport of B12-conjugated nanoparticles and on subsequent cell 
sorting processes in Caco-2 cells. Whether the presence of IF in the system is a 
crucial parameter influencing the uptake and transport of B12-bearing nanoparticles 
was not clear prior to this work as, similarly to soluble vitamin B12, routes other than 
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the cubilin-mediated pathway could contribute to the uptake and transport of B12-
conjugated nanoparticles. Experiments assessing the effect of IF on the trafficking 
pathways of B12-nanoparticles were conducted to establish whether IF dictates the cell 
trafficking of B12-bearing nanoparticles. Overall, the data suggests that in the absence 
of IF, B12-conjugated nanoparticles are internalised and transported by cells to a 
lesser extent than when co-administered with IF, although the magnitude of this effect 
was not substantial. The findings also demonstrate that soluble vitamin B12 trafficking 
(without IF) occurs via a different route to that used by vitamin B12 in the presence of 
IF (i.e. cubilin mediated). Interestingly, while the uptake of vitamin B12-nanoparticle in 
the presence of IF was found to exploit a caveolae-mediated route, cell internalisation 
and transport of B12-conjugated nanoparticles in the absence of IF were predominantly 
affected by inhibition of the clathrin pathway. This suggests the involvement of a 
different cell uptake and trafficking route to that in the presence of IF, which implicates 
a role for the TCII receptor. 
Work in Chapter 7 investigated the presence of the B12-transport system and its 
potential role in the uptake and transport of B12-bearing nanoparticles in polarised 
bronchial Calu-3 cells. This work is important as cubilin expression and the B12 
transcytosis pathway in epithelial cell lines originating from the airways have not been 
previously reported. Initial experiments revealed cubilin, TCII receptor and TCII carrier 
protein expression in Calu-3 cells. Similarly to the findings in intestinal Caco-2 cells, 
B12-conjugated nanoparticles were found to internalise and transport across the cell 
layers markedly more efficiently compared to unmodified nanoparticles. Calu-3 cells 
were also capable of internalising B12-conjugated nanoparticles in an IF-dependent 
and IF-independent fashion, with particle size bearing a considerable effect on the 
extent of both uptake and transport.  Lysosomal studies revealed that the cell uptake 
and trafficking of nanoparticles in the bronchial Calu-3 cell line mirrored the cell sorting 
processes found in Caco-2 cells, with the surface decoration of vitamin B12 playing a 
profound role on intracellular trafficking in both Caco-2 cells and in Calu-3 cells, giving 
rise to lysosomal bypass
.  
Inhibitor studies complemented previous reports in Caco-2 
cells (and the earlier findings in this thesis) that soluble vitamin B12 (in the presence of 
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IF) predominantly exploits a clathrin-mediated route in the process of internalisation in 
Calu-3 cells. However, contrary to findings in Caco-2 cells where caveolae played no 
role in the internalisation of vitamin B12, the data suggested that to a degree, there 
could be an element of cross-talk between the two pathways in Calu-3 cells. The 
polystyrene nanoparticles employed in this work (Chapters 5-7) were merely used as 
'model' therapeutic carriers to demonstrate whether transmucosal transport can be 
achieved following their conjugation to a biological ligand (vitamin B12). The promising 
results obtained from in vitro work detailed in this thesis pave the way for further 
investigations in vivo, wherein the vitamin B12 ligand can be used to navigate 'real' 
therapeutic carriers across the epithelium. To this end, it was envisaged that the 
vitamin B12 transmucosal absorption strategy can perhaps, in the future be applied not 
only to nanocarriers but also protein therapeutics formulated in nano-sized entities, 
such as protein 'nanocrystal' formulations, which becomes the subject of the final 
chapter of this thesis. 
 
Work in Chapter 8 was therefore conducted to investigate the formulation of a protein 
therapeutic as nanocrystals, with the view of exploring the potential of this carrier-free, 
nanoscale drug delivery strategy. Protein therapeutics formulated as nanoparticulates 
have highly desirable drug delivery properties. In this method development study, a 
heterogeneous population of nano- and micron-sized insulin crystals were prepared by 
a modification of the batch crystallisation approach. The first task in this investigation 
was to establish and optimise a protocol for the development of insulin crystals of sub-
micron range. This was achieved by optimisation of the formulation conditions, 
including the ratio of components of the crystallisation buffer and the centrifugal 
HYDSRUDWLRQ VWHS /DWHU WKH HIIHFWV RI 7+33 ȕ-[Tris(hydroxymethyl) phosphino] 
propionic acid) as a proof-of-concept crystal stabiliser were investigated. The work 
aimed to address the problem of colloidal instability of insulin in the absence of the 
crystallisation buffer. The surface of formulated crystals was initially partially cross-
linked with THPP, followed by optimisation of this cross-linking to produce stable 
nano- and micro-sized protein crystals that permit slow/controlled release profile of the 
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biologically active insulin. Importantly, in vitro cytotoxicity assays revealed that THPP 
is not harmful to cells and that THPP-stabilised insulin crystals were generally stable 
in the absence of their crystallisation buffer, displayed a slow-release profile and the 
released insulin had retained its biological activity in vitro (as determined by 
measuring its bioactivity in mouse 3T3 fibroblasts). Future optimisation of the 
formulation conditions to achieve protein crystals of desirable sizes (e.g. 50-200 nm 
range) and incorporation of suitable ligands, such as vitamin B12 in the system, has the 
potential to enhance mucosal delivery of protein-based therapeutics to therapeutically 
acceptable levels. 
9.2 Future directions 
Important factors for selecting a drug delivery method for commercial development 
generally includes market competition, patient convenience and compliance, 
requirement for local or topical delivery and systemic toxicity or other safety issues. 
However, with formulations of biological therapeutics such as proteins the delivery 
method has been dictated by the physicochemical properties of this class of 
therapeutics and the inability to overcome the mucosal barrier to achieve non-invasive 
delivery. Although researchers have actively worked to identify painless and non-
invasive alternatives for administration of these drugs, ground-breaking advances are 
currently lacking. This is reflected by the fact that apart from a few peptide products 
(with a modest molecular weight) in the form of nasal sprays, commercially popular 
formulations of larger proteins and antibodies designed for oral or other mucosal 
delivery routes are virtually non-existent.   
The mucosal barrier presents unique challenges for drug delivery scientists. 
Traditional approaches studied with the aim of overcoming this barrier for systemic 
delivery of biologics have mainly focused on the use of absorption enhancers or 
delivery systems that prolong the contact of the drug with the mucosal surface. These 
rather crude approaches are not without problems, as highlighted by the damaging 
effect of repeated application of some absorption enhancers such as surfactants. 
Exploiting the receptor-mediated cellular transport machinery for the purpose of 
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transmucosal drug delivery is potentially a more elegant approach. This strategy has 
recently received considerable attraction in the field of drug and gene delivery, with 
the potential of allowing targeted delivery. The use of drug carrier systems, such as 
nanoparticles, appended with ligands to target these receptors has opened new 
avenues for cellular or intra-cellular targeting. For the purpose of receptor-mediated 
delivery of macromolecular therapeutics across the mucosal surfaces, biological 
transport systems that transport cargo from the external environment (lumen) into the 
systemic circulation are of huge interest. Unfortunately not many such biological 
pathways are currently known and of the handful of identified systems, only some 
have demonstrated potential for mucosal drug delivery.  
Current nanoparticle-mediated mucosal drug delivery research is restricted by an 
overall lack of understanding in the complex cell internalisation and cell sorting 
processes at the molecular level, which was the inspiration behind this work. The 
findings from this thesis overall demonstrated that surface-conjugation of vitamin B12 
ligand to nanoparticles resulted in an unexpected intracellular trafficking behaviour in 
epithelial Caco-2 and Calu-FHOOOD\HUVZLWKDµVZLWFK¶WRDQRQ-degradative caveolae 
pathway, which is more desirable from a drug delivery perspective. This discovery is a 
previously unreported example of pathway switching via ligand decoration and may 
have important implications for non-invasive delivery of nanocarrier-associated 
therapeutic or diagnostic systems and diagnostics and warrants further investigation. 
7KH ILQGLQJV VXJJHVW WKDW µGHVLJQ UXOHV¶ IRU QDQRSDUWLFXODWH V\VWHPV PD\ H[Lst, 
governing their cellular uptake processes and the resulting usefulness for drug 
delivery.   
The vitamin B12 biological pathway is one of few epithelial biological transport systems 
which are being commercially exploited for the purpose of oral delivery of nanoscale 
drug carriers. This thesis confirms its potential in this area and adds important 
information in terms of the biological mechanisms. However, many questions remain 
unanswered about the use of nanoparticulate drug carriers for mucosal drug delivery 
in general. Therefore, any future advances in the area of nanoparticle-mediated 
mucosal protein delivery via the vitamin B12 pathway depends on future improvements 
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in our understanding relating to the long term safety concerns associated with the use 
of nanoparticles for mucosal drug delivery alongside parallel developments in 
'targeted' protein nanocrystal formulations. 
 
 
 
